Document:

API Supply Agreement

 Exhibit 10.1 
 CONFIDENTIAL 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND
REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934. 
  
  

 
 API SUPPLY AGREEMENT

 by and between 
 AMARIN PHARMACEUTICALS IRELAND LTD. 
 and 

EQUATEQ LIMITED 
 Dated as of May 25, 2011 
  

 
  

 API SUPPLY AGREEMENT 

THIS API SUPPLY AGREEMENT (this “Agreement”) is entered into and dated as of the 25th day of May, 2011 (the “Effective
Date”) by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland
(“Amarin”), and Equateq Limited, a company incorporated in England with registered number [5507387] and with its registered office at Lion House, Red Lion Street, London, WC1R 4GB but with its principal offices at Callanish, Isle of Lewis,
HS2 9ED (“Equateq”). Amarin and Equateq are sometimes referred to herein individually as a “Party” and collectively as “Parties.” 
 RECITALS 
 WHEREAS, Amarin is engaged in the research, development and
commercialization of proprietary pharmaceutical products; 
 WHEREAS, Equateq is a company that has developed substantial
expertise in manufacturing polyunsaturated fatty acids, including ethyl-EPA, for use in nutritional supplement and pharmaceutical products; 
 WHEREAS, the Parties desire to enter into a supply agreement pursuant to which Equateq will manufacture a certain active pharmaceutical ingredient for Amarin. 

NOW, THEREFORE, in consideration of the foregoing recitals, mutual covenants, agreements, representations and warranties contained
herein, the Parties hereby agree as follows: 
 Article I 
 Definitions 
 “Adverse Event” has the meaning in Section 6.7
of this Agreement. 
 “Affiliate” means a corporation or non-corporate business entity that, directly or indirectly,
controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the
voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the
management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 

“Agreement” has the meaning in the preamble of this Agreement. 

“Amarin” has the meaning in the preamble of this Agreement. 

“Amarin Competitors” mean the entities listed in Schedule 3.7, and any successor in interest to such entities.

 “Amarin Confidential Information” has the meaning provided in Section 13.1 of this Agreement. 

“Amarin Data” means any and all data and information, in any form, relating to: (a) the business of Amarin;
(b) licensees, customers and suppliers (other than Equateq) of Amarin; (c) the Product and the development and manufacture thereof (excluding Equateq’s data and information related to the API); and (d) the API Specifications.

  
 2 

 “Amarin Intellectual Property” means any and all Intellectual Property that is
(i) owned, licensed or controlled by Amarin or Amarin Affiliates as of the Effective Date, or (ii) developed or acquired by Amarin or Amarin Affiliates after the Effective Date. 

“API” means [***]. 
 “API Price” has the meaning provided in Section 4.1(d) of this Agreement. 
 “API Price Adjustment Methodology” has the meaning provided in Section 4.1(d)(vi) of this Agreement. 
 “API Shipping Qualification” has the meaning provided in Section 4.5(a) of this Agreement. 
 “API Specifications” mean all specifications set forth on Schedule 5.1 to this Agreement. 
 “Audit Representatives” has the meaning provided in Section 9.2 of this Agreement. 
 “Calendar Quarter” means each three (3) month period beginning each January 1, April 1, July 1 and October 1 during the Term. The initial Calendar Quarter
shall begin on the Effective Date and end on June 30, 2011, and the last Calendar Quarter shall end on the expiration or earlier termination date of the Term. 
 “Calendar Year” means each twelve (12) month period beginning each January 1 during the Term. The initial Calendar Year shall begin on the Effective Date and end on December 31,
2011, and the last Calendar Year shall begin on January 1 of the last year of the Term and end on the expiration or earlier termination date of the Term. 
 “Certificate of Analysis” means a document identified as such and provided by Equateq to Amarin in the form set forth in Schedule 6.2 that (i) sets forth the analytical test results
for a specified lot of API shipped to Amarin or its designee hereunder and includes a certified quality control protocol, (ii) states that such API is in conformance with the Drug Application and API Specifications, and (iii) states that
such API is manufactured in accordance with the API Specifications, Legal Requirements, cGMPs, all other regulatory documents. 

“Certificates” has the meaning provided in Section 6.2 of this Agreement. 

“Change of Control” means any proposed transaction or series of transactions which shall result in: 

(a) in the case of Equateq (i) any party other than Equateq, or an entity that is an Affiliate of Equateq as of the Effective Date,
owning the Facility, (ii) direct or indirect ownership of more than fifty percent (50%) of the voting stock or assets of Equateq or an Affiliate that controls Equateq being owned by Persons who are not shareholders of Equateq or the
Affiliate that controls Equateq as of the Effective Date, or (iii) the merger of Equateq with or into a Third Party in a transaction in which Equateq is not the surviving or acquiring party; and 

(b) in the case of Amarin (i) direct or indirect ownership of more than fifty percent (50%) of the voting stock or assets of
Amarin or an Affiliate that controls Amarin being owned by Persons who are not shareholders of Amarin or the Affiliate that controls Amarin as of the Effective Date, or (iii) the merger of Amarin with or into a Third Party in a transaction in
which Amarin is not the surviving or acquiring party. 
 “Commercial API” has the meaning provided in
Section 4.1(d)(iv) of this Agreement. 

  
 3 

 “Commercial Launch Forecast” has the meaning provided in Section 3.4(a) of
this Agreement. 
 “Commercial Validation Batches” has the meaning provided in Section 3.2(c) of this Agreement.

 “Confidential Information” has the meaning provided in Section 13.3 of this Agreement. 

“Consent” means any consent, authorization, permit, certificate, license or approval of, exemption by, or filing or
registration with, any Governmental Body or other Person. 
 “Compound” means ethyl ester of eicosapentaenoic acid
and/or DHA ethyl ester. 
 “Current Good Manufacturing Practices” or “cGMPs” means all applicable standards
relating to manufacturing practices for intermediates, active pharmaceutical ingredients or finished pharmaceutical products, including without limitation (i) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R.
Parts 210 and 211, The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, and Q7A Good Manufacturing Practice Guidance For Active Pharmaceutical Ingredients (ICH Q7A),
(ii) the principles promulgated by any applicable Governmental Body having jurisdiction over the manufacture of the API, in the form of laws, rules, or regulations, and (iii) the principles promulgated by any applicable Governmental Body
having jurisdiction over the manufacture of the API, in the form of guidance documents (including but not limited to advisory opinions, compliance policy guides and guidelines), which guidance documents are being implemented within the
pharmaceutical manufacturing industry for such products; in each case as in effect at the Effective Date and as amended, promulgated or accepted by any applicable Governmental Body from time to time during the Term. 

“Days” (whether or not the word is capitalized) means, except where specified otherwise, calendar days. 

“Development Plan” has the meaning provided in Section 2.1 of this Agreement. 

“Development Fees” has the meaning provided in Section 4.1(b) of this Agreement. 

“DMFs” has the meaning provided in Section 7.4 of this Agreement. 

“Drug Application” means the New Drug Application filed with the FDA for the Product, including, without limitation, any
supplements thereto, any product license or any equivalent drug application or similar pharmaceutical product approval for the Product administered by any foreign Governmental Body, or supplement, extension or renewal of any of the foregoing.

 “Effective Date” has the meaning in the preamble of this Agreement. 

“Equateq” has the meaning in the preamble of this Agreement. 

“Equateq Confidential Information” has the meaning provided in Section 13.2 of this Agreement. 

“Equateq Data” means all data and information, in any form, relating to: (a) the business of Equateq; (b) licensees,
customers (other than Amarin) and suppliers of Equateq; and (c) the API and the development and manufacture thereof. 

“Equateq Intellectual Property” means (i) all Intellectual Property owned or licensed by Equateq as of the Effective Date,
and (ii) all Intellectual Property relating to the manufacture of API and solely developed or acquired by Equateq after the Effective Date that does not relate to the Product or the development or manufacture of the Product, except that
Intellectual Property developed by Equateq related to the API shall be included in Equateq Intellectual Property. 

  
 4 

 “Europe” means the member states from time to time of the [***]. 

“Expanded Manufacturing Process” has the meaning set forth in Section 2.2 of this Agreement. 

“Expansion” has the meaning set forth in Section 2.2 of this Agreement. 

“Expansion Plan” has the meaning set forth in Section 2.2 of this Agreement. 

“Facility” means Equateq’s manufacturing facility located at [***], or such other facility as agreed in writing by the
Parties. 
 “FDA” means the United States Food and Drug Administration, or any successor agency thereof. 

“Force Majeure Event” has the meaning provided in Section 14.1 of this Agreement. 

“Fourth Minimum Purchase Requirement” has the meaning set forth in Section 3.3(d) of this Agreement. 

“Governmental Body” means any nation or government, any state, province, or other political subdivision thereof, any entity
with legal authority to exercise executive, legislative, judicial, regulatory or administrative functions, or any division of the FDA (as applicable) and any other applicable counterpart agency or foreign equivalent that administers the Legal
Requirements. 
 “Indemnified Party” has the meaning provided in Section 11.3 of this Agreement. 

“Indemnifying Party” has the meaning provided in Section 11.3 of this Agreement. 

“Inflammatory Cardiovascular Disease” means atherosclerosis, acute coronary syndrome, vasculitis and other inflammatory
cardiovascular diseases. 
 “Initial Minimum Purchase Requirement” has the meaning provided in Section 3.3(a) of
this Agreement. 
 “Initial Term” has the meaning provided in Section 15.1 of this Agreement. 

“Intellectual Property” means (i) patents, patent rights, provisional patent applications, patent applications, design
rights, registered designs, registered design applications, industrial designs, industrial design applications and industrial design registrations, including any and all divisions, continuations, continuations-in-part, extensions, restorations,
substitutions, renewals, registrations, revalidations, reexaminations, reissues or additions, including supplementary certificates of protection, of or to any of the foregoing items; (ii) copyrights, copyright registrations, copyright
applications, original works of authorship fixed in any tangible medium of expression, including literary works (including all forms and types of computer software, including all source code, object code, firmware, development tools, files, records
and data, and all documentation related to any of the foregoing), musical, dramatic, pictorial, graphic and sculptured works; (iii) trade secrets, technology, developments, discoveries and improvements, know-how, proprietary rights, formulae,
confidential and proprietary information, technical information, techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not patentable or copyrightable, including all biological,
chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability information and 

  
 5 

 
data which have actual or potential commercial value and are not available in the public domain; (iv) trademarks, trademark registrations, trademark applications, service marks, service mark
registrations, service mark applications, business marks, brand names, trade names, trade dress, names, logos and slogans, internet domain names, and all goodwill associated therewith; (v) database right, and (vi) all other intellectual
property or proprietary rights worldwide, in each case whether or not subject to statutory registration or protection. 

“Legal Requirements” means any and all local, municipal, state, provincial, federal and international laws, statutes,
ordinances, rules, or regulations now or hereafter enacted or promulgated by any Governmental Body within Europe and North America applicable to the development, approval, manufacture, sale, shipment or licensing of any pharmaceutical products,
ingredients for inclusion therein, or any aspect thereof, and the obligations of Equateq or Amarin, as the context requires, under this Agreement, including, without limitation, applicable laws, statutes, ordinances, rules and regulations of
Scotland, as well as the United States Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder. 
 “Losses” means, collectively, any and all claims, liabilities, damages, losses, costs, expenses, including reasonable fees and disbursements of counsel and any consultants or experts and
expenses of investigation, obligations, liens, assessments, judgments, fines and penalties imposed upon or incurred by an Indemnified Party. 
 “Metabolic Disease” means diabetes or metabolic syndrome. 

“Minimum Purchase Requirements” has the meaning provided in Section 3.3(d) of this Agreement. 

“[***] Forecast” has the meaning provided in Section 3.4(b) of this Agreement. 

“Nonconformity” has the meaning provided in Section 6.4(a) of this Agreement. 

“Nonconforming API” means API that is subject to a Nonconformity. 

“North America” means the [***]. 
 “Original NDA” means the original New Drug Application filed with the FDA for the product incorporating API from a source other than Equateq. 

“Party” and “Parties” have the meanings given such terms, respectively, in the preamble of this Agreement.

 “Person” means any individual, corporation, company, partnership, trust, incorporated or unincorporated
association, joint venture or other entity of any kind. 
 “Product” means finished pharmaceutical product currently
known as AMR101 that incorporates the API supplied by Equateq. 
 “Proposed Opportunity” has the meaning provided in
Section 3.7(b) of this Agreement. 
 “Purchase Orders” has the meaning provided in Section 3.5 of this
Agreement. 
 “Quality Agreement” means the agreement identified in Section 5.6 of this Agreement. 

“Registration/Stability Batches” has the meaning provided in Section 3.2(b) of this Agreement. 

  
 6 

 “Sample Product” means Product packaged and labeled by Amarin or a Third Party as
samples intended to be distributed at no charge to physicians and intended for further distribution, at no charge, to patients. 

“Secondary Supplier” has the meaning set forth in Section 3.5 of this Agreement. 

“Second Minimum Purchase Requirement” has the meaning set forth in Section 3.3(b) of this Agreement. 

“Shipment Date” means the date specified by Equateq that Equateq shall ship the API in accordance with this Agreement.

 “Shipping Validation” means a documented test related to the shipment that demonstrates with a high degree of
assurance that a specific process will meet its pre-determined acceptance criteria. 
 “Subcontractor” means any Third
Party that performs any of Equateq’s obligations under this Agreement on Equateq’s behalf with the written consent of Amarin. 
 “Technical Batches” has the meaning provided in Section 3.2(a) of this Agreement. 
 “Term” has the meaning provided in Section 15.1 of this Agreement. 

“Third Minimum Purchase Requirement” has the meaning set forth in Section 3.3(c) of this Agreement. 

“Third Party” means any Person other than the Parties or their respective Affiliates. 

“Third Party Materials” means (i) all raw materials, components, work-in-process and other ingredients required to
manufacture the API, and (ii) all packaging materials used in the manufacture, storage and shipment of the API. 

“Third Party Materials Payment” has the meaning provided in Section 4.1(c) of this Agreement. 

“Third Party Materials Payment Refund” has the meaning provided in Section 4.1(c) of this Agreement. 

“Third Party Supplier” means any Third Party that provides to Equateq any Third Party Materials for any API produced under this
Agreement. 
 “Upfront Commitment Payment” has the meaning provided in Section 4.1(a) of this Agreement.

 Article II 
 Initial Regulatory Activities and Expansion 
 2.1 Development Plan.
Equateq will execute and complete all DMF preparation, analytical methods and validation, testing and other regulatory activities required for DMF and Drug Application filing as well as registration stability activities, all as will be detailed in a
development plan substantially in the form of the draft attached at Schedule 2.1 (the “Development Plan”) and subject to Section 7.4. The Parties agree to finalize the Development Plan within [***] after the Effective Date.
Equateq and Amarin shall develop a validation protocol to the extent not covered in Schedule 2.1 as soon as practicable, and Equateq shall deliver a final report to Amarin. 

  
 7 

 2.2 Expansion. Equateq shall expand its capacity to manufacture API such that it can
manufacture Amarin each [***] no less than [***] of API (the “Expansion”). Equateq shall use commercially reasonable efforts to complete the Expansion within [***] after the Effective Date, but in no event shall Equateq complete the
Expansion later than [***] after the Effective Date. The Expansion shall be completed, including the validation of the manufacturing process as expanded (the “Expanded Manufacturing Process”), in accordance with a plan to be developed by
Equateq and submitted to Amarin within [***] after the Effective Date, which plan shall include [***] (the “Expansion Plan”). A summary of what the Expansion Plan will contain is set forth in Schedule 2.2. Amarin shall be
entitled to make comments and suggestions on the Expansion Plan to Equateq but responsibility for the Expansion Plan and its implementation shall rest with Equateq. 
 2.3 Security Interest. To secure the timely shipment of the Minimum Purchase Requirements and/or payment of the Third Party Materials Payment Refund, if applicable, Equateq shall grant to Amarin a
floating charge over the Third Party Materials owned by Equateq up to [***] and which value shall be reduced by [***] such that when the total API Price for such API shipped reaches $[***] (or if this Agreement terminates early, upon Equateq’s
fulfillment of its remaining payment obligations hereunder and delivery of API required to be delivered by Equateq in respect of an obligation arising prior to termination hereunder) the floating charge shall be fully discharged. Equateq covenants
that until the floating charge is released in accordance with this Section 2.3, Equateq will [***]. Equateq agrees to sign and deliver one or more instruments as Amarin may from time to time require to comply with applicable law to preserve,
protect and enforce the security interest of Amarin and to pay all costs of filing such statements or instruments. In the event Equateq fails to comply with the obligations pursuant to the preceding sentence, Equateq hereby authorizes Amarin to file
such instruments without the signature of Equateq in such form and in such filing offices as Amarin reasonably determines appropriate to perfect the security interests of Amarin under this Agreement. 

2.4 Communication. 
 (a) Equateq will provide process progress reports to Amarin with respect to its progress on the Development Plan and Expansion no less frequently than monthly, which reports shall include, for example,
details related to construction, equipment installation and process implementation. 
 (b) Equateq and Amarin
shall participate in project teleconferences with Amarin as reasonably requested by Amarin to successfully complete the Development Plan and Expansion. During the performance of the Development Plan and Expansion, Equateq will
accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by Amarin. 
 Article
III 
 Sale and Purchase of API 
 3.1 General. Subject to the terms and conditions of this Agreement, Equateq agrees to manufacture API at the Facility for sale to Amarin. Equateq may manufacture API for sale to Amarin at locations
other than the Facility only with the prior written consent of Amarin. For the avoidance of doubt, the Parties agree that this Agreement does not obligate Amarin to purchase all of its requirements of the API from Equateq, nor does it obligate
Amarin to purchase any particular volumes of API from Equateq except as expressly set forth herein. Amarin retains the right to engage or appoint additional suppliers and contract manufacturers from time to time in its sole discretion. 

  
 8 

 3.2 Supply of Pre-Commercial Batches. 

(a) Equateq shall supply to Amarin upon Amarin’s issuance of Purchase Orders [***] technical batches of [***] each
(the “Technical Batches”). Equateq shall ship the Technical Batches in accordance with the schedule set forth in the Development Plan. Equateq will confirm a ship date within [***] of receiving a Purchase Order; provided, however, that
Equateq shall not be entitled to reject Shipment Dates that are consistent with the Development Plan. Each Technical Batch shall be [***]. 
 (b) Equateq shall supply to Amarin upon Amarin’s issuance of Purchase Orders [***] registration and stability batches of [***] each (the “Registration/Stability Batches”). Equateq shall
ship the Registration/Stability Batches in accordance with, and within [***] of the issuance of, the Purchase Orders, which Purchase Orders will be submitted in accordance with the Development Plan. Each Registration/Stability Batch shall be [***].

 (c) Equateq shall supply to Amarin upon Amarin’s issuance of a Purchase Order [***] commercial validation
batches manufactured using the Expanded Manufacturing Process (together with the batches to be supplied pursuant to Section 3.2(d), the “Commercial Validation Batches”) of [***] each. Equateq shall ship such Commercial Validation
Batches in accordance with, and within [***] of the issuance of, the Purchase Order. 
 (d) Equateq shall supply
to Amarin upon Amarin’s issuance of a Purchase Order [***] Commercial Validation Batches manufactured using the Expanded Manufacturing Process of [***] each. Equateq shall ship such Commercial Validation Batches in accordance with the
Development Plan. Equateq shall ship such Commercial Validation Batches in accordance with, and within [***] of the issuance of, the Purchase Order. 
 3.3 Minimum Purchase Requirements. 
 (a) Within [***] of
Equateq’s supply of API meeting the requirements of this Agreement in accordance with Section 3.2 and, provided [***], Amarin agrees to purchase from Equateq, and Equateq agrees to supply to Amarin, [***] of API (the “Initial Minimum
Purchase Requirement”). 
 (b) Within [***] of Equateq’s completion of the shipment of the Initial
Minimum Purchase Requirement, Amarin agrees to purchase from Equateq, and Equateq agrees to supply to Amarin, [***] of API (the “Second Minimum Purchase Requirement”). 

(c) Within [***] of Equateq’s completion of the shipment of the Second Minimum Purchase Requirement, Amarin agrees to
purchase from Equateq, and Equateq agrees to supply to Amarin, [***] of API (the “Third Minimum Purchase Requirement”). 
 (d) Within [***] of Equateq’s completion of the shipment of the Third Minimum Purchase Requirement, Amarin agrees to purchase from Equateq, and Equateq agrees to supply to Amarin, [***] of API (the
“Fourth Minimum Purchase Requirement,” and, together with the Initial Minimum Purchase Requirement, Second Minimum Purchase Requirement, and Third Minimum Purchase Requirement, the “Minimum Purchase Requirements”). 

(e) The Minimum Purchase Requirements shall be ordered [***] over the period of the relevant [***] and in accordance with
the forecasts provided pursuant to Section 3.4. 

  
 9 

 (f) For the avoidance of doubt, the Minimum Purchase Requirement shall be
Amarin’s sole purchase requirement under this Agreement, save to the extent that Amarin agrees to make further purchases through the [***] Forecasts under Section 3.4 or otherwise by agreement with Equateq. 

(g) If Equateq ships Nonconforming API intended to be incorporated into Product for commercial sale pursuant to [***]
Purchase Orders in any [***] period, but for the avoidance of doubt excluding any API supplied pursuant to Section 3.2 or Section 4.1(e), Amarin shall be relieved of purchasing the Minimum Purchase Requirement applicable to such time
period. 
 3.4 Forecasts. 
 (a) Not later than [***] following [***], Amarin shall provide Equateq with [***], nonbinding forecast of the quantity of API Amarin projects it may purchase from Equateq beginning [***] prior to the
anticipated commercial launch of the Product (the “Commercial Launch Forecast”). 
 (b) Not later than
[***] after [***], Amarin shall, on a [***] basis, provide Equateq with a [***] rolling forecast of the quantity Amarin intends to order during each [***] (each such forecast referred to herein as a “[***] Forecast”). The forecast amount
for the first [***] of the [***] Forecast shall be binding on both Parties. The forecast amounts for the remaining [***] of each [***] Forecast, i.e., [***], shall be non-binding forecast amounts. The [***] Forecast shall identify any quantity of
API required for Sample Product for each [***] in accordance with Section 4.1(e), which quantity, prior to the completion of the Minimum Purchase Obligations, shall not exceed [***] of the quantity of API required for the relevant [***] if
Option A applies, [***] if Option B applies or [***] if Option C applies; and which quantity, after the completion of the Minimum Purchase Obligations, shall not exceed [***] of the quantity of API required for the relevant [***]. Equateq shall not
be obligated to supply API in excess of the binding forecast amounts contained in the [***] Forecasts and in no event shall Equateq be obligated to manufacture in any [***] more than the Facility’s annual capacity divided by [***]. 

3.5 Purchase Orders. Amarin shall deliver to Equateq one or more purchase orders (“Purchase Orders”) for the aggregate
API volumes in each binding portion of a [***] Forecast. Each Purchase Order shall specify the volumes of API ordered, which shall be consistent with the binding portion of the [***] Forecast, the Shipment Date and the destination for shipment of
the API. The Purchase Orders may be delivered electronically or by other means to such location as Equateq shall designate. Equateq shall ship such API on the Shipment Date specified by Amarin; provided, however that the Shipment Date is no less
than [***] after the date of the submission of the Purchase Order. In the event that Equateq shall not be able to ship API by the Shipment Date specified in a Purchase Order, Equateq shall notify Amarin promptly in writing upon discovery of its
inability to comply with the terms of this Section 3.5; provided, however, that such notification shall not relieve Equateq of any liability for failure to ship on such Shipment Date. In addition, Equateq will take such actions as may be
reasonably requested by Amarin to minimize the damage to Amarin caused by Equateq’s inability to fulfill the terms of a Purchase Order. To the extent that (i) Equateq is or will be unable to supply Amarin with substantially the full
quantity of API ordered in a Purchase Order on or before the applicable Shipment Date and is unable to provide an alternative Shipment Date which is acceptable to Amarin, acting reasonably in all the circumstances, and (ii) Amarin engages a
Third Party (a “Secondary Supplier”) to supply such API, Equateq shall, in addition to any other remedies available to Amarin, reimburse Amarin for the difference in price paid to the Secondary Supplier for such API and the API Price
provided that such difference shall not exceed [***] of the then current API Price that Equateq is charging Amarin for API. 

  
 10 

 3.6 Accommodations. From time to time, Amarin may deliver to Equateq a Purchase Order
for API volumes in excess of those specified in any binding portion of a [***] Forecast. Equateq shall use commercially reasonable efforts, but shall not be obligated, to provide Amarin with all such ordered API volume. 

3.7 Supply Covenants. 
 (a) In recognition of Amarin’s commitments under this Agreement (i) Equateq shall not export, sell or distribute a pharmaceutical product incorporating Compound having an EPA purity level equal
to or greater than [***] by weight and/or a DHA level of less than [***] by weight that [***], (ii) Equateq shall not export, sell or distribute Compound having an EPA purity level equal to or greater than [***] by weight and/or a DHA level of
less than [***] by weight to any Third Party that exports, sells or distributes a pharmaceutical product incorporating such Compound that [***], (iii) Equateq shall not export, sell or distribute a non-prescription nutritional supplement
product incorporating Compound having an EPA purity level equal to or greater than [***] by weight and/or a DHA level of less than [***] by weight for use in [***], (iv) Equateq shall not export, sell or distribute Compound having an EPA purity
level equal to or greater than [***] by weight and/or a DHA level of less than [***] by weight to any Third Party for use in [***], (v) Equateq shall not export, sell or distribute Compound to any Third Party that [***], as reasonably
determined by Amarin and Equateq, and (vi) in the event Amarin purchases [***] or more of Equateq’s [***] capacity in any [***], Equateq shall not export, sell or distribute Compound to [***] and Equateq shall not export, sell or
distribute any product [***], in each case having a purity level of pure ethyl ester of eicosapentaenoic acid equal to or greater than [***] by weight, in the immediately succeeding [***]. For the avoidance of doubt, this provision does not limit
Equateq’s ability to [***]. 
 (b) Before Equateq (i) exports, sells or distributes in [***] any
pharmaceutical product incorporating Compound having an EPA purity level equal to or greater than [***] by weight that has an indication [***] having an EPA purity level equal to or greater than [***] by weight, or (ii) exports, sells or
distributes such Compound to a Third Party that exports, sells or distributes in [***] any pharmaceutical product incorporating such Compound that has an indication [***] having an EPA purity level equal to or greater than [***] by weight (in either
case, the “Proposed Opportunity”), then, subject to confidentiality restrictions, Equateq shall provide written notice to Amarin describing the Proposed Opportunity in reasonable detail and shall give Amarin an opportunity within the
commercial constraints of the Proposed Opportunity to discuss and, if Amarin wishes, to negotiate in good faith potential terms for Amarin to participate in the Proposed Opportunity in place of the said Third Party. 

(c) This Section 3.7 shall expire in the event Amarin does not (i) order at least [***] in the first full
Calendar Year following [***] in which Amarin completes the purchase of the Initial Minimum Purchase Requirement, or (ii) order at least [***] of API from Equateq in any full Calendar Year during the Term (or shorter period if this Agreement is
earlier terminated) thereafter. For the final Calendar Year of the Term where that is a shorter period because this Agreement is earlier terminated this [***] threshold shall be pro rated for such period. 

3.8 Amarin shall only use the API supplied by Equateq for or in connection with the manufacture of the Product and shall not sell,
distribute, export or otherwise supply or deal in the API other than by way of a Product incorporating the API. 
 3.9
Meetings. Unless otherwise mutually agreed, the Parties shall meet or otherwise communicate no less than [***] to discuss the forecasts delivered by Amarin pursuant to this Agreement and other matters relevant to the supply of API hereunder.
Equateq shall accommodate technical meetings as requested by Amarin. At Amarin’s request, such meetings shall take place at the Facility. 

  
 11 

 Article IV 
 Financial Matters 
 4.1 Payments. 

(a) Upfront Commitment Payment. Amarin shall make a one time payment to Equateq of one million dollars ($1,000,000)
(the “Upfront Commitment Payment”) within five (5) Days of the Effective Date. Equateq shall notify Amarin when the financing to perform its obligations under this Agreement is in place, which notification shall describe the financing
terms with a reasonable level of detail and in the absence of notice of objection from Amarin within [***] of Equateq’s notification it shall be deemed accepted by Amarin. In the event Equateq has not, in Amarin’s reasonable determination
after good faith consultation with Equateq, raised sufficient capital to perform its obligations under this Agreement within [***] after the Effective Date, Amarin shall give notice to Equateq of that determination forthwith and Equateq shall refund
the Upfront Commitment Payment to Amarin upon written request and whereupon this Agreement shall terminate automatically. 
 (b) Development Plan Fees. Amarin shall pay to Equateq the fees for the performance of the Development Plan as set forth in Schedule 2.1 (the “Development Fees”); provided,
however, that the Development Fees shall not exceed five hundred thousand dollars ($500,000) unless Amarin requests Equateq to perform additional activities or services not within the scope of Schedule 2.1. Any activities or services not
included within the scope of Schedule 2.1 or the Development Plan must be agreed to by both Parties in the form of written change order signed by both Parties. Upon the finalization of the Development Plan pursuant to Section 2.1, if the
scope of activities has narrowed or broadened, the parties shall mutually agree upon any corresponding adjustment to the costs. With respect to each stage of the Development Plan identified therein, Amarin shall pay [***] of the Development Fees
designated for such stage within [***] of receipt of invoice issued upon the initiation of such phase, and [***] of the Development Fees designated for such stage within [***] of receipt of invoice issued upon the completion of such stage.

 (c) Starting Material Payment. Amarin shall pay to Equateq five million dollars ($5,000,000) for the
sole purpose of Equateq purchasing Third Party Materials as follows (the “Third Party Materials Payment”): 
 (i) [***] upon [***]; 
 (ii) [***] upon [***]. 

The Third Party Materials Payment will be applied as a credit against the API Price for the Initial Minimum Purchase
Requirement. 
 In the event the Expansion is not completed or the Expanded Manufacturing Process is not
validated and operational within [***] after the Effective Date and there is no reasonable prospect of it being so completed or validated and operational as appropriate within a further [***], or if the Expansion is not completed or the Expanded
Manufacturing Process is not validated and operational within [***] after the Effective Date, or in either case such longer period where the additional time is reasonably required by Equateq as a result of scheduling or other delays by the FDA
beyond the reasonable control of Equateq, Equateq shall refund within [***] the Third Party Materials Payment to Amarin (the “Third Party Materials Payment Refund”). 

  
 12 

 In the event that Amarin does not [***] without prejudice to any other
rights or remedies hereunder, Equateq shall have the right to [***]. Equateq shall be entitled to [***] except for the [***]. Equateq shall promptly pay to Amarin up to the [***]. Equateq shall keep complete and accurate records related to its
purchase of Third Party Materials with the Third Party Materials Payment and the [***] of such Third Party Materials. Such records may be inspected by Amarin in accordance with Section 9.2. 

(d) API Price. The price for API (the “API Price”) shall be as set forth in this Section 4.1(d).

 (i) The API Price for the Technical Batches and Registration/Stability Batches shall be [***]. 

(ii) The API Price for the Commercial Validation Batches shall be [***]. 

(iii) The API Price for the Initial Minimum Purchase Requirement shall be [***]. 

(iv) The API Price for Second Minimum Purchase Requirement, Third Minimum Purchase Requirement, Fourth Minimum Purchase
Requirement and additional quantities of API purchase by Amarin after the purchase of the Minimum Purchase Requirements (“Commercial API”) shall be $[***], as adjusted from time to time in accordance with Section 4.1(d)(vi).

 (v) Prior to the end of each [***], the Parties will meet to (A) discuss Amarin’s projected,
non-binding demand forecast requirements for the next [***], and (B) [***], consistent with the API Price adjustment mechanism set forth in Section 4.1(d)(vi). 

(vi) From time to time, but in no event more than [***] during a [***] (including any adjustment made in accordance with
Section 4.1(d)(v), above), the API Price for the Second Minimum Purchase Requirement, the Third Minimum Purchase Requirement, the Fourth Minimum Purchase Requirement and future Commercial API shall be adjusted by changes in the prices payable
by Equateq for [***]. API Price adjustments made pursuant to this Section 4.1(d)(vi) shall be calculated using the methodology in substantially the same form as set forth in Schedule 4.1(d)(vi) attached hereto (the “API Price
Adjustment Methodology”). A duly authorised officer of Equateq shall provide Amarin with a written certification of any proposed adjustment and, if requested by Amarin, Equateq shall also provide written verification from its auditors of that
certification. Subject to the [***] per [***] limitation, either Party may request in writing the application of the foregoing API Price adjustment to the then-current API Price. The API Price, as adjusted, will become effective for all purchases
made during and after the [***] immediately following the [***] that such adjustment was determined. For the avoidance of doubt, this Section 4.1(d)(vi) does not apply to the API Price for the Initial Minimum Purchase Requirement. 

(vii) Amarin will have the right, during regular business hours and upon reasonable advance notice, to have such books
and records of Equateq which 

  
 13 

 
document any API Price adjustment described in (vi) above, audited by an independent auditor reasonably acceptable to both parties no more than [***] time per [***] so as to verify such API
Price adjustment provided that such auditor shall only be required (and permitted) to disclose whether the API Price adjustment described in (vi) above is correct and consistent with the API Price Adjustment Methodology, and if it is not
correct the amount that such auditor determines is the correct API Price adjustment by reference to (vi) above. Such audit may cover the [***] preceding the date of the request for such audit and may not cover any other [***]; provided,
however that Amarin may exercise its audit right in respect of a given [***]. Such audit right shall continue for [***]. The auditor will undertake pursuant to terms reasonably acceptable to Equateq to keep confidential any information obtained
during such audit. The cost of such audit will be borne by Amarin; however, if as a result of such audit, it is determined that the API Price paid by Amarin during the audited period is greater than or equal to [***] more than the amount it should
have paid during the audited period, the reasonable cost of the audit will be borne by Equateq. Within [***] after both Parties have received a copy of an audit report, Equateq or Amarin, as appropriate, will compensate the other Party for payment
errors or omissions revealed by the audit. 
 (e) Sample Product. Notwithstanding anything to the contrary
in this Section 4.1, Equateq will sell API that is incorporated into Sample Product to Amarin at [***] of the API Price applicable at that time subject to the terms of either Option A, B or C set forth in this Section 4.1(e) with respect
to the time period prior to the [***]. Prior to [***], Amarin shall select either Option A, B or C in writing, which Option shall apply until the [***]. In any case, the quantities purchased in accordance with this Section 4.1(e) shall be in
addition to the applicable Minimum Purchase Requirement, if any, to be purchased by Amarin. This Section 4.1(e) shall terminate upon the early termination of Section 3.7 in accordance with Section 3.7(c). 

OPTION A 
 Such price shall apply for volumes of such purchases up to [***] of [***] made during a [***]. For the avoidance of doubt, the Minimum Purchase Requirements shall not be increased from the quantities set
forth in Section 3.3 if Amarin selects OPTION A. 
 OPTION B 

(i) For time periods associated with the Minimum Purchase Requirements, such price shall apply for volumes of such
purchases up to [***] of the applicable Minimum Purchase Requirement for such time period. 
 (ii) In the event
Amarin selects OPTION B, each of the Initial Minimum Purchase Requirement, Second Minimum Purchase Requirement, Third Minimum Purchase Requirement and Fourth Minimum Purchase Requirement shall be increased by [***] (i.e. the Initial Minimum Purchase
Requirement would be [***], the Second Minimum Purchase Requirement would be [***], and each of the Third Minimum Purchase Requirement and Fourth Minimum Purchase Requirement would be [***]). 

  
 14 

 OPTION C 

(i) For time periods associated with the Minimum Purchase Requirements, such price shall apply for volumes of such
purchases up to [***] of the applicable Minimum Purchase Requirement for such time period. 
 (ii) In the event
Amarin selects OPTION C, each of the Initial Minimum Purchase Requirement, Second Minimum Purchase Requirement Third Minimum Purchase Requirement and Fourth Minimum Purchase Requirement shall be increased by [***] (i.e. the Initial Minimum Purchase
Requirement would be [***], the Second Minimum Purchase Requirement would be [***], and each of the Third Minimum Purchase Requirement and Fourth Minimum Purchase Requirement would be [***]). 

Upon completion of the [***], such price shall apply for volumes of such purchases up to [***] of all purchases made
during a [***]. 
 4.2 Invoices. Equateq shall invoice Amarin for API on the date of shipment and payment will be net
[***] days from the date of receipt of the invoice by Amarin or its designee pursuant to Section 4.5(a). All invoices shall include the following: (i) ‘Invoice’ written on the top of the document, (ii) the date of the
invoice, (iii) the number of the Purchase Order, (iv) an invoice number, (v) the quantity of API, (vi) the total amount being invoiced, and (vii) a reference to this Agreement, and shall be submitted to: 

Amarin Pharmaceuticals Ireland Ltd. 

c/o Amarin Pharma, Inc. 

12 Roosevelt Avenue, 3rd Floor 
 Mystic, CT, USA 06355 
 Facsimile: 860 572-4940 

Attention: Accounts Payable 

Email: [***] 
 4.3 Payment. Payments for API invoiced consistent with Section 4.2 above and except where expressed to the contrary any other payments from Amarin to Equateq or from Equateq to Amarin arising
under this Agreement shall be due [***] from the date of receipt of invoice. If payment of an invoice is not made in full by the due date and such invoice is not being disputed in good faith, the Party issuing the invoice shall, without prejudice to
any other rights or remedies, have the right to: 
 (a) in the case of Equateq as the issuing Party, [***]; 

(b) in the case of Amarin as the issuing Party, [***]; and 
 (c) charge the delinquent Party interest (both before and after any judgment) on the amount unpaid at the rate of [***]. 
 4.4 Payment Denominations. The Initial Payment, Development Fees, Third Party Materials Payment, the API Price, all invoiced amounts and all other payments to be made under this Agreement shall be
in [***]. 

  
 15 

 4.5 Shipment; Title; Transport. 

(a) General. All API shall be shipped [***] (as defined in INCOTERMS 2010). Equateq shall insure each shipment in a
manner reasonably acceptable to Amarin at Amarin’s expense. The Parties shall develop and execute a Shipping Qualification for API that defines API shipping container and method of transportation (the “API Shipping Qualification”).
The API Shipping Qualification must satisfy the Shipping Validation provided that Equateq shall not be obliged to pay any shipment costs in excess of those costs which are necessary for compliance with Equateq’s customary shipping procedures
but both parties will discuss in good faith at Amarin’s request the allocation of any such additional costs. Equateq shall package the API for shipment (including but not limited to containers, packaging, container closure systems and labeling)
in accordance with the API Specifications, the API Shipping Qualification and its customary practices therefore. All shipments of API by Equateq’s shall be processed in accordance with API Shipping Qualification and Equateq standard operating
procedures and otherwise consistent with cGMP practices. Equateq shall include the following with each shipment of the API: (i) the Purchase Order number; (ii) the lot and batch numbers; (iii) the quantity of the API; (iv) the
Certificates, as applicable; and (v) such customs and other export documentation as is necessary or appropriate. 
 (b) Title/Risk of Loss. Title to and risk of loss for any API shall pass from Equateq to Amarin when such API is [***]; provided, however, that nothing in this Article IV shall in any manner limit
Amarin’s rights under Article VI. If API is rejected by Amarin after shipment under this Agreement, and such API is to be returned to Equateq, then title to and risk of loss for such rejected API shall pass from Amarin to Equateq when such API
is [***]. 
 (c) Single Order. To the extent possible, API which is purchased in a single order shall be
shipped by Equateq in a single shipment, unless Amarin directs that such API should be shipped to more than one location. 
 (d) Shelf Life. The API shall have a minimum shelf life of [***] as of the applicable Shipment Date, conditional upon Amarin complying with Equateq’s reasonable recommendations from time to
time to as to the conditions of storage of API by Amarin and in any event with all applicable opinions, policies, guidelines and practices in the pharmaceutical industry for the storage and handling of the API (or equivalents) by Amarin. The minimum
shelf life set forth in the immediately preceding sentence is based on existing stability data. In the event future stability data justifies a longer shelf life, the Parties agree to discuss in good faith an extended minimum shelf life as of the
applicable Shipment Date. Equateq shall ship API to the destination designated by Amarin within [***] of the manufacture date. 

4.6 Taxes. 
 (a) Each Party shall pay and otherwise be responsible for all applicable duties, charges, sales taxes, VAT, goods, services, transfer and other taxes for which it is responsible pursuant to this Agreement
or the Legal Requirements. 
 (b) Any income or other tax that one Party is required by the Legal Requirements to
withhold and pay on behalf of the other Party with respect to amounts payable under this Agreement shall be deducted from said amounts prior to payment to the other Party; provided, however, that in regard to any tax so deducted, the Party making
the withholding shall give or cause to be given to the other Party such assistance as may reasonably be necessary to enable that other Party to claim exemption therefrom or credit therefor, and in each case shall furnish the Party on whose behalf
amounts were withheld, proper evidence of the taxes paid on its behalf. Each Party shall comply with reasonable requests of the other Party to take any proper actions that may minimize any withholding obligation. 

  
 16 

 Article V  
 Manufacture of API 
 5.1 General. Equateq shall manufacture, test,
package, store, handle, label, release and deliver all API in accordance with the applicable Drug Applications, API Specifications, cGMPs, Legal Requirements, this Agreement and the Quality Agreement. 

5.2 API Specification Changes. 
 (a) Amarin Requested Changes. Amarin shall be entitled to change the API Specifications from time to time and, upon consent of Equateq, which shall not be unreasonably withheld or delayed, Equateq
shall make all revisions to the API Specifications requested by Amarin, but reserves the right to adjust the API Price to the extent the changes to the API Specifications cause an increase or decrease in Equateq’s cost of purchase of goods,
manufacture, testing, packaging, storing, handling, releasing and shipping of API; provided, however, that the Parties shall endeavour to agree to any adjustment in API Price using good faith efforts prior to the implementation of revision to the
API Specification and in the absence of such agreement Amarin may either accept the price adjustment as notified by Equateq or retract the request for a revision to the API Specifications. Amarin retains the right and responsibility for final
approval of the API Specifications prior to implementation. Except to the extent Amarin-requested changes are generally applicable to the Facility or Equateq’s manufacture of other products or as otherwise provided in Section 5.2(c) below,
Amarin shall pay Equateq the documented reasonable amounts incurred in implementing a change to the API Specifications requested by Amarin under this Section 5.2(a). For all changes to the API Specifications requested by Amarin pursuant to this
Section 5.2, Amarin shall, in its discretion, either (i) perform, or arrange for the performance of, all development work in connection therewith, or (ii) have Equateq perform such development work at the Facility. For clarity, Amarin
shall not have the right to access Equateq Intellectual Property or the Facility for purposes of performing development work pursuant to (i) in the immediately preceding sentence. At the request of Amarin, Equateq shall evaluate the estimated
costs and timing of potential revisions to the API Specifications. Equateq agrees to use commercially reasonable efforts to minimize its costs associated with any API Specification change. 

(b) Equateq Changes. Equateq shall not make any revisions to (i) the API Specifications, (ii) the
manufacturing process which are likely to impact the process validation or cause a required change to the DMF, or (iii) Third Party Suppliers not approved by Amarin, in each case, without prior written consent of Amarin, such consent not to be
unreasonably withheld or delayed. With respect to revisions to the manufacturing process which are not likely to impact the process validation or cause a required change to the DMF and to Third Party Suppliers that are approved by Amarin, Equateq
shall provide advance written notice. If the Parties implement a change in the API Specifications or the manufacturing process under this Section 5.2, they shall negotiate any changes in any affected Purchase Order to provide reasonable
accommodation for changed circumstances. The costs of revisions requested by Equateq under this Section 5.2(b) shall be borne by Equateq without any increase in the API Price. 

(c) Changes Mandated by Legal Requirements. Notwithstanding anything in subsections (a) and (b) of this
Section 5.2 to the contrary, (i) Equateq shall implement all changes to the API Specifications intended to maintain compliance with Legal Requirements, to bring the API Specifications into compliance with Legal Requirements or to
accommodate the demands or requests of any Governmental Body; and (ii) if such changes are directly applicable to the API or the Product, Amarin shall bear the expense of any of such changes; and (iii) if the changes are generally
applicable to the Facility or Equateq’s manufacture of other products, Equateq shall bear the expense of any of such changes. 

  
 17 

 5.3 Storage and Handling Obligations. When storing and handling API, Third Party
Materials, Nonconforming API, or API-derived wastes, Equateq shall comply with, and shall maintain all storage facilities in compliance with, the API Specifications, cGMPs, and Legal Requirements. 

5.4 Validations and Stability Studies. 
 (a) Process Validation for Improved Manufacturing Processes. Equateq acknowledges that Amarin or Equateq may from time to time pursue strategies and efficiencies for improving the manufacturing
processes for the API. Amarin may propose to implement a manufacturing process improvement that Amarin reasonably believes in good faith will result in a significant cost savings in the manufacture of the API. If the Parties agree to implement such
changes, Equateq will use commercially reasonable efforts to establish and validate as soon as practical such manufacturing process improvement following consultation with and written agreement from Amarin. 

(b) General. Without limiting the foregoing, Equateq shall perform at no additional cost to Amarin on an on-going
basis all stability studies required by the applicable Drug Applications, the API Specifications, cGMPs or Legal Requirements in connection with the regular course of manufacturing the API for commercial supply. 

(c) Duties. In performing its duties under this Section 5.4, Equateq shall perform the following tasks:

 (i) pull, store and analyze data and maintain a database containing applicable information in accordance with
cGMPs and ICH Guidelines; 
 (ii) notify Amarin’s head of regulatory affairs, or his or her designee,
promptly, but within not more than [***] and best efforts to inform within [***], if any batch of API fails any stability tests; 
 (iii) report to Amarin’s head of head of regulatory affairs, or his or her designee, promptly, but within not more than [***] and best efforts to inform within [***], any significant atypical
results, deviations or adverse trends exhibited during testing; and 
 (iv) without limiting the foregoing,
Equateq shall establish a stability program that collects no less than [***] data. Equateq shall consult with Amarin with respect to the details of the stability program, including stability container requirements. 

(d) Product Review Meetings. The Parties will meet regularly for the purpose of reviewing such matters related to
manufacturing of the API, including discussing strategies for improving the API manufacturing processes. 
 5.5 Third Party
Materials. 
 (a) General. Equateq shall be responsible for procuring, inspecting, testing and
releasing adequate Third Party Materials as necessary to meet a Purchase Order. Equateq will obtain Third Party Materials for API produced under this Agreement only from Third Party Suppliers named in the API Specifications and agreed by the
Parties, where applicable, from 

  
 18 

 
Third Party Suppliers who are cGMP-compliant and compliant with all Legal Requirements. Equateq shall perform all testing of Third Party Materials required by the applicable API Specifications,
cGMP, Legal Requirements, this Agreement and the Quality Agreement. For the avoidance of doubt, (i) all Third Party Materials shall comply in all respects with all Legal Requirements, and (ii) Equateq’s Third Party Supplier of crude
starting materials shall only use starting materials from Third Parties that are compliant in all respect with all Legal Requirements. Without limiting any of the foregoing, Equateq shall have in place and shall follow a qualification program for
Third Party Suppliers reasonably acceptable to Amarin. In the event the Parties disagree whether a Third Party Supplier, Third Party Supplies or starting materials used by a Third Party Supplier of crude starting materials are compliant in all
respects with all Legal Requirements, the Parties shall submit the dispute to a Third Party consultant reasonably acceptable to both Parties that is an expert in compliance with the Legal Requirements, including without limitation, cGMP. If the
Parties are unable to agree on a Third Party consultant, each Party shall nominate a Third Party consultant that is an expert in compliance with the Legal Requirements, and those two (2) consultants shall nominate the Third Party consultant who
shall decide the issue. The decision of the Third Party consultant shall be binding on the Parties, absent manifest error. The fees chargeable by the Third Party consultant(s) shall be paid by the non-prevailing Party. 

(b) Audits. Equateq shall be responsible for qualifying all Third Party Suppliers and periodically performing
audits of each Third Party Supplier that provides key Third Party Materials, including as specified by Amarin, to be used in the manufacture of the API and shall provide copies of reports prepared in connection with any such audit within [***] of
the audit’s completion. 
 (c) Materials Certifications. Equateq shall prepare or cause to be
prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements. 
 5.6 Quality Agreement. The Parties shall use commercially reasonable efforts to enter into a Quality Agreement within [***] after the Effective Date (the “Quality Agreement”). In the
event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions of this Agreement shall govern. 
 5.7 Compliance Standards. Equateq is solely responsible for the safety and health of its employees, consultants and visitors and compliance with all Legal Requirements related to health, safety and
the environment, including, without limitation, providing its employees, consultants and visitors with all required information and training concerning any potential hazards involved in the manufacture, packaging, storage and supply of the API and
taking any precautionary measures to protect its employees from any such hazards. Equateq shall ensure that all health, safety and environmental issues are handled by qualified professionals. In addition, Equateq shall comply with all applicable
environmental rules, regulations, and statutes in connection with the disposal of waste generated by Equateq in connection with the manufacture of the API. 
 Article VI  
 Testing and Quality Assurance 

6.1 Quality Assurance; Quality Control; Retains. 

(a) Equateq shall implement and perform operating procedures and controls for sampling, stability, release and other
testing of Third Party Materials and API, and for validation, documentation and release of the API and such other quality assurance and quality control procedures as required by the API Specifications, cGMPs, Legal Requirements, this Agreement and
the Quality Agreement. 

  
 19 

 (b) Equateq shall maintain for a period of time required by Legal
Requirement, but in no event less than [***] after the expiration date of such API such quantities of the API from each batch of the API as are sufficient to conduct [***] testings of the API in accordance with this Agreement. 

6.2 Testing of API. Prior to release of the API, Equateq shall test the API in accordance with the testing procedures described in
the (i) applicable Drug Applications, (ii) API Specifications, (iii) cGMPs, (iv) Legal Requirements, (v) those procedures and in-plant quality control checks applicable to any products manufactured by Equateq, and
(vi) such other methods and procedures as Amarin shall reasonably determine from time to time. Equateq shall provide Amarin with a copy of the records pertaining to such testing if requested subject to the overriding condition that nothing in
this Agreement shall oblige Equateq to disclose its batch records in whole or in part to Amarin; provided, however, that redacted batch records may be reviewed by Amarin as part of any audit subject to and in accordance with Section 9.2.
Additionally, Equateq shall provide Amarin with a Certificate of Analysis and/or any other certificate required by any applicable Governmental Body for release of API (collectively, the “Certificates”) for each batch of API. Amarin shall
be under no obligation to accept any shipment of API without the accompanying Certificates. 
 6.3 Amarin Holds, Rejections
and Revocation of Acceptance. 
 (a) General. Amarin may test or cause to be tested the API in
accordance with Amarin’s customary procedures but in any event forthwith upon receipt of any API. At Amarin’s request, Equateq shall provide appropriate analytical reference standards for such testing to Amarin or its designee. Amarin
shall promptly notify Equateq (i) of Amarin’s placing any API on hold for further investigation of a Nonconformity (as described below in Section 6.4) or reasonably suspected Nonconformity, or (ii) of Amarin’s rejection or
revocation of acceptance of any batch (or part thereof) of any API. Amarin’s notice shall state the basis for the hold, rejection or revocation together with such further information as Equateq may reasonably request. 

(b) Independent Testing. If the Parties disagree as to whether API subject to hold, rejection or revocation is
subject to a Nonconformity, Equateq’s and Amarin’s respective designees shall confer to review samples and/or redacted batch records (redacted subject to and in accordance with Section 9.2), as appropriate. If the disagreement is not
resolved within [***], then samples, such redacted batch records and other data relating to the shipment in dispute shall promptly be submitted for testing and evaluation to a qualified independent Third Party mutually agreed between the Parties
(including a testing laboratory qualified to perform such testing using validated methods) approved in writing by the Parties. The findings of such independent Third Party shall be binding on the Parties, absent manifest error. The expenses incurred
by the Parties for the testing and evaluation by the Third Party shall be borne by Equateq unless Amarin has claimed that the API is subject to (or is suspected of being subject to) a Nonconformity and the API in question is ultimately found not to
be Nonconforming API, in which case the said expenses shall be borne by Amarin. In the event that either Party disagrees with the responsibility for expenses the matter shall be determined by the said independent Third Party. 

(c) Interim Replacement. During the pendency of any dispute concerning whether API is subject to a Nonconformity,
Equateq shall replace the shipment under dispute, at the request of Amarin, subject to Equateq’s capacity limitations, but otherwise the provisions of this Agreement shall apply to such replacement API in all other respects. 

  
 20 

 6.4 Nonconformity. 

(a) Nonconformity. If either Party becomes aware or has a reasonable basis to believe that any shipment of API may
have a Nonconformity, at any time regardless of the status of Equateq’s testing and quality assurance activities, such Party shall notify the other Party in writing within [***] of becoming aware of a Nonconformity. “Nonconformity”
means a product characteristic that (i) results from Equateq’s failure to manufacture, test, package, store, label, release or ship API in accordance with the API Specifications, cGMPs, Legal Requirements, this Agreement or the Quality
Agreement, (ii) causes any API to fail to conform to the API Specifications, cGMPs or Legal Requirements, or (iii) constitutes an adulteration. In the event of a Nonconformity or reasonably suspected Nonconformity, the Parties shall
immediately conduct an investigation in accordance with Section 6.8 below and, until resolution of the investigation, handle the API as provided in Section 6.4(b) below. 

(b) API That May Be Subject to a Nonconformity. Any batch or shipment of API that reasonably may be suspected to be
subject to a Nonconformity shall be handled as follows: 
 (i) Such API held in inventory at Equateq shall be
placed on “Hold” and shall not be shipped to Amarin or its designee, unless directed otherwise by Amarin; 
 (ii) Any such API shipped to Amarin or its designee and held in stock as API or Product by Amarin or its designee shall maintain a “hold” or “unpassed” status, and shall not be
released into passed inventory of Amarin or its designee until the Parties have completed any investigations pursuant to Section 6.8 and Amarin has approved the disposition of the API in writing; and 

(iii) Payment for such API whether shipped or unshipped shall [***]. 

Upon learning of a Nonconformity, Amarin shall have the right to [***]. 

6.5 Quantitative Deficiencies. In the event Amarin determines there is a quantitative deficiency in any shipment, with respect to
the API volumes indicated on the applicable Purchase Order(s), Amarin may: (i) pay only for actual quantities shipped; and (ii) require Equateq to rectify any such deficiency by shipping the appropriate quantities of API to or as directed
by Amarin, in which case Amarin shall be obligated to pay for any such additional quantities pursuant to the terms and conditions of this Agreement. Equateq shall use commercially reasonable efforts to rectify any such deficiency, and shall ship
such additional quantities of API as soon as possible. 
 6.6 Product Complaints. Any and all complaints of which Equateq
becomes aware relating to the Product shall promptly be forwarded to Amarin’s head of regulatory affairs, or his or her designee. Without limiting the foregoing, Equateq shall forward any such complaint that might be associated with an Adverse
Event (as defined in Section 6.7) no later than [***] following its receipt. Amarin shall no later than [***] inform Equateq of any and all complaints that Amarin receives which implicate Equateq’s manufacturing or other processes at the
Facility. Notification shall be given by telephone, with an email or facsimile confirmation immediately following. 
 6.7
Adverse Events. For the purposes of this Agreement, “Adverse Event” shall mean any adverse event associated with the use of the Product in humans, whether or not considered drug-related, including but not limited to “adverse
event” as defined in ICH guidelines. Equateq shall notify Amarin’s head of regulatory affairs, or any successor department specified by Amarin, as soon as possible, but no later than [***] following its receipt, of information concerning a
possible Adverse Event. Notification shall be given by telephone, with a facsimile or email confirmation immediately following. Equateq shall provide to Amarin all the information Equateq has available concerning the

  
 21 

 
Adverse Event and shall cooperate fully with any investigation conducted or directed by Amarin as set forth in Section 6.8 below. Amarin shall within no later than [***] following its
receipt of information concerning a possible Adverse Event inform Equateq of such Adverse Event and shall disclose to Equateq any information Amarin has regarding that Adverse Event, the potential implications for the Product in the market-place and
whether or not such Adverse Event implicates Equateq’s manufacturing or other processes at the Facility. Notification shall be given by telephone, with a facsimile or email confirmation immediately following. 

6.8 Investigations; Equateq’s Obligations. 

(a) General. The Parties shall investigate all reports of Nonconformity, Product complaints and Adverse Events. The
Parties shall act promptly and shall cooperate fully in such investigations. 
 (b) Direction. Amarin
shall have the sole right, in its discretion, to control and direct any or all aspects of an investigation conducted under this Section 6.8. Amarin shall advise Equateq, and to the extent practicable, consult with Equateq in good faith, from
time to time throughout such investigation of Amarin’s intentions regarding control and direction of the investigation. 
 (c) Equateq’s Assistance. Upon written request by Amarin, Equateq shall provide all reasonably requested testing, assistance and information to Amarin in connection with an investigation of
any Nonconformity, Product complaint or Adverse Event, including chemical/microbial analysis of complaint samples (if available), analysis of retained samples and review of batch documentation (redacted subject to and in accordance with
Section 9.2). Equateq shall have the right to conduct at its own expense any further tests it deems appropriate regarding such investigation provided that it shall share the results with Amarin. 

(d) Reporting. Equateq shall provide to Amarin (i) [***], and [***]. Any final report regarding a
Nonconformity shall be submitted by Equateq within thirty (30) Days of the notification regarding that Nonconformity given under Section 6.4 above. Amarin shall provide to Equateq a written report of [***]. Each Party shall hold all
communications related to such investigation, testing or other requested assistance under this Section 6.8 in confidence, and those communications shall be subject to the terms of Article XIII hereof. 

(e) Costs of Investigations. Equateq shall reimburse Amarin for [***] incurred by Amarin in connection with [***]
and in any other event Amarin shall reimburse Equateq for [***] incurred by Equateq in connection with [***]. 
 6.9 Certain
Product Events. 
 (a) Notification and Cooperation. In the event Amarin shall be required (or shall
voluntarily decide) to initiate a recall, withdrawal or field correction of, field alert report or comparable report with respect to, Product, Amarin shall notify Equateq’s authorized quality assurance officer, and Equateq shall fully cooperate
with Amarin to implement the same. 
 (b) Coordination of Efforts. In the event Equateq becomes aware of
information that may warrant Amarin taking any action with respect to any Product, Equateq shall immediately provide the Amarin head of regulatory affairs such information. The Parties shall cooperate with each other in determining the necessity and
nature of such action; provided, however, that Equateq shall take no action to effect the same without the written concurrence of Amarin. 

  
 22 

 (c) Contacts and Statements. With respect to any recall, withdrawal,
field correction, field alert report or comparable report with respect to Product, Amarin or its designee shall make all contacts with the applicable Governmental Body and shall be responsible for coordinating all of the necessary activities in
connection with any such recall, withdrawal, field correction, field alert report or comparable report. Amarin or its designee shall make all statements to the media, including press releases and interviews for publication or broadcast. Equateq
agrees to make no statement to the media, unless otherwise required by law and in any such event, Equateq shall collaborate with Amarin on the content of any such statement. 

(d) Remedies. If any recall, withdrawal, field correction, field alert report or comparable report with respect to
any Product is initiated because of Nonconforming API, or due to any negligence, recklessness or wrongful intentional acts or omissions by, or strict liability of, or breach of representation or warranty by, Equateq, then Amarin shall, in addition
to any other remedies available to it, be entitled to handle the affected Product and charges relating thereto as provided in Sections 6.10 and 6.11 below. 
 (e) Other Notice. Notwithstanding anything herein, Equateq agrees to notify Amarin as promptly as possible of any incident it becomes aware of pertaining to the Product or API that would require
notification to any Governmental Body, including but not limited to, fire, explosion, environmental event, serious injury or physical damage. 
 6.10 Disposition of Certain API. In the event that (i) any quantity of API is found to be Nonconforming API or (ii) any recall, withdrawal, field correction, field alert report or
comparable report or Third Party return of any Product is initiated because of Nonconforming API or due to any negligence, recklessness or wrongful intentional acts or omissions by, or strict liability of, or breach of representation or warranty by,
Equateq, then Amarin may, at Amarin’s discretion: [***]. In connection with the destruction of API or Product incorporating the Nonconforming API, Equateq shall be solely responsible for [***]. Equateq shall use best efforts to perform any
rework, reprocessing and replacement of affected API on a priority basis, and shall ship such reworked, reprocessed or replacement API as soon as possible. 
 6.11 Credits/Reimbursement. In the event that Equateq is obligated to Amarin pursuant to Section 6.10, Equateq shall, at Amarin’s discretion, reimburse or credit Amarin for [***]. Amarin
shall provide Equateq with such documentation as Equateq may reasonably request to confirm any of the foregoing charges, costs or expenses. If there is outstanding credit to Amarin on the termination of this Agreement, Equateq shall reimburse Amarin
for the amount of such credit within [***] after this Agreement is terminated. 
 Article VII  

Regulatory Matters 
 7.1 Consents. Equateq shall obtain and hold all Consents required for the performance of its obligations under this Agreement. At all times, Equateq shall maintain and comply with all the Consents
which may from time to time be required by any Governmental Body having jurisdiction with respect to Equateq’s manufacturing operations and facilities and otherwise to be obtained by Equateq to permit the performance of its then current
obligations under this Agreement. Equateq shall bear all expenses incurred in connection with its obligations under this Section 7.1. In the event any Consent held by Equateq relating to the Facility or its ability to manufacture the API in
accordance with this Agreement is hereafter suspended or revoked, or Equateq has material restrictions imposed upon it by any Governmental Body affecting the API or the Facility, Equateq shall immediately provide written notification to Amarin
identifying such material restrictions, a schedule of compliance and such other information related thereto as is reasonably requested by Amarin. Without limiting the foregoing, Equateq will use best efforts to cooperate with Amarin in a reasonable
and timely manner in preparation for pre-approval inspection of API manufacture at the Facility by any Governmental Body. 

  
 23 

 7.2 Compliance. In carrying out their respective obligations under this Agreement,
the Parties shall comply in all respects with cGMPs, Legal Requirements, and the highest industry standards, as applicable to such Party, in effect from time to time. 
 7.3 Drug Application Documentation. Upon reasonable request from Equateq, Amarin shall provide Equateq with information regarding Drug Applications, or discrete sections thereof, to the extent
available and necessary for Equateq, or as reasonably requested by Equateq, to perform its obligations under this Agreement; provided, however, that information provided hereunder shall not be provided or disclosed to any other party without
Amarin’s prior consent. In the event that any Governmental Body makes an inquiry of or provides any information to Equateq that is or may be related to a Drug Application, Equateq shall promptly forward such inquiry or information to Amarin.

 7.4 DMFs. Equateq shall file and maintain the Drug Master Files for API in jurisdictions designated by Amarin from
time to time (the “DMFs”). Amarin shall [***]. Equateq hereby grants to Amarin the right to reference the DMFs and any other filings held in Equateq’s name in any relevant Drug Application or other documentation to the extent such
reference is necessary or useful for the approval and maintenance of a Drug Application. 
 7.5 Regulatory Changes. The
Parties will promptly notify each other of any material revisions, amendment of or additions to the DMFs and cGMPs and will confer with each other with respect to the best means to comply with such requirements. 

7.6 Regulatory Inspections. 
 (a) Procedures. If Equateq is notified that API or the portion of the Facility relating to the supply of API will be subject to an inspection by any Governmental Body, Equateq shall: 

(i) Immediately advise Amarin’s head of regulatory affairs, or his or her designee, by telephone and facsimile and
provide all relevant information known to Equateq regarding such investigation; 
 (ii) Fully cooperate with and
allow any such inspection to the extent required by Legal Requirements; 
 (iii) To the extent permitted by Legal
Requirements, all inquiries related to API, Product, any Drug Application or Amarin’s Confidential Information covered by Article XIII of this Agreement shall be directed to Amarin, and Amarin and its licensees shall have the right to be
present at any inspection involving the API; 
 (iv) Promptly send Amarin a copy of any inspection report
observations issued by any Governmental Body related to the manufacture, generation, processing, storage, transportation, distribution, treatment, disposal or other management of API or Third Party Materials as well as responses to any inspection
reports prepared in accordance with this Section 7.6; and 
 (v) Respond to all inspection report
observations by any Governmental Body in a timely manner and take all appropriate corrective actions required or recommended by such Governmental Body. 

  
 24 

 Notwithstanding the foregoing provisions of this Section 7.6(a), nothing shall require
Equateq to disclose information to Amarin specifically relating to any other customer of Equateq or those customer’s products to which the inspection relates. 

(b) Notification. If any Governmental Body shall take any action which shall require a response or action by
Equateq with respect to API, Product, API Specifications, Third Party Materials, the Facility, or any operating procedure affecting the API, Equateq agrees immediately to notify Amarin of the required response or action and, in the case of API,
Product and/or API Specifications, shall proceed only with the prior advice and written consent of Amarin, which shall not be unreasonably withheld. Notwithstanding anything contained in this Agreement to the contrary, Equateq shall not initiate or
participate in any communications with any Governmental Body concerning the API, Product or the API Specifications unless required to do so by Legal Requirements or requested to do so by Amarin, in each case, only after consultation with Amarin
provided that nothing in this Agreement shall delay or risk prejudice to or add cost to Equateq’s compliance with its Legal Requirements. 
 7.7 Other Regulatory Matters. Equateq shall provide to each Governmental Body and, at Amarin’s request, shall provide to Amarin, all documents and information requested by each such
Governmental Body in support of Equateq’s and Amarin’s regulatory filings, including without limitation, all relevant DMFs, except that nothing in this Agreement shall require Equateq to disclose to Amarin the closed section of any DMFs.
Copies of all documents to be provided to any Governmental Body shall be provided to Amarin at least [***] Days in advance of delivery to such Governmental Body, if possible, or otherwise as soon as practicable thereafter. Equateq may redact from
such deliveries to Amarin any Third Party or Equateq Confidential Information that is not relevant to the API. 
 Article VIII
 
 Intellectual Property 
 8.1 Ownership. 
 (a) Amarin Ownership. Equateq
acknowledges and agrees that, as between Amarin and Equateq, Amarin owns all rights in and to the Amarin Intellectual Property, including all Intellectual Property rights in and to the Product, the Drug Applications, the Amarin Data and
documentation, specifications and processes associated with the Product, except for the Equateq Intellectual Property. 
 (b) Equateq Ownership. Amarin acknowledges and agrees that Equateq owns all rights in and to the Equateq Data and Equateq Intellectual Property, including all Intellectual Property in and to the
API supplied by Equateq. 
 (c) For avoidance of doubt, and notwithstanding anything in this Agreement to the
contrary, nothing herein shall be construed as preventing Amarin from filing for Intellectual Property protection relating to the Product including, without limitation, combination products involving the Product, inventions relating the package
insert or labeling associated with the Product, or new methods of treatment utilizing the Product, and Amarin shall own all such Intellectual Property provided in each case that such protection does not comprise Equateq Intellectual Property or
Equateq Data. 
 8.2 Infringement. Amarin shall promptly notify Equateq of any suspected or threatened
infringement, misappropriation or other unauthorized use of Equateq Intellectual Property licensed by Equateq to Amarin under this Agreement that comes to Amarin’s attention. Amarin shall provide to Equateq all information and assistance in
relation thereto, including making witnesses available and providing copy documentation, as Equateq shall reasonably 

  
 25 

 
request and at Equateq’s cost. Equateq shall have the sole right, but not the obligation, to institute, prosecute and control, at its expense, any action or proceeding against the Third
Party infringer of such Equateq Intellectual Property licensed hereunder. 
 8.3 Data. As between Equateq and Amarin,
Amarin shall be and remain the sole and exclusive owner of any and all Amarin Data and Equateq shall be and remain the sole and exclusive owner of any and all Equateq Data. For the avoidance of doubt and subject to limitations in respect of batch
records in accordance with Section 9.2, Amarin shall have access to and shall be entitled to use any Equateq Data reasonably necessary for Amarin to comply with all Legal Requirements. 

8.4 Amarin License. Equateq hereby grants Amarin a [***] license under the Equateq Intellectual Property to [***] Product using
API supplied by Equateq. This license shall terminate upon the later of (i) the expiration or termination of this Agreement or (ii) such time that Amarin is no longer in possession of [***]. 

Article IX  

Information; Access; Audit Rights 
 9.1 Provision of Information. 
 (a) Data. Equateq
shall provide to Amarin copies (in electronic or hard-copy form, as requested by Amarin) of or access to all Equateq Data and any other information or data generated during the Term of this Agreement as may be requested from time to time by Amarin.
Equateq shall provide final reports for batch failures, including recommendation for API disposition for all investigations involving (i) foreign matter or particulate contamination; or (ii) any test results indicating non-compliance with
the applicable Drug Applications, cGMP, compendial requirements or the API Specifications. 
 (b) Annual
Report. Equateq shall prepare and provide to Amarin a written annual report no later than each [***] documenting [***]. For the avoidance of doubt, except with respect to access during audits performed pursuant to Section 9.2, nothing in
this Agreement shall oblige Equateq to show its batch records to Amarin. 
 9.2 Audit and Inspection Rights. During the
Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Amarin representatives (collectively, “Audit Representatives”) shall have the right, in Amarin’s discretion but not more
than on [***] in any [***], to audit and inspect those portions of the Facility (or the facility of a Third Party Supplier or Subcontractor, as the case may be) used in, and documents and records related to, the manufacture, generation, storage,
testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Notwithstanding the foregoing, Amarin may perform additional “for cause” audits during a [***] to the extent
Equateq supplies Nonconforming API or in the event of Product complaints or Adverse Events cause by Nonconforming API. Equateq may redact from such documents and Third Party or Equateq Confidential Information that is not relevant to the supply of
API to Amarin and specifically Equateq may redact Equateq Confidential Information from batch records and provide view-only access to such redacted records provided that the Audit Representatives can nevertheless reasonably complete such audits to
its reasonable satisfaction, and such redaction does not prevent Amarin from compliance with its Legal Requirements. Audit Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the
Facility (or the facility of a Third Party Supplier or Subcontractor, as the case may be). Equateq agrees to cooperate and assist Amarin (and to require any Third Party Supplier or Subcontractor to cooperate and assist Amarin) in connection with any
audits or inspections pursuant to this Section 9.2 provided that Equateq shall not be obliged to interrupt its business operations and Amarin shall procure that its Audit Representative shall not disrupt Equateq’s business operations in
the conduct of such 

  
 26 

 
audits or inspections. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Audit Representatives at least [***] in advance; provided,
however, that in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of Equateq or a Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third
Party Materials, Audit Representatives shall have the right at any time, upon written notice to Equateq (or any Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the
facility of such Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.
Equateq shall have the benefit of equivalent arrangements in any contract with Third Party Suppliers so as to ensure that Audit Representatives have access to Third Party Supplier’s and Subcontractor’s facilities in the manner set forth in
this Section 9.2. Without limiting the generality of the foregoing, Amarin or a third party consultant acceptable to both Parties shall have the right to conduct a mock inspection of the Facility and to request potential corrective actions in
advance of any regulatory authority’s pre-approval inspection(s) for cGMP compliance. Amarin shall be entitled to review the results of such pre-approval inspection if performed by a third party consultant. Equateq shall promptly take any
corrective action reasonably requested by Amarin in connection with this Section 9.2, including corrective action requested as a result of the mock pre-approval inspection. 

9.3 Record Retention. Each Party shall maintain, in accordance with and for the period required under the applicable Drug
Application, cGMPs, and Legal Requirements, complete and adequate records pertaining to all activities in connection with, and facilities used for, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution, or
other handling or receiving of the API or Third Party Materials. 
 9.4 Amarin Representative. Equateq shall provide
reasonable cooperation to any employee or other representative of Amarin in the exercise of Amarin’s audit, inspection and other rights arising under this Agreement. 
 Article X  
 Representations and Warranties 

10.1 Representations and Warranties of Equateq. Equateq represents and warrants that: 

(a) Compliance. The manufacture, generation, processing, distribution, transport, treatment, storage, disposal and
other handling of any Third Party Materials and API by Equateq shall be in accordance with and conform to the API Specifications, cGMPs, all Legal Requirements, this Agreement and the Quality Agreement. The API shall comply with the applicable Drug
Applications, cGMPs, API Specifications and Legal Requirements; shall be free from defects in materials and workmanship; and shall not be adulterated or misbranded within the meaning of applicable Legal Requirements. 

(b) Status; Enforceability. Equateq is a validly existing corporation in good standing under the laws of the
jurisdiction of its incorporation; the execution, delivery and performance of this Agreement by Equateq has been duly authorized by all requisite corporate action; this Agreement constitutes a legal, valid and binding obligation of Equateq,
enforceable against Equateq in accordance with the terms hereof; and the execution, delivery and performance of this Agreement by Equateq will not violate or conflict with any other agreement or instrument to which Equateq is a party. 

(c) Ability to Perform under the Agreement. Equateq has allocated and will allocate equipment, production lines,
staffing, physical space and other resources sufficient to 

  
 27 

 
manufacture the quantities of API required by Amarin pursuant to this Agreement. Equateq shall ensure that the API and the services under this Agreement are performed in a competent,
professional, workmanlike and timely manner by qualified personnel in conformance with cGMP, Legal Requirements, the standard of care usually and reasonably expected in the performance of such services, the Quality Agreement, this Agreement and the
applicable Purchase Order. 
 (d) Persons. Equateq has not used, and will not use, in any capacity
associated with or related to the manufacture of the API, the services of any Persons who have been, or are in the process of being, (i) debarred under 21 U.S.C. § 335a(a) or (b) or any comparable Legal Requirements, or
(ii) excluded from participation in the Medicare program, any state Medicaid program or any other health care program. Furthermore, neither Equateq nor any of its officers, employees, or consultants has been convicted of an offense under
(x) either a federal or state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval or suspension, (y) any other law cited in any comparable Legal Requirements as a ground for debarment, denial of
approval or suspension. Equateq shall notify Amarin immediately upon learning of any circumstance that would cause this certification under this Section 10.1(d) to become false or inaccurate. 

(e) Regulatory Consents. Equateq has all Consents necessary to perform its obligations hereunder and to manufacture
the API. 
 (f) Maintenance of Facility. During the Term of this Agreement, Equateq shall maintain the
Facility, the equipment used to manufacture the API, Equateq Intellectual Property, and any applicable contracts necessary to manufacture the API in accordance with the API Specifications, Legal Requirements, cGMPs, the Quality Agreement and
Equateq’s standard operating procedures. 
 (h) Negative Pledge. Equateq shall not pledge or
otherwise transfer, without Amarin’s prior written consent, any work-in-process or finished goods inventory of API for supply to Amarin, other than to Amarin as expressly provided in this Agreement. The transfer of the API by Equateq to Amarin
is and shall be rightful and free and clear of any liens or encumbrances. 
 (i) Security Measures.
Equateq shall maintain reasonable security policies at the Facility and shall use commercially reasonable efforts to have security measures in place to protect the integrity of the API, Third Party Materials, Data and works-in-process at the
Facility. 
 (j) Non-infringement. To Equateq’s best knowledge, Equateq’s performance of its
obligations under this Agreement will not infringe upon, nor cause Amarin’s use of the API to infringe upon, the Intellectual Property rights of any Third Party. 
 10.2 Representations and Warranties of Amarin. Amarin represents and warrants that: 
 (a) it is a validly existing corporation in good standing under the laws of the jurisdiction of its incorporation; the execution, delivery and performance of this Agreement by Amarin has been duly
authorized by all requisite corporate action; this Agreement constitutes the legal, valid and binding obligation of Amarin, enforceable against Amarin in accordance with the terms hereof; and the execution, delivery and performance of this Agreement
by Amarin will not violate or conflict with any other agreement or instrument to which Amarin is a party; 

  
 28 

 (b) to Amarin’s best knowledge Equateq’s performance of its
obligations under this Agreement and Amarin’s manufacture, distribution, sale or other supply of the Product incorporating the API will not infringe upon the Intellectual Property rights of any Third Party. 

10.3 Disclaimer. OTHER THAN AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTIES, EITHER EXPRESS OR
IMPLIED, AND THE PARTIES EXPRESSLY DISCLAIM ALL IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NONINFRINGEMENT. 

Article XI  

Liability and Indemnification 
 11.1 Indemnity by Equateq. Equateq shall defend, indemnify, and hold harmless Amarin and Amarin’s Affiliates and licensees and distributors and its and their respective directors, officers,
employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with any of Equateq’s covenants, agreements, obligations, representations or warranties
under this Agreement or the terms of this Agreement; (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or strict liability of, Equateq or Equateq Affiliates, their respective directors, officers,
employees, agents or Subcontractors; or (c) Equateq Intellectual Property infringing upon the intellectual property or proprietary rights of any Third Party within Europe or North America. 

11.2 Indemnity by Amarin. Amarin shall defend, indemnify, and hold harmless Equateq and Equateq’s Third Party Suppliers,
Subcontractors, Affiliates and its and their respective directors, officers, employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with any of
Amarin’s covenants, agreements, obligations, representations or warranties under this Agreement or the terms of this Agreement; or (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or strict
liability of, Amarin or Amarin Affiliates, their respective directors, officers, employees, agents or contractors; or (c) Amarin Intellectual Property infringing upon the intellectual property or proprietary rights of any Third Party within
Europe or North America. 
 11.3 Procedures. Any person that may be entitled to indemnification under this Agreement (an
“Indemnified Party”) shall give written notice to the Person obligated to indemnify it (an “Indemnifying Party”) with reasonable promptness upon becoming aware of any claim or other facts upon which a claim for indemnification
will be based. The notice shall set forth such information with respect thereto as is then reasonably available to the Indemnified Party. The Indemnifying Party shall have the right to undertake the defense of any such claim with counsel reasonably
satisfactory to the Indemnified Party and the Indemnified Party shall cooperate in such defense and make available all records, materials and witnesses reasonably requested by the Indemnifying Party at the Indemnifying Party’s expense. If the
Indemnifying Party shall have assumed the defense of the claim with counsel reasonably satisfactory to the Indemnified Party, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by the
Indemnified Party in connection with the defense thereof. The Indemnifying Party shall not be liable for any claim settled without its consent, which consent shall not be unreasonably withheld. The Indemnifying Party shall obtain the written consent
of the Indemnified Party, which shall not be unreasonably withheld, prior to ceasing to defend, settling or otherwise disposing of any claim if as a result thereof the Indemnified Party would become subject to injunctive or other equitable relief or
if the Indemnified Party may reasonably object to such disposition of such claim based on a continuing adverse effect on the Indemnified Party. 
 11.4 Limitation. Except for liability for fraud, gross negligence, willful misconduct or for any liability which cannot be excluded by law, each Party’s liability whether in respect of Losses
or 

  
 29 

 
otherwise under or pursuant to this Agreement and whether in contract, negligence or howsoever arising shall be limited per occurrence and in aggregate to an amount equal to, (i) for causes
of action accruing prior to the completion of the purchase of the Second Minimum Purchase Requirement, [***], and (ii) for causes of action accruing after the completion of purchase of the Second Minimum Purchase Requirement, the greater of
(A) [***] and (B) [***]. 
 11.5 No Special Damages. Notwithstanding anything to the contrary contained herein,
except as expressly set forth herein and with respect to breaches of confidentiality obligations, fraud, gross negligence, willful misconduct, and indemnification obligations related to Third Party claims, the Parties shall not be liable to each
other for any special, indirect, incidental or consequential damages (including for lost profits). 
 Article XII 

 Insurance 
 12.1 Coverage Requirements. Equateq shall maintain in full force and effect during the Term of this Agreement and for a period of [***] after expiration or termination of this Agreement,
worker’s compensation, property, general liability, and product liability insurance coverage in such amounts and with such scope of coverages as are adequate to cover Equateq’s obligations under this Agreement and as are customary in the
industry for companies of like size and activities and taking into account the nature of the API to be manufactured under this Agreement. Without limiting any of the foregoing, (i) Equateq’s product liability insurance coverage limits
shall be no less than [***] per occurrence and in the aggregate; (ii) such insurance shall include coverage for [***]; and (iii) such policy(ies) shall include [***]. Equateq shall name Amarin as an additional insured upon any of its
insurance polices required by this Section 12.1. Equateq shall provide evidence of such insurance to Amarin and ensure that Amarin will receive no less than [***] notice of any cancellation, non-renewal or material change in the policy(ies).

 Article XIII  
 Confidentiality 
 13.1 Definition of “Amarin Confidential
Information”. As used herein, the term “Amarin Confidential Information” shall mean all confidential business and technical communications, documents and other information, whether in written, oral or other form, which Amarin or
an Amarin Affiliate furnishes or discloses to Equateq or which Equateq otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to Amarin, an Amarin Affiliate or any Third Party for which Amarin has an
obligation of confidentiality), including the API Specifications and the terms of this Agreement and any information disclosed prior to the Effective Date. Equateq represents and warrants that prior to the Effective Date, it has not used or
disclosed to any Third Party any Amarin Confidential Information, except as would be permitted hereunder. 
 13.2 Definition
of “Equateq Confidential Information”. As used herein, the term “Equateq Confidential Information” shall mean (i) all confidential business information, and (ii) technical communications, documents or other
information, in each case not constituting Amarin Intellectual Property or Amarin Data, whether in written, oral or other form, of Equateq or a Equateq Affiliate that are disclosed to Amarin by Equateq or a Equateq Affiliate or Amarin otherwise
learns in connection with the negotiation or performance of this Agreement. Amarin agrees that the provisions of this Agreement shall apply to all Equateq Confidential Information disclosed by Equateq or any Equateq Affiliate or learned by Amarin
prior to the Effective Date. 

  
 30 

 13.3 Treatment of Confidential Information. Both during the Term of this Agreement
and thereafter, Amarin Confidential Information and Equateq Confidential Information (collectively for this Section 13.3 “Confidential Information”) shall be treated in accordance with the requirements of this Article XIII.

 (a) Nondisclosure and Non-Use. A Party receiving Confidential Information of the other Party shall
(i) maintain in confidence such Confidential Information to the same extent such Party maintains its own proprietary information of similar kind and value (but at a minimum each Party shall use commercially reasonable efforts to maintain
Confidential Information in confidence); (ii) not disclose such Confidential Information to any Third Party without prior written consent of the disclosing Party, except, in the case of Equateq, for disclosures as necessary to Third Party
Suppliers and Subcontractors and, in the case of Amarin, for disclosures to Amarin’s licensees and commercial partners for the Product and in all such cases who agree to be bound by obligations of non-disclosure and non-use at least as
stringent as those contained in this Article XIII; and (iii) not use such Confidential Information for any purpose except those purposes permitted by this Agreement. 

(b) Exceptions. Notwithstanding any other provision of this Agreement, the receiving Party may disclose
Confidential Information of the disclosing Party to a Third Party: (i) to the extent and to the Persons as required by an applicable law, rule, regulation, legal process or court order, or an applicable disclosure requirement of any
Governmental Body, the U.S. Securities and Exchange Commission, the Nasdaq market or any other securities exchange or market; or (ii) to the extent necessary to exercise the rights granted to the receiving Party under this Agreement in filing
or prosecuting patent applications, prosecuting or defending litigation or otherwise establishing rights or enforcing obligations under this Agreement, or conducting clinical trials or seeking regulatory approval of the Product; provided, however,
that the receiving Party shall first have given prompt notice to the disclosing Party to enable the disclosing Party to seek any available exemptions from or limitations on any applicable disclosure requirement and shall reasonably cooperate in such
efforts by the disclosing Party. Without prejudice to the protection of Equateq Confidential Information, Equateq shall reasonably cooperate with Amarin in providing prospective commercial partners with access to the Facility during normal business
hours and allowing the prospective partners to perform reasonable due diligence related to the manufacture and supply of API hereunder. 
 (c) Terms of Agreement. The Parties agree that the existence of and the material terms of this Agreement shall be considered Confidential Information of both Parties, subject to the special
authorized disclosure provisions set forth below in this Section 13.3(c) (in lieu of the authorized disclosure provisions set forth in Section 13.3(b), to the extent of any conflict) and without limiting the generality of the definition of
Confidential Information set forth in Sections 13.1 and 13.2. If either Party desires to make a public announcement concerning this Agreement or the terms hereof, such Party shall give reasonable prior advance notice of the proposed text of such
announcement to the other Party for its prior review and approval. A Party shall not be required to seek the permission of the other Party to repeat any information as to the existence and terms of this Agreement that has already been publicly
disclosed by such Party in accordance with the foregoing or by the other Party. Equateq may disclose terms of this Agreement as may be reasonably necessary to Third Party Suppliers and Subcontractors for compliance with its obligations and either
Party may disclose the terms of this Agreement to such Party’s existing investors, directors and professional advisors and to potential investors, acquirors or merger partners and their professional advisors and in all such cases who are bound
by written or professional obligations of non-disclosure and non-use that are at least as stringent as those contained in this Article XIII or are customary for such purpose. Equateq acknowledges that Amarin or its Affiliates may be obligated to
file a copy of this Agreement with the SEC with its next quarterly report on Form 10-Q, annual report on Form 10-K or current report on Form 8-K or with any registration statement filed with the SEC pursuant to the Securities Act of 1933, as
amended, and Amarin shall be entitled to make such filings. 

  
 31 

 13.4 Excluded Information. Notwithstanding any provision herein to the contrary, the
requirements of this Article XIII shall not apply to any information of either Party which: 
 (a) at the time of
disclosure hereunder is generally available to the public; 
 (b) after disclosure hereunder becomes generally
available to the public, except through breach of this Article XIII by the receiving Party or its Affiliates; 

(c) was not acquired directly or indirectly from the disclosing Party or its Affiliates and which the receiving Party
lawfully had in its possession prior to disclosure by the disclosing Party without confidentiality, nondisclosure and nonuse obligations; 
 (d) is independently developed by employees or agents of the receiving Party without the use of the Confidential Information of the disclosing Party; or 

(e) becomes available to the receiving Party from a Third Party that is not legally prohibited from disclosing such
Confidential Information, provided such information was not acquired by such Third Party directly or indirectly from the disclosing Party or its Affiliates. 
 13.5 Return of Confidential Information. At any time upon the request of the other Party, to the extent such Confidential Information is not reasonably necessary to enable a Party to perform its
obligations under this Agreement, or upon expiration or termination of this Agreement, the Party receiving Confidential Information will cease its use and, upon request, within [***] either return or destroy (and certify as to such destruction) all
Confidential Information of the other Party, including any copies or other embodiments thereof, except that the receiving Party may retain a copy for archive purposes. The return and/or destruction of such Confidential Information as provided above
shall not relieve the receiving Party of its other obligations under this Article XIII. 
 Article XIV  

Force Majeure Event 
 14.1 General. Neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in
fulfilling or performing any obligation of this Agreement when such failure or delay is due to a Force Majeure Event, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, a “Force Majeure
Event” is defined as: acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; failure of public utilities and similar events which are
beyond the reasonable control of the Party affected. For the avoidance of doubt, the failure of Equateq to timely perform any of its obligations hereunder due to an order, injunction or any other action by a Governmental Body shall not constitute a
Force Majeure Event. In the event of a Force Majeure Event, Amarin or Equateq, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such
notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the extent possible, each Party shall use reasonable efforts to minimize the duration
of any Force Majeure Event. 
 14.2 Termination Due to Event of Force Majeure; Transition. If as a result of the
conditions referred to in Section 14.1, Equateq is unable to fully perform its obligations for a period of [***], Amarin shall have the right to terminate this Agreement upon [***] prior notice to Equateq. 

  
 32 

 Article XV  
 Term; Termination; Remedies 
 15.1 Term. This
Agreement shall commence on the Effective Date and, unless earlier terminated by either Party in accordance with this Article XV, will continue until the eighth (8th) anniversary of the Effective Date (the “Initial Term”). Commencing no later than one (1) year
prior to the expiration of the Initial Term, the Parties shall negotiate in good faith renewal term(s) of the Agreement. The Initial Term together with any renewal term(s) is the “Term.” 

15.2 Termination for Breach. This Agreement may be terminated by either Party in the event of the material breach by the other
Party of the terms and conditions hereof and any infringement by one Party of the Intellectual Property of the other Party shall be considered a material breach; provided, however, the other Party shall first give to the breaching Party written
notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefore. Upon receipt of such notice, the breaching Party shall have sixty (60) Days to respond by curing such breach. If the breaching Party does
not cure such breach within such cure period, then (a) if Amarin is the breaching Party, Equateq shall (i) have the right to terminate this Agreement in whole or in part and (ii) as its sole remedy, subject to Section 15.7,
require Amarin to purchase any quantity of API that is the subject of a Purchase Order submitted by Amarin prior to such termination and other quantities set forth in the binding portion of a [***] Forecast (but not other quantities forecasted in a
[***] Forecast or the Technical Batches, the Registration/Stability Batches, the Commercial Validation Batches or the Minimum Purchase Requirements); or (b) if Equateq is the breaching Party, Amarin (i) shall have the right to terminate
this Agreement, in whole or in part, and as its sole remedy, subject to section 15.8, (ii) Equateq shall pay to Amarin the price payable in excess of the API Price in engaging a Secondary Supplier to supply API not supplied by Equateq prior to
the effective date of termination which API is the subject of a Purchase Order submitted by Amarin prior to such termination and other such quantities set forth in the binding portion of the [***] Forecast (but not other quantities forecasted in a
[***] Forecast or the Technical Batches, the Registration/Stability Batches, the Commercial Validation Batches or the Minimum Purchase Requirements). 
 15.3 Insolvency; Bankruptcy. To the extent permitted by Legal Requirements, each Party will have the right to terminate this Agreement immediately upon notice to the other Party, if any of the
following occurs: (i) such other Party is declared bankrupt or insolvent, (ii) there is an assignment for the benefit of such other Party’s creditors, (iii) a receiver is appointed or there is a voluntary or involuntary petition
filed or an action or proceeding commenced for bankruptcy, reorganization, dissolution or winding up of such other Party that is not dismissed within sixty (60) Days, or (iv) there is a foreclosure or sale of a material part of such other
Party’s assets by or for the benefit of any creditor or governmental agency. 
 15.4 Discontinuance or Suspension of
Product Program. Amarin may terminate this Agreement upon thirty (30) Days written notice to Equateq if Amarin, in its sole and absolute discretion, (i) discontinues or indefinitely suspends the development and/or commercialization of
the Product, or (ii) determines that the Regulatory Approval will not be approved by the FDA. Upon the termination of this Agreement pursuant to this Section 15.4: 

(a) if such termination is prior to Amarin having delivered to Equateq one or more Purchase Orders for the binding portion
of a [***] Forecast after the Commercial Launch Forecast pursuant to Sections 3.4 and 3.5 then Amarin shall as its sole obligation [***] provided, however, that Equateq shall use commercially reasonable efforts to [***]; and 

(b) if such termination is after delivery of any such Purchase Order as referred to in (a) above, then as its sole
obligation Amarin shall [***]. 

  
 33 

 For avoidance of doubt, if Amarin terminates this Agreement pursuant to this Section 15.4, Amarin shall
have no obligation to purchase the quantities set forth in any Purchase Orders, quantities set forth in any binding portion of a [***] Forecast, the Technical Batches, the Registration/Stability Batches, the Commercial Validation Batches or the
Minimum Purchase Requirements. 
 15.5 Termination by Amarin. Without limiting any other Section of this Article XV,
Amarin may terminate this Agreement upon written notice to Equateq upon the occurrence of any of the following events: 
 (a) Failure to Validate Expanded Manufacturing Process. Equateq fails to substantially complete the validation of the Expanded Manufacturing Process prior to [***] months after the Effective Date
and provided that Equateq fails to complete or has no reasonable prospect of completing the said validation within [***] Days following notice from Amarin of its intention to terminate. 

(b) Failure to Achieve Acceptance of Pre-Approval Inspection. Equateq receives at any time correspondence from FDA
indicating that the Facility or facility of a Third Party Supplier is not approved for the manufacture of API and Equateq is unable to provide a written strategy and plan to and does in fact remove or otherwise address the FDA’s objections
within [***] days. 
 (c) Failure to Supply Unrelated to Force Majeure. In the event of the continued
failure of Equateq to ship API to Amarin for reasons not associated with a Force Majeure Event, Amarin shall have the right to terminate this Agreement upon [***] Days prior written notice to Equateq. “Continued” for purposes of
determining a continued failure to supply shall be a failure to ship at least [***] of the API required to be shipped over a [***]. 
 (d) Supply of Nonconforming API. 
  

	 	(i)	Equateq ships Nonconforming API intended to be incorporated into Product for commercial sale pursuant to [***] or more Purchase Orders in any [***] period, but for the
avoidance of doubt excluding any API supplied pursuant to Section 3.2 or Section 4.1(e); or 

  

	 	(ii)	Equateq ships Nonconforming API intended to be incorporated into Product for commercial sale pursuant to [***] or more Purchase Orders in each of [***] during the Term,
but for the avoidance of doubt excluding any API supplied pursuant to Section 3.2 or Section 4.1(e). 

 (e) Late Delivery. Equateq ships API intended to be incorporated into Product for commercial sale pursuant to [***] or more Purchase Orders more than [***] Days after the applicable Shipment Date
during any [***] period. 
 (f) Failure to Obtain or Maintain Consents. Equateq fails to obtain, maintain
and comply in all material respects with all Consents required for the performance of its obligations under this Agreement. 
 (g) Change of Control. A Change in Control of Equateq with an Amarin Competitor and provided Amarin gives notice of its termination hereunder within sixty (60) days of receiving written notice
of such Change in Control. 

  
 34 

 15.6 Termination by Equateq. Without limiting any other Section of this Article XV,
Equateq may terminate this Agreement upon written notice to Amarin in the event that: 
 (a) Amarin does not
receive Regulatory Approval for the Product on or before [***]; or 
 (b) [***]. 

15.7 Effect of Termination by Equateq. If Equateq terminates this Agreement pursuant to Sections 15.2, 15.3 or 15.6: 

(a) prior to Amarin having delivered to Equateq [***] then, as Equateq’s sole remedy, Amarin shall [***] provided,
however, that [***]; and 
 (b) after delivery of any such [***] as referred to in (a) above, then as its
sole obligation Amarin shall [***]. 
 15.8 Effect of Termination by Amarin. In the event Amarin terminates this
Agreement pursuant to Sections 14.2, 15.2, 15.3 or 15.5, (i) Amarin shall [***]; and [***] as its sole obligation in relation to termination by Amarin pursuant to Sections 15.2, 15.3 or 15.5, Equateq shall pay to Amarin [***]. 

15.9 For the avoidance of doubt, nothing in this Article XV shall be construed as limiting (i) either Party’s rights or
obligations which are expressed to survive termination of this Agreement, and (ii) either Party’s indemnification rights set forth in Article XI related to Third Party claims. 

Article XVI  
 Miscellaneous 
 16.1 Notices. In addition to the other specific
procedures for notification provided herein, all notices, demands, requests and other communications made hereunder shall be in writing and shall be given by personal delivery or by facsimile or by electronic mail or by internationally recognized
overnight courier (with charges prepaid) and shall be deemed to have been given or made: (i) if personally delivered, on the Day of such delivery; (ii) if sent by facsimile or by electronic mail, on the Day it is sent or, if not sent on a
business day, the next business day; or (iii) if sent by overnight courier, on the business day following the date deposited with such overnight courier service, in each case pending the designation of another address, addressed as follows:

 If to Amarin: 
 Amarin Pharmaceuticals Ireland Ltd. 
 c/o Byrne Wallace; Attention:
[***] 
 2 Grand Canal Square 

Dublin 2 
 Ireland 
 Telephone +353 1 691 5000 

Fax +353 1 691 5010 
 Email: 
 and 

  
 35 

 Amarin Pharmaceuticals Ireland Ltd. 

c/o Amarin Pharma, Inc. 
 Mystic Packer Building, Suite 300 
 12 Roosevelt Avenue 

Mystic, CT 06355 
 USA 
 Attention: Vice President, Corporate Development 

Telephone: +1 860-572-4979 
 Fax: +1 860-572-4940 
 Email: 

With a copy (which shall not constitute notice) to: 

Dan L. O’Korn 
 Smith, Anderson, Blount, Dorsett, Mitchell 
 & Jernigan,
L.L.P. 
 2500 Wachovia Capitol Center 

P.O. Box 2611 
 Raleigh, North Carolina 27602-2611 
 Facsimile: (919) 821-6800

 Email: [***] 
 If to Equateq: 
 Equateq Limited 

Suite 10 Redan House 
 27 Redan Place, London, W2 4SA 

			
	Attention:	 	Adam Kelliher
	Facsimile:	 	+44-20-7727-0517
	Email:	 	[***]

 With a copy (which shall not constitute notice) to: 

Equateq Limited 
 Breasclete, Callanish, 
 Isle of Lewis, HS2 9ED, Scotland

			
	Attention:	 	Annie MacLeod
	Facsimile:	 	+44-1851-621-222
	Email:	 	[***]

 16.2 Independent Contractors. Each Party shall be treated as an independent contractor of the
other. Neither Party shall be deemed to be a co-venturer, partner, employee or a legal representative of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other
Party or incur any charges or expenses for or in the name of the other Party. 
 16.3 Entire Understanding. The Parties
agree, on their own and their respective Affiliates’ behalf, that this Agreement, including Schedules hereto, and any other document identified herein, constitutes the entire agreement between the Parties and their Affiliates relating to the
subject matter hereof, and all prior agreements or arrangements, written or oral, between the Parties and their Affiliates relating to the subject matter hereof are hereby superseded and merged with this Agreement. 

  
 36 

 16.4 Assignment. This Agreement will be binding upon and inure to the benefit of the
Parties, their successors and permitted assigns. Neither Party shall delegate, transfer, convey, assign or pledge this Agreement, in whole or in part, or any of its rights or obligations under this Agreement, without the prior written consent of the
other Party in each instance, and any such action without consent shall be void and have no effect. For the avoidance of doubt a Change of Control of Amarin shall not affect Amarin’s or its successor in interest’s obligations, as
applicable, under or in connection with this Agreement. A Change of Control of Equateq with an Amarin Competitor shall be deemed to be an assignment of this Agreement and such assignment shall be subject to Amarin’s consent. 

16.5 Dispute Resolution. If the Parties fail to resolve any claim, dispute, or controversy of whatever nature arising out of or
relating to this Agreement (other than one relating to the validity, enforceability, infringement or misappropriation of Intellectual Property rights, which shall not be subject to this Section 16.5), the Parties shall refer the dispute, to
their respective officers designated below or such other officers as the Parties may designate in writing from time to time, for attempted resolution by good faith negotiations within [***] after so submitting the dispute. The designated officers
are as follows: 
  

							
	For Amarin:	  	President (or designee)	  	
		  	c/o Amarin Pharma, Inc.	  	
		  	Mystic Packer Building, Suite 300	  	
		  	12 Roosevelt Avenue, 3rd Floor	  	
		  	Mystic, CT 06355	  	
		  	USA	  	
		  	Attention: President	  	
		  	Telephone: +1 860-572-4979	  	
		  	Fax: +1 860-572-4940	  	
			
	For Equateq:	  	Managing Director	  	
		  	c/o Equateq Limited	  	
		  	Suite 10 Redan House	  	
		  	27 Redan Place, London, W2 4SA	  	
		  	Attention:	  	Managing Director	  	
		  	Facsimile:	  	+44-20-7727-0517	  	
		  	Email:	  	[***]	  	

 If such dispute is not resolved by the end of the [***] period, the Parties shall be free to pursue any legal or
equitable remedy available to them. Each Party will bear its own attorneys’ fees and other costs and expenses incurred pursuant to this Section 16.5. For avoidance of doubt, the foregoing shall not prohibit or delay a Party from seeking
appropriate injunctive or other equitable relief. 
 16.6 Subcontractors. Equateq may utilize Subcontractors with
appropriate expertise and experience in the performance of its obligations under this Agreement; provided, however, that Amarin must give its written approval in each instance prior to the use of Subcontractors by Equateq and may require
Subcontractors to agree to conditions consistent with those contained herein. Nothing in this Section 16.6 shall relieve Equateq from any obligation under this Agreement. 
 16.7 Amendment. This Agreement, including any Schedule hereto, may not be amended or modified in any manner except by an instrument in writing signed by a duly authorized officer of each Party.

 16.8 Severability. If and to the extent that any court of competent jurisdiction holds any provision (or any part
thereof) of this Agreement to be invalid or unenforceable, such holding shall in no way affect the validity or enforceability of the remainder of this Agreement, and the invalid or 

  
 37 

 
unenforceable provision shall be fully severed from this Agreement and there shall automatically be added in lieu thereof a provision as similar in terms and intent to such severed provision as
may be legal, valid and enforceable. 
 16.9 Waiver. Any failure of a Party to comply with any obligation, covenant,
agreement or condition herein contained may be expressly waived, in writing only, by the other Party hereto and such waiver shall be effective only in the specific instance and for the specific purpose for which made or given. 

16.10 Survival. Articles I (to the extent required to enforce other surviving rights or obligations), VIII, IX, X, XI, XII,
XIII, XV, XVI and Sections 2.3, 4.2, 4.3, 6.1(b), 6.3 to 6.11 (inclusive), 7.4, 7.6, 7.7 and any other provision which by its terms specifically shall so state, together with any obligations accrued hereunder at the time of termination or
expiration, shall survive the termination or expiration of this Agreement. 
 16.11 Drafting Ambiguities. Each
Party to this Agreement and its counsel have reviewed and revised this Agreement. The rule of construction to the effect that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of this Agreement
or any amendment or Schedules hereto. 
 16.12 Headings; Schedules; Counterparts. 

(a) Headings. The headings of the Sections of this Agreement are for reference purposes only, are not part of this
Agreement and shall not in any way affect the meaning or interpretation of this Agreement. 
 (b)
Schedules. All Schedules and Exhibits delivered pursuant to this Agreement shall be deemed part of this Agreement and incorporated herein by reference, as if fully set forth herein. In the event that any Schedule conflicts with any of the
terms or provisions of this Agreement, the terms and provisions of this Agreement shall prevail. 
 (c)
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. Facsimile signatures shall be treated as
original signatures. 
 16.13 Governing Law. This Agreement and all matters arising out of or relating to this Agreement
shall be governed, construed and enforced in accordance with the laws of the State of New York, USA, without regard to principles of conflicts of law, and the Parties hereby irrevocably consent to the exclusive jurisdiction of the state and federal
courts of the State of New York, USA. Each of the Parties hereby waives and agrees not to assert in any such dispute, to the fullest extent permitted by Legal Requirements, any claim that (i) such Party is not personally subject to the
jurisdiction of such courts, (ii) such Party and such Party’s property is immune from any legal process issued by such courts or (iii) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum.
The Parties agree that the provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply. 
 16.14 Remedies. None of the remedies set forth in this Agreement are intended to be exclusive, and each Party shall have available to it all remedies available under law or in equity or in any
other agreement between the Parties. 
 16.15 Injunctive Relief. In the event that either Equateq or Amarin breaches or
threatens to breach any provision of Article VIII or Article XIII of this Agreement, the Parties agree that irreparable harm to the other Party should be presumed and the damages to such Party would probably be very

  
 38 

 
difficult to ascertain and would be inadequate. Accordingly, in the event of such circumstances, each of Equateq and Amarin agree that, in addition to any other right and remedies available at
law or in equity, the other Party shall have the right to seek injunctive relief from any court of competent jurisdiction. 

16.16 Standard Forms. In all communications, Amarin and Equateq may employ their standard forms, but nothing in those forms shall
be construed to be in addition to or modify or amend the terms and conditions of this Agreement, and in the case of any conflict herewith, the terms and conditions of this Agreement shall control. 

16.17 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 16.18
Counterparts. This Agreement may be executed in two counterparts and by facsimile or PDF signature, each of which shall be deemed an original and which together shall constitute one instrument. 

16.19 English Language. The English language version of this Agreement will be controlling on the Parties. All information,
documents, reports, notices, writings and communications to be provided by one Party to the other Party hereunder will be provided in the English language. 
 [Remainder of page intentionally left blank.] 

  
 39 

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be duly executed
as of the date first written above. 
  

			
	AMARIN PHARMACEUTICALS IRELAND LTD.
		
	By:	 	 /s/ Thomas G. Lynch

	Name:	 	 Thomas G. Lynch

	Title:	 	
	
	EQUATEQ LIMITED
		
	By:	 	 /s/ Adam Kelliher

	Name:	 	 Adam Kelliher

	Title:	 	 CEO

 SCHEDULE 2.1 

DRAFT DEVELOPMENT PLAN 
 (to be formalized within [***] from the Effective Date) 
 [***]

  
 41 

 SCHEDULE 2.2 

SUMMARY EXPANSION PLAN 
 [***] 

  
 42 

 SCHEDULE 3.7 

AMARIN COMPETITORS 
 [***] 

  
 43 

 SCHEDULE 4.1(d)(vi) 

API PRICE ADJUSTMENT METHODOLOGY 
 [***] 

  
 44 

 SCHEDULE 5.1 

API SPECIFICATIONS 
 [***] 

  
 45 

 SCHEDULE 6.2 

CERTIFICATE OF ANALYSIS 
 [***] 

  
 46API Commercial Supply Agreement

 Exhibit 10.2 
 CONFIDENTIAL 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND
REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934. 
  
  

 
 API COMMERCIAL SUPPLY
AGREEMENT 
 by and between 
 AMARIN PHARMACEUTICALS IRELAND LTD. 
 and 

CHEMPORT INC. 
 Dated as of May 25, 2011 
  

 
  

 API COMMERCIAL SUPPLY AGREEMENT 

THIS API COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is entered into and dated as of the 25th day of May, 2011 (the
“Effective Date”) by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland
(“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”). Amarin and Chemport are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS

 WHEREAS, Amarin is engaged in the research, development and commercialization of proprietary pharmaceutical products;

 WHEREAS, Chemport is a company that has developed substantial expertise in manufacturing polyunsaturated fatty acids,
including the Compound (as defined herein), for use in nutritional supplement and pharmaceutical products; and 
 WHEREAS, the
Parties desire to enter into a supply agreement pursuant to which Chemport will manufacture a certain active pharmaceutical ingredient for Amarin. 
 NOW, THEREFORE, in consideration of the foregoing recitals, mutual covenants, agreements, representations and warranties contained herein, the Parties hereby agree as follows: 

Article I 

Definitions 
 “Additional Expansions” has the meaning in Section 3.1(a) of this Agreement. 
 “Adverse Event” has the meaning in Section 6.7(a) of this Agreement. 
 “Affiliate” means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as
such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least fifty percent (50%) of the voting securities or capital stock of such entity, or has other comparable
ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity,
as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 
 “Agreement”
means this API Commercial Supply Agreement, including all Schedules hereto. 
 “Amarin” has the meaning in the
preamble of this Agreement. 
 “Amarin Confidential Information” has the meaning provided in Section 13.1 of this
Agreement. 
 “Amarin Intellectual Property” means any and all Intellectual Property relating to the Product (as
defined below) or the development or manufacture thereof that was (a) owned, licensed or controlled by Amarin or Amarin Affiliates as of the Effective Date, or (b) developed or acquired by Amarin or Amarin Affiliates after the Effective
Date. 
 “Amarin License” has the meaning provided in Section 8.3 of this Agreement. 

  
 2 

 “API” means [***]. 

“API Price” has the meaning provided in Section 3.1(a) of this Agreement. 

“API Product Developments” has the meaning provided in Section 8.2(a) of this Agreement. 

“API Specifications” mean all specifications set forth on Schedule 5.1 to this Agreement. 

“Approved Representatives” has the meaning provided in Section 5.4(a) of this Agreement. 

“Calendar Quarter” means each three (3) month period beginning each January 1, April 1, July 1
and October 1 during the Term. The initial Calendar Quarter shall begin on the Effective Date and end on June 30, 2011, and the last Calendar Quarter shall end on the expiration or earlier termination date of the Term. 

“Calendar Year” means each twelve (12) month period beginning each January 1 during the Term. The initial Calendar
Year shall begin on the Effective Date and end on the first December 31 during the Term, and the last Calendar Year shall begin on January 1 of the last year of the Term and end on the expiration or earlier termination date of the Term.

 “Certificate of Analysis” means a document identified as such and provided by Chemport to Amarin in the form set
forth in Schedule 6.2 that (a) sets forth the analytical test results for a specified lot of API shipped to Amarin or its designee hereunder and includes a certified quality control protocol, (b) states that such API is in
conformance with the Drug Application and API Specifications, and (c) states that such API is manufactured in accordance with the API Specifications, Legal Requirements and cGMPs. 

“Certificates” has the meaning provided in Section 6.2 of this Agreement. 

“Change of Control” means any proposed transaction or series of transactions which shall result in (a) any Person other
than a Party having direct or indirect ownership of more than fifty percent (50%) of the voting stock or assets of such Party or an Affiliate that controls such Party by Persons who are not shareholders of such Party or the Affiliate that
controls such Party as of the Effective Date, or (b) the merger of a Party with or into a Third Party in a transaction in which such Party is not the surviving or acquiring Person. 

“Chemport” has the meaning in the preamble of this Agreement. 

“Chemport Approval(s)” means the approval of the Facility as a cGMP facility for the manufacture of the API by the FDA and, as
applicable, by any other applicable Governmental Body having jurisdiction to approve the Facility. 
 “Chemport
Confidential Information” has the meaning provided in Section 13.2 of this Agreement. 
 “Chemport Intellectual
Property” means (a) all Intellectual Property owned, licensed or controlled by Chemport as of the Effective Date, and (b) all Intellectual Property developed or acquired by Chemport after the Effective Date that does not relate to the
Product or the development or manufacture of the Product, except that Intellectual Property developed by Chemport related to the API shall be included in Chemport Intellectual Property. 

“Chemport’s Initial Minimum Capacity” has the meaning provided in Section 4.1 of this Agreement. 

  
 3 

 “Chemport’s Minimum Capacity” has the meaning provided in Section 4.1 of
this Agreement. 
 “CMC” means the chemistry, manufacturing and controls section(s) and data in a Drug Application.

 “Commercial Launch Forecast” has the meaning provided in Section 2.4(a) of this Agreement. 

“Compound” means ethyl ester of eicosapentaenoic acid. 

“Confidential Information” has the meaning provided in Section 13.3 of this Agreement. 

“Consent” means any consent, authorization, permit, certificate, license or approval of, exemption by, or filing or
registration with, any Governmental Body or other Person. 
 “Current Good Manufacturing Practices” or
“cGMPs” means all applicable standards relating to manufacturing practices for intermediates, active pharmaceutical ingredients or finished pharmaceutical products, including without limitation (a) the principles detailed in the U.S.
Current Good Manufacturing Practices, 21 C.F.R. Parts 210 and 211, The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, and Q7A Good Manufacturing Practice Guidance For
Active Pharmaceutical Ingredients (ICH Q7A), and (b) the principles promulgated by any applicable Governmental Body having jurisdiction over the manufacture of the API, in the form of laws, rules or regulations, in each case as in effect at the
Effective Date and as amended, promulgated or accepted by any applicable Governmental Body from time to time during the Term. 

“Days” (whether or not the word is capitalized) means, except where specified otherwise, calendar days. 

“Development and Process Validation Plan” means the development and validation plan to be agreed to by the Parties within [***]
days of the Effective Date. 
 “DMFs” has the meaning provided in Section 7.5 of this Agreement. 

“Drug Application” means a ‘new drug application’ (as such term is used under the United States Federal Food, Drug
and Cosmetic Act) filed with the FDA for the Product, including, without limitation, any supplements thereto, any product license or any equivalent drug application or similar pharmaceutical product approval for the Product administered by any
foreign Governmental Body, or supplement, extension or renewal of any of the foregoing. 
 “Effective Date” has the
meaning in the preamble of this Agreement. 
 “Effective Supply Date” means the date of completion of the Expansion in
accordance with Sections 4.1 and 4.2 of this Agreement. 
 “Expansion” has the meaning set forth in Section 4.1
of this Agreement. 
 “Facility” means Chemport’s manufacturing facility located at [***] (as the same may be
expanded as provided herein), or such other FDA approved facility as agreed in writing by the Parties. 
 “FDA” means
the United States Food and Drug Administration, or any successor agency thereof. 
 “Force Majeure Event” has the
meaning provided in Section 14.1 of this Agreement. 

  
 4 

 “Governmental Body” means any nation or government, any state, province or other
political subdivision thereof, any entity with legal authority to exercise executive, legislative, judicial, regulatory or administrative functions, or any division of the FDA (as applicable) and any other applicable counterpart agency or foreign
equivalent that administers the Legal Requirements. 
 “Indemnified Party” has the meaning provided in
Section 11.3 of this Agreement. 
 “Indemnifying Party” has the meaning provided in Section 11.3 of this
Agreement. 
 “Initial Manufacturing Process” has the meaning provided in Section 5.4(a) of this Agreement.

 “Initial Term” has the meaning provided in Section 15.1 of this Agreement. 

“Intermediate” means a material produced during steps in the synthesis of API that must undergo further molecular change or
processing before it becomes API. 
 “Intellectual Property” means (a) patents, patent rights, provisional patent
applications, patent applications, designs, registered designs, registered design applications, industrial designs, industrial design applications and industrial design registrations, including any and all divisions, continuations,
continuations-in-part, extensions, restorations, substitutions, renewals, registrations, revalidations, reexaminations, reissues or additions, including supplementary certificates of protection, of or to any of the foregoing items;
(b) copyrights, copyright registrations, copyright applications, original works of authorship fixed in any tangible medium of expression, including literary works (including all forms and types of computer software, including all source code,
object code, firmware, development tools, files, records and data, and all documentation related to any of the foregoing), musical, dramatic, pictorial, graphic and sculptured works; (c) trade secrets, technology, developments, discoveries and
improvements, know-how, proprietary rights, formulae, confidential and proprietary information, technical information, techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not
patentable or copyrightable, including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability information and data
which have actual or potential commercial value and are not available in the public domain; (d) trademarks, trademark registrations, trademark applications, service marks, service mark registrations, service mark applications, business marks,
brand names, trade names, trade dress, names, logos and slogans, Internet domain names, and all goodwill associated therewith; and (e) all other intellectual property or proprietary rights worldwide, in each case whether or not subject to
statutory registration or protection. 
 “Legal Requirements” means any and all local, municipal, state, provincial,
federal and international laws, statutes, ordinances, rules or regulations now or hereafter enacted or promulgated by any Governmental Body applicable to the development, approval, manufacture, sale, shipment or licensing of any pharmaceutical
products, ingredients for inclusion therein, or any aspect thereof, and the obligations of Chemport or Amarin, as the context requires, under this Agreement, including, without limitation, applicable laws, statutes, ordinances, rules and regulations
of South Korea, as well as the United States Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder. 
 “Losses” means, collectively, any and all claims, liabilities, damages, losses, costs, expenses, including reasonable fees and disbursements of counsel and any consultants or experts and
expenses of investigation, obligations, liens, assessments, judgments, fines and penalties imposed upon or incurred by an Indemnified Party. 

  
 5 

 “Material Third Party Supplier” means a Third Party Supplier that provides
materials used in the cGMP manufacture, testing or processing of cGMP Intermediate or API. 
 “[***] Forecast” has the
meaning provided in Section 2.4(b) of this Agreement. 
 “Nonconformity” has the meaning provided in
Section 6.4(a) of this Agreement. 
 “Nonconforming API” means API that is subject to a Nonconformity.

 “Party” and “Parties” have the meanings given such terms, respectively, in the preamble of this
Agreement. 
 “Person” means any individual, corporation, company, partnership, trust, incorporated or unincorporated
association, joint venture or other entity of any kind. 
 “Pre-Approval Inspection” means an inspection of
manufacturing operations, records and facilities conducted prior to approval of a new product by the FDA or by any other applicable Governmental Body having jurisdiction to approve the Facility as a cGMP facility for the manufacture of the API.

 “Product” means (a) Amarin’s AMR101 product, and (b) any finished pharmaceutical product of Amarin
that incorporates the API supplied by Chemport pursuant to this Agreement. 
 “Purchase Orders” has the meaning
provided in Section 2.5 of this Agreement. 
 “Quality Agreement” means the agreement identified in
Section 5.6 of this Agreement. 
 “Secondary Supplier” has the meaning set forth in Section 2.5 of this
Agreement. 
 “Second Expansion” has the meaning provided in Section 4.3 of this Agreement. 

“Shipment Date” means the date specified by Amarin in a Purchase Order that Chemport shall ship the API in accordance with this
Agreement. 
 “Subcontractor” means any Third Party that performs any of the activities with respect to the
manufacture and supply of API under this Agreement on Chemport’s behalf. 
 “Term” has the meaning provided in
Section 15.1 of this Agreement. 
 “Third Party” means any Person other than the Parties or their respective
Affiliates. 
 “Third Party Materials” means (a) all raw materials, components, work-in-process and other
ingredients required to manufacture the API, and (b) all packaging materials used in the manufacture, storage and shipment of the API. 
 “Third Party Supplier” means any Third Party that provides to Chemport any Third Party Materials for any API produced under this Agreement. 

“Validation” means a procedure for establishing documentation evidence that a specific system or facility is constructed and
operates according to a predetermined set of specifications, protocols and guidelines. 
 “Validation Batch” has the
meaning provided in Section 4.2 of this Agreement. 

  
 6 

 Article II 
 Sale and Purchase of API 
 2.1 General. 

(a) Development and Process Validation Plan. Subject to the terms and conditions of this Agreement, Chemport agrees
to conduct the Development and Process Validation Plan. 
 (b) Manufacture of API. Subject to the terms
and conditions of this Agreement, Chemport agrees to manufacture API at the Facility for sale to Amarin. Chemport may not manufacture API at locations other than the Facility without the prior written Consent of Amarin, such Consent not to be
unreasonably withheld or delayed and as provided in the Quality Agreement. For the avoidance of doubt, the Parties agree that this Agreement does not obligate Amarin to purchase all of its requirements of the API from Chemport, nor does it obligate
Amarin to purchase any particular volumes of API from Chemport except as expressly set forth herein, nor does it obligate Chemport to sell the API exclusively to Amarin except as set forth in Section 2.3. Amarin retains the right to engage or
appoint additional suppliers and contract manufacturers of the API from time to time in its sole discretion and Chemport retains the right to supply API to Third Party customers and to appoint Third Party distributors of the API from time to time in
its sole discretion. 
 2.2 Minimum Purchase Requirement and Supply of Development Quantities. Amarin agrees to purchase
from Chemport, and Chemport agrees to supply to Amarin, (a) no more than [***] batches (each batch shall be in a quantity of [***], which shall include the quantity of the Validation Batches) of API upon the Validation of the Initial
Manufacturing Process pursuant to the Development and Process Validation Plan, (b) [***] of API annually (or such prorated amount in the case of a partial year) following [***], and (c) [***] of API annually (or such prorated amount in the
case of a partial year) following [***]. From time to time during Chemport’s expansion activities, as may be reasonably necessary, and upon no less than ten (10) days’ advance written notice, Chemport shall deliver to Amarin (at no
cost) quantities of API not to exceed two (2) kilograms for Amarin to evaluate and test. 
 2.3 Limited Exclusivity;
Capacity Allocation. 
 (a) During the Term (i) Chemport shall not export, sell or distribute a [***]
product incorporating Compound having a purity level greater than [***] that [***] for use in [***], (ii) Chemport shall not export, sell or distribute Compound having a purity level greater than [***] to any Third Party that exports, sells or
distributes a [***] product incorporating the Compound that [***] for use in [***], (iii) Chemport shall not export, sell or distribute a [***] product incorporating Compound having a purity level greater than [***] for use in the [***], and
(iv) Chemport shall not export, sell or distribute Compound having a purity level greater than [***] to any Third Party for use in a [***] product in the [***]; provided, however, for the avoidance of doubt, the prohibitions in this
Section 2.3 shall not apply to (A) sales of a generic form of [***], (B) [***] in Chemport’s export, sale or distribution of Compound having a purity level greater than [***] to any Third Party that exports, sells or distributes
a [***] product incorporating the Compound that [***] for use in the [***]; and (C) [***] in Chemport’s export, sale or distribution of Compound having a purity level greater [***] to any Third Party for use in a [***] product in the
[***]. 
 (b) Except as set forth in Section 2.3(a), above, Chemport shall be entitled to maximize its
capacity utilization of the Facility by manufacturing products for Third Parties or itself in addition to the API; provided, however, that if Chemport is expected to be unable to supply all of the API forecast by Amarin and all of the needs of such
other Persons, Chemport shall allocate such Facility capacity on a first priority basis to Amarin. 

  
 7 

 (c) This Section 2.3 shall expire in the event Amarin does not order
the minimum annual quantities set forth in Section 2.2(b) or (c), as applicable, in any Calendar Year. For purposes of determining the quantities ordered by Amarin in a Calendar Year, (i) all quantities subject to Purchase Orders placed in
such Calendar Year, (ii) all quantities of Validation Batches of API purchased pursuant to Section 5.4(a) in such Calendar Year, (iii) all quantities ordered from a Secondary Supplier due to Chemport’s failure to supply API
hereunder in such Calendar Year, and (iv) all quantities ordered from a Secondary Supplier due to a Force Majeure Event in such Calendar Year shall be included in such determination. 

2.4 Forecasts. 
 (a) Not later than [***] following the Effective Date, Amarin shall provide Chemport with a [***], nonbinding forecast of the quantity of API Amarin projects it may purchase from Chemport beginning [***]
prior to the anticipated commercial launch of the Product (the “Commercial Launch Forecast”). Amarin shall submit an updated Commercial Launch Forecast (which shall also be nonbinding) within [***] after [***]. 

(b) Not later than [***] after the [***], Amarin shall, on a [***] basis, provide Chemport with a [***] rolling forecast
of the quantity Amarin intends to order during each [***] (each such forecast referred to herein as a “[***] Forecast”). The forecast amount for the first [***] of the [***] Forecast shall be binding on both Parties. The forecast amounts
for the remaining [***] of each [***] Forecast, i.e., [***], shall be non-binding forecast amounts. Chemport shall not be obligated to supply API in excess of the binding forecast amounts contained in the [***] Forecasts. Notwithstanding anything in
this Agreement to the contrary, (i) in no event shall Chemport be obligated to manufacture during a [***] prior to the Expansion more than its then-existing [***] capacity divided by [***] and (ii) in no event shall Chemport be obligated
to manufacture in [***] following the Expansion more than Chemport’s [***] divided by [***]. 
 2.5 Purchase Orders.
From time to time, Amarin shall deliver to Chemport one (1) or more purchase orders (“Purchase Orders”) for the aggregate API volumes in each binding portion of a [***] Forecast. Each Purchase Order shall specify the volumes of API
ordered, the Shipment Date and the destination for delivery of the API. The Purchase Orders may be delivered electronically or by other means to such location as Chemport shall designate. Chemport shall deliver such API to Amarin’s carrier on
the Shipment Date specified by Amarin; provided, however, that the Shipment Date is no less than [***] after the date of the submission of the Purchase Order. In the event that Chemport shall not be able to deliver API to Amarin’s carrier by
the Shipment Date specified in a Purchase Order, Chemport shall notify Amarin promptly in writing upon discovery of its inability to comply with the terms of this Section 2.5; provided, however, that such notification shall not relieve Chemport
of any liability for failure to deliver API to Amarin’s carrier on such Shipment Date. 
 If Chemport fails to meet the Purchase Order or
any portion thereof on or before the applicable Shipment Date, in addition to other remedies that may be available to Amarin under the Legal Requirements, Amarin may purchase the shortage of such API from Third Parties and Chemport shall pay to
Amarin the difference in price of such API purchased from a Third Party (a “Secondary Supplier”) and the API Price for the API shortage; provided, however, that in no event shall such payment exceed an amount equal to the volume of
shortage times [***] of the then applicable API Price that Chemport is charging to Amarin for API. 

  
 8 

 If Amarin fails to order API in the amount specified in the binding portion of the [***] Forecast, in
addition to other remedies that may be available to Chemport under the Legal Requirements, Amarin shall pay to Chemport [***] of the then current API Price that Chemport is charging to Amarin for API for the volume of API under the binding portion
of the [***] Forecast less the actual amount ordered by Amarin. 
 If Amarin fails to purchase the relevant minimum yearly purchase requirement
as set forth above, in addition to other remedies that may be available to Chemport under the Legal Requirements, Amarin shall pay to Chemport [***] of the then current API Price that Chemport is charging to Amarin for API for the relevant minimum
yearly purchase requirement as set forth above less the actual amount purchased by Amarin in the relevant year. 
 2.6
Accommodations. From time to time, Amarin may deliver to Chemport a Purchase Order for API volumes in excess of those specified in any binding portion of a [***] Forecast. Chemport shall notify Amarin in writing as to whether Chemport is able
to supply the excess volume of API, but shall not otherwise be obligated to supply the excess volume of API. 
 2.7
Meetings. Unless otherwise mutually agreed, the Parties shall meet or otherwise communicate no less than [***] to discuss the progression of the Development and Process Validation Plan, the Expansion, the Second Expansion, the forecasts
delivered by Amarin pursuant to this Agreement and other matters relevant to the supply of API hereunder. The Parties shall use commercially reasonable efforts to accommodate technical meetings requested by both Parties. 

Article III 

Financial Matters 
 3.1 API Price. 
 (a) API Price. Schedule
3.1 to this Agreement sets forth the price for API (the “API Price”) based on (i) the aggregate [***] represented by Purchase Orders in a Calendar Year (such aggregate quantities and associated pricing are delineated in Tier 1 of
Matrix I and Tier 1, 2, 3, 4, 5 and 6 of Matrix II of Schedule 3.1) and (ii) timely completion of the Expansion and/or the Second Expansion (the associated pricing are delineated in Matrices I and II of Schedule 3.1). In the event
Chemport expands the Facility beyond the Second Expansion (“Additional Expansions”), the Parties will negotiate in good faith the price of the API supplied in excess of [***] per year based on a tiered pricing scheme that recognizes
relevant investments, the efficiencies in the manufacturing processes of the expanded Facility and any change in Chemport’s cost of manufacturing API. 
 (b) Calculation. Following Amarin’s first delivery of a [***] Forecast in each [***] during the Term of this Agreement, Amarin shall estimate: 

(i) The aggregate forecast orders for such [***] to estimate whether pricing Tier 1 of Matrix I or Tier 1, 2, 3, 4, 5 or 6
of Matrix II (as set forth in Schedule 3.1) is applicable. 
 (ii) The aggregate [***] subject to the
pricing set forth in Schedule 3.1. Up to [***] shall be subject to Matrix I pricing (as set forth in Schedule 3.1) once the Expansion is completed. In the event Amarin invests in the Second Expansion, up to [***] shall be subject to
Column A of Matrix II pricing (as set forth in Schedule 3.1) once the Second Expansion is completed. In the event Amarin does not invest in the 

  
 9 

 
Second Expansion, up to [***] shall be subject to Column B of Matrix II pricing (as set forth in Schedule 3.1) once the Second Expansion is completed. All other amounts shall be subject to
subsequent negotiation between the Parties. For the avoidance of doubt, the API Prices listed in Schedule 3.1 for quantities in excess of [***] are target prices and are subject to good faith negotiations. Furthermore, in the event the price for
Column B of Tier 1 or Tier 2 of Matrix II (currently marked as “TBD”) becomes necessary, Chemport and Amarin shall negotiate in good faith to reach an agreement on such prices. 

Based on such estimates in (i) and (ii) above, Amarin shall advise Chemport in writing, and provide Chemport supporting
documentation and calculations, of the weighted average API Price under Schedule 3.1. Chemport shall thereafter have the right to review Amarin’s calculation of the weighted average API Price and consult with Amarin with respect thereto.
In the event Chemport does not agree with Amarin’s calculation of the weighted average API Price, the Parties shall use their respective commercially reasonable efforts to agree to the proper calculation of the weighted average API Price. In
the event the Parties are unable to agree within [***], the dispute shall be resolved as provided in Section 16.5. The API Price determined by this subsection (b) shall be the API Price invoiced and paid for Purchase Orders submitted
during such [***] (and retroactively applied to any Purchase Orders delivered in such [***] prior to the determination of such API Price). Such API Price, however, shall be subject to a year-end retroactive adjustment pursuant to subsection
(c) below. 
 (c) Annual Adjustment. Within [***] after each December 31 during the Term of this
Agreement and within [***] following the termination of this Agreement, Chemport will determine: 
 (i) The
aggregate [***] represented by Purchase Orders in the prior Calendar Year to determine whether pricing Tier 1 of Matrix I or Tier 1, 2, 3, 4, 5 or 6 of Matrix II (as set forth in Schedule 3.1) is applicable. Chemport shall include
in such determination the aggregate amount of API, if any, for which Amarin submits a purchase order to a Secondary Supplier in such Calendar Year due to (A) Chemport’s failure to supply API hereunder and/or (B) a Force Majeure Event.
Any Validation Batches of API purchased pursuant to Section 5.4 in such Calendar Year shall also be included. In the case of a partial year, the aggregate [***] represented by Purchase Orders in such prior partial year shall be annualized in
such determination. 
 (ii) The aggregate [***] for the pricing is set forth in Schedule 3.1 based on
(A) timely completion of the Expansion and Amarin’s investment in the Second Expansion and (B) the limits set forth in Section 3.1(b). 
 (iii) The aggregate amounts paid to Chemport under Purchase Orders issued in the prior Calendar Year. 
 Based on such determinations set forth in (i), (ii) and (iii) above, Chemport shall advise Amarin in writing, and provide supporting documentation and calculations, of (A) the weighted
average API Price for such prior Calendar Year, (B) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year, and (C) the difference between (1) the aggregate amounts paid to Chemport
under Purchase Orders issued in the prior Calendar Year and (2) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year. Amarin shall thereafter have the right to review Chemport’s
calculations and consult with Chemport with respect thereto. In the event Amarin does not agree with Chemport’s calculations, the Parties shall use their respective commercially reasonable efforts to

  
 10 

 
agree to the proper calculations. In the event the Parties are unable to agree within thirty (30) days, the dispute shall be resolved as provided in Section 16.5. The API Price for such
prior Calendar Year, the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year, and the difference between (x) the aggregate amounts paid to Chemport under Purchase Orders issued in the prior
Calendar Year and (y) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year determined by this Subsection (c) shall be the final determinations thereof. In the event that (x) the
aggregate amounts paid to Chemport under Purchase Orders issued in the prior Calendar Year are greater than (y) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year, Chemport shall pay Amarin
the difference within [***] of the final determination thereof. In the event that (x) the aggregate amounts paid to Chemport under Purchase Orders issued in the prior Calendar Year are less than (y) the aggregate purchase price for all API
subject to all Purchase Orders issued in the prior Calendar Year, Amarin shall pay Chemport the difference within [***] of the final determination thereof. In addition, the final API Price for the prior Calendar Year determined by this
Subsection (c) shall be the price for API subject to Purchase Orders placed in the prior Calendar Year but not invoiced prior to final determination of the API Price, and Chemport shall invoice such amounts accordingly. 

(d) Packaging. The Parties hereby agree that Chemport shall be responsible for up to [***] of the cost of each
packaging container used for transportation of the API to Amarin. The rest of the cost of each such packaging container shall be borne by Amarin. 
 (e) Price Adjustment. Effective from the [***] anniversary date of the Effective Supply Date, Chemport shall be entitled to make an adjustment to the API Prices listed in Schedule 3.1 in
accordance with the methodology described in Schedule 3.1(e) by giving Amarin written notice of such new API Prices at least [***] prior to the relevant anniversary of the Effective Supply Date. Amarin may request in writing that Chemport
make such an API Price adjustment, if applicable, by providing such written notice at least [***] prior to the relevant anniversary of the Effective Supply Date. If so requested by Amarin, Chemport shall provide Amarin written notice of such new API
Prices, if applicable, at least [***] prior to the relevant anniversary of the Effective Supply Date. Within [***] from the date of receipt of written notice of any API Price change, Amarin may request Chemport to provide its API Price adjustment
records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by Chemport are correct and in accordance with the methodology described in
Schedule 3.1(e). Such certification shall be made in writing on the auditing firm’s letterhead and delivered to Amarin at least [***] prior to the relevant anniversary of the Effective Supply Date. No increase in the API Prices may occur
until the audit has been completed and the price adjustment has been certified as described above. In the event the audit reveals that the increase is appropriate, Amarin shall bear the cost of the audit, and shall pay the increased API Prices for
API in purchase orders from the relevant anniversary of the Effective Supply Date. In the event the audit reveals that the increase is not appropriate, then Chemport shall bear the cost of the audit and the API Prices of API may not increase. The
increase of the API Prices of API shall be deemed accepted by Amarin if Amarin fails to make a timely request for an audit as described above or the requested audit is not completed at least [***] prior to the relevant anniversary of the Effective
Supply Date. 
 3.2 Commercial Invoices. Chemport may invoice Amarin for API on or before the Shipment Date of such API
to Amarin or its designee pursuant to Section 3.5(a). All invoices shall be commercial invoices and shall include the following: (a) ‘Commercial Invoice’ written on the top of the document, (b) the date of the invoice,
(c) the number of the Purchase Order, (d) an invoice number, (e) the quantity of API, (f) the total amount being invoiced, and (g) a reference to this Agreement, and shall be submitted to: 

Amarin Pharmaceuticals Ireland Ltd. 

c/o Amarin Pharma, Inc. 

12 Roosevelt Avenue, 3rd Floor 
 Mystic, CT, USA 06355 
 Facsimile: 860 572-4940 

Attention: Accounts Payable 

Email: [***] 

  
 11 

 3.3 Payment. Payments for API invoiced consistent with Section 3.2 above shall
be due [***] from the date of shipment, subject in each case to Amarin’s right to dispute invoice amounts and/or delay the payment of invoiced amounts disputed by Amarin in good faith, including, without limitation, the rights set forth in
Article VI. 
 3.4 Payment Denominations. The API Price, all invoiced amounts and all payments to be made under this
Agreement shall be in [***]. 
 3.5 Shipment; Title; Transport. 

(a) General. All API shall be shipped [***] (as defined in INCOTERMS® 2010) [***]. Subject to
Section 3.1(d), Chemport shall package the API for shipment (including but not limited to containers, packaging, container closure systems and labeling) in accordance with the API Specifications, Amarin’s reasonable instructions and its
customary practices therefor. In the event of any conflict between Amarin’s packaging instructions and Chemport’s customary practices, the Parties shall endeavor in good faith to resolve such conflict as quickly as practicable. Chemport
shall include the following with each shipment of the API: (i) the Purchase Order number; (ii) the lot and batch numbers; (iii) the quantity of the API; (iv) the Certificates, as applicable; and (v) such customs and other
documentation as is necessary or appropriate. Chemport shall ship API to the destination designated by Amarin within [***] of the manufacture date for Purchase Orders of quantities up to [***] and [***] of the manufacture date for Purchase Orders of
quantities exceeding [***]. 
 (b) Title/Risk of Loss. Title to and risk of loss for
any API shall pass from Chemport to Amarin when such API is [***]; provided, however, that nothing in this Article III shall in any manner limit Amarin’s rights under Article VI. If API is rejected by Amarin after delivery under this Agreement,
and such API is to be returned to Chemport, then title to and risk of loss for such rejected API shall pass from Amarin to Chemport when such API is [***]. All returned API shall be shipped [***] (as defined in INCOTERMS® 2010) [***]. 
 (c) Single Order. To the extent reasonably possible, API which is purchased in a single order shall be delivered by Chemport in a single shipment, unless Amarin directs that such API should be
delivered to more than one location. 
 (d) Shelf Life. The API shall have a minimum shelf life of [***]
as of the applicable date of manufacture. The minimum shelf life set forth in the immediately preceding sentence is based on existing stability data. In the event future stability data justifies a longer shelf life, the Parties agree to discuss in
good faith an extended minimum shelf life as of the applicable date of manufacture. 

  
 12 

 3.6 Taxes. 

(a) Amarin shall pay and otherwise be responsible for all applicable sales, VAT, goods, services, transfer and similar
taxes in connection with the supply of API pursuant to this Agreement, excluding any income tax or taxes levied with respect to gross receipts, payable by Chemport under the Legal Requirements with respect to amounts payable under this Agreement.

 (b) Any tax that one Party is required to withhold and pay on behalf of the other Party with respect to
amounts payable under this Agreement shall be deducted from said amounts prior to payment to the other Party; provided, however, that, in regard to any tax so deducted, the Party making the withholding shall give or cause to be given to the other
Party such assistance as may reasonably be necessary to enable that other Party to claim exemption therefrom or credit therefor and in each case shall furnish the Party on whose behalf amounts were withheld proper evidence of the taxes paid on its
behalf. Each Party shall comply with reasonable requests of the other Party to take any proper actions that may minimize any withholding obligation. 
 Article IV 
 Capacity, Expansion 

4.1 Capacity. Within [***] after the Effective Date, Chemport shall expand the Facility’s capacity to supply annually [***]
of API (with design capacity of [***] annually) as further detailed in Schedule 4.1 (the “Expansion”). In the event that the Expansion is not complete (as described in Section 4.2) within such [***] period, Chemport shall
provide Amarin a written request to extend such period accompanied with a summary of the progression of the Expansion and steps needed to complete the Expansion. Upon submission of such request, Chemport shall have an additional [***] period to
complete the Expansion. Following completion of the Expansion, Chemport shall maintain at all times during the Term the capacity to supply Amarin no less than [***] of API each Calendar Year (“Chemport’s Initial Minimum Capacity”).
Chemport’s capacity as further expanded in accordance with this Agreement, together with Chemport’s Initial Minimum Capacity, shall be referred to herein as “Chemport’s Minimum Capacity.” 

4.2 Completion. The Expansion will be deemed to be completed for purposes of this Agreement if all of the requirements set forth
in Schedule 4.1 have been satisfied and Chemport has manufactured [***] successful, consecutive batches (each batch shall be in a quantity of [***]) of API (each a “Validation Batch”) in the expanded Facility that satisfy the
requirements of this Agreement. 
 4.3 Second Expansion. Upon [***], Chemport will initiate a second expansion of the
Facility to expand the capacity to [***] of API (with a design capacity of [***]) each Calendar Year (the “Second Expansion”), provided, however, the Parties shall mutually agree on the timing and schedule of such expansion activity. The
summary plan for the Second Expansion is set forth in Schedule 4.5, and Chemport shall submit a detailed development and validation plan for the Second Expansion within thirty (30) days of the later to occur of [***] and [***]. The
Second Expansion will be deemed completed for purposes of this Agreement if all the requirements set forth in Schedule 4.5 have been satisfied and Chemport has manufactured [***] successful, consecutive Validation Batches in the expanded
Facility that satisfy the requirements of this Agreement. 
 Article V  

Manufacture of API 
 5.1 General. Chemport shall manufacture, test, package, store, handle, label, release and ship all API in accordance with the applicable Drug Applications, API Specifications, cGMPs, Legal
Requirements, this Agreement and the Quality Agreement. 

  
 13 

 5.2 API Specification Changes. 

(a) Amarin Requested Changes. During the Term, except as set forth in Section 5.2(c), Amarin shall not be entitled to
change the API Specifications related to Chemport’s performance of its obligations hereunder related to API unless it receives the Consent of Chemport, which Consent shall not be unreasonably withheld or delayed. If Amarin requests, and
Chemport approves, a discretionary change to the API Specifications, Chemport shall make all revisions to the API Specifications requested by Amarin. Amarin retains the right and responsibility for final approval of the API Specifications. Amarin
shall pay Chemport all documented reasonable amounts incurred in implementing a change to the API Specifications requested by Amarin under this Section 5.2(a). For all changes to the API Specifications requested by Amarin pursuant to this
Section 5.2, Amarin shall, in its discretion, following consultation with Chemport, if reasonably practicable, either (i) perform, or arrange for the performance of, all development work in connection therewith or (ii) have Chemport
perform such development work at the Facility at Amarin’s expense. For the avoidance of doubt, Section 5.2(a)(i) does not give Amarin any right to use or disclose (A) any Chemport Intellectual Property (except as may be permitted by
any express license from Chemport), or (B) any Chemport Confidential Information (except as may be permitted under Article XIII hereof). Chemport agrees to use commercially reasonable efforts to minimize its costs associated with any API
Specification change. At the request of Amarin, Chemport shall evaluate the estimated costs and timing of potential revisions to the API Specifications.  
 (b) Chemport Changes. Chemport shall not make any revisions to the API Specifications, the manufacturing process or Material Third Party Suppliers, without prior written Consent of Amarin, which
Consent shall not be unreasonably withheld or delayed. If the Parties implement a change in the API Specifications or the manufacturing process under this Section 5.2, they shall negotiate any changes in any affected Purchase Order to provide
reasonable accommodation for changed circumstances. The costs of revisions requested by Chemport under this Section 5.2(b) shall be borne by Chemport without any increase in the API Price. 

(c) Changes Mandated by Legal Requirements. Notwithstanding anything in subsections (a) and (b) of this
Section 5.2 to the contrary, (i) Chemport shall implement all changes to the API Specifications intended to maintain compliance with Legal Requirements, to bring the API Specifications into compliance with Legal Requirements or to
accommodate the demands or requests of any Governmental Body; (ii) unless such changes are generally applicable to the Facility or Chemport’s manufacture of other products, the Parties shall bear equally the expense of any of such changes;
and (iii) if the changes are generally applicable to the Facility or Chemport’s manufacture of other products, Chemport shall bear the expense of any of such changes. Notwithstanding the foregoing, if changes to Legal Requirements
generally affecting manufacturers of drugs containing the Compound significantly increase the cost for Chemport to supply API hereunder, then the Parties agree to negotiate in good faith any appropriate adjustments to this Agreement. 

5.3 Storage and Handling Obligations. When storing and handling API, Third Party Materials, Nonconforming API or API-derived
wastes, Chemport shall comply with, and shall maintain all storage facilities in compliance with, the API Specifications, cGMPs, Legal Requirements and the Quality Agreement. 

  
 14 

 5.4 Validations and Stability Studies. 

(a) Initial Manufacturing Process Validation. Chemport shall as soon as practicable complete the Validation of the
manufacturing process for the API in connection with the Expansion (the “Initial Manufacturing Process”) in accordance with activities set forth in the Development and Process Validation Plan at no additional cost to Amarin. The
Development and Process Validation Plan shall, among other things, include activities necessary to establish the Facility as a cGMP facility, a validation plan and appropriate protocols. Without limiting the foregoing, Chemport will provide process
progress reports to Amarin no less frequently than [***], which reports shall include, without limitation, reasonable details related to construction, equipment installation and process implementation, subject to redaction of any Chemport
Confidential Information. Promptly following completion of Validation of the Initial Manufacturing Process, Chemport shall deliver a final report to Amarin that includes a summary of regulatory data and documentation respecting the manufacture of
the API, without disclosing any confidential process information, all in compliance with applicable FDA guidelines and any other applicable Legal Requirements but subject to redaction of any Chemport Confidential Information. 

(i) The Parties shall participate in project teleconferences with each other as reasonably requested by the other Party to
successfully complete the Validation of the Initial Manufacturing Process. During development and Validation of the Initial Manufacturing Process, Chemport will accommodate in person technical meetings at the Facility and technical inspections as
reasonably requested by Amarin. Without limiting the foregoing, during process development and in support of API process characterization and Validation activities, Amarin will be permitted to conduct reviews of the Facility and the pertinent
records maintained by Chemport, subject to restriction on access to all Chemport Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon Amarin’s request and with reasonable notice to
permit Chemport to support such technical reviews. 
 (ii) In conjunction with the foregoing Validation pursuant
to the Development and Process Validation Plan, Chemport will produce process Validation Batches. Amarin shall be required to purchase Validation Batches of API provided that they comply with the API Specifications and Validation acceptance criteria
and are otherwise in compliance with the terms of this Agreement. The establishment and Validation of the Initial Manufacturing Process shall be deemed to be complete upon the manufacture of such [***] successful, consecutive Validation Batches that
comply with the API Specifications and Validation criteria and are otherwise in compliance with the terms of this Agreement and the Development and Process Validation Plan. 

(iii) With the prior written consent of the other Party, a Party may engage in teleconferences, in-person meetings,
Facility reviews, quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates’) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to
exercise its rights and discharge its obligations under this Agreement, provided that (A) each such employee and consultant has executed a written confidentiality agreement containing use and disclosure restrictions at least as protective as
those set forth in Article XIII, and (B) any Amarin consultant shall be reasonably acceptable to Chemport (such persons, “Approved Representatives”). 

(b) Process Validation for Improved Manufacturing Processes. The Parties acknowledge that Amarin or Chemport may
from time to time desire to pursue strategies and 

  
 15 

 
efficiencies for improving the manufacturing processes for the API. Each Party agrees to reasonably evaluate and discuss any such suggestions for improvements that the other Party reasonably
believes in good faith may result in significant cost or time savings in the manufacturing process. 
 (c)
General. Without limiting the foregoing, Chemport shall perform at no additional cost to Amarin on an on-going basis all Validations and stability studies required by the applicable Drug Applications, the API Specifications, cGMPs or Legal
Requirements in connection with the regular course of manufacturing the API for commercial supply. 
 (d)
Duties. In performing its duties under this Section 5.4, Chemport shall perform the following tasks, consistent with the Quality Agreement: 
 (i) implement and operate an ICH complaint stability program; 

(ii) notify Amarin’s head of regulatory affairs, or his or her designee, promptly, but within not more than [***], if
any batch of API fails any stability tests; and 
 (iii) report to Amarin’s head of regulatory affairs, or
his or her designee, promptly, but within not more than [***], any Nonconformity, significant atypical results, deviations or adverse trends exhibited during final release or stability testing. 

(e) Manufacturing Process Review. At either Party’s reasonable request, the Parties shall promptly meet, in
person or telephonically, for the purpose of reviewing such matters related to manufacturing of the API as may be specified by a Party, including discussing strategies for improving the API manufacturing processes. 

(f) Confidential Information. Notwithstanding anything to the contrary contained in this Agreement, Chemport may
redact or limit from any deliveries of or access to data, reports or any other information to Amarin any Third Party confidential information or Chemport Confidential Information, at Chemport’s sole discretion; provided, however, that Chemport
may not redact or limit any Chemport Confidential Information that is reasonably necessary for Amarin to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether
contained in a DMF or otherwise, shall, subject to Section 13.4, constitute Chemport Confidential Information and shall not be disclosed to Amarin under any circumstances, notwithstanding anything herein to the contrary; provided, however,
Chemport shall provide the relevant Governmental Body with all information necessary to support Amarin’s Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information
provided to Amarin under this Section 5.4 is Chemport Confidential Information and nothing in this Section 5.4 shall be construed as giving Amarin any right to use or disclose (A) any Chemport Intellectual Property (except as may be
permitted by any express license from Chemport), or (B) any Chemport Confidential Information (except as may be permitted under Article XIII hereof). 
 5.5 Third Party Materials. 
 (a) General. Chemport
shall be responsible for procuring, inspecting, testing and releasing adequate Third Party Materials that comply with cGMP and this Agreement as necessary to meet a Purchase Order for API. Chemport shall perform all testing of Third Party Materials
required by the applicable API Specifications, cGMP, Legal Requirements, this Agreement and the Quality Agreement. 

  
 16 

 (b) Audits. Chemport shall be responsible for selecting all Third
Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a). Chemport shall provide the results of any such audit, including copies of
any reports prepared in connection with any such audit, within [***] of the audit’s completion. 
 (c)
Materials Certifications. Chemport shall prepare or cause to be prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements. 

5.6 Quality Agreement. Within [***] following the Effective Date, the Parties shall enter into a quality agreement with such
scope, terms and conditions as are customary within the pharmaceutical industry (such agreement, the “Quality Agreement”). In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions
of this Agreement shall govern. 
 5.7 Compliance with Specifications, cGMPs and Legal Requirements. Chemport shall be
responsible for identifying and implementing, in accordance with its obligations under Section 5.1, any actions required to bring Chemport, Material Third Party Suppliers and Third Party Suppliers of starting materials for the Compound into
compliance with API Specifications, cGMPs and Legal Requirements. Chemport shall implement any such changes as soon as reasonably practicable (even if, in the case of cGMPs and Legal Requirements, a later effective date is specified), unless the
required effective date for implementing such change falls after the effective date of any termination of this Agreement for which notice has been previously given. 
 Article VI 
 Testing and Quality Assurance 

6.1 Quality Assurance; Quality Control; Retains. 

(a) Chemport shall implement and perform operating procedures and controls for sampling, ICH stability, release and other
testing of Third Party Materials and API, and for Validation, documentation and release of the API and such other quality assurance and quality control procedures as required by the API Specifications, cGMPs, Legal Requirements, this Agreement and
the Quality Agreement. Without limiting the foregoing, Chemport shall establish an ICH stability program that collects no less than [***] data. Chemport shall consult with Amarin with respect to the details of the stability program, including
analytical methods and stability container requirements. 
 (b) Chemport shall maintain for a period of time
required by Legal Requirements, but in no event less than [***] after the expiration date of such API (i.e., a total of [***] from manufacture, subject to Section 3.5(d)), such quantities of the API from each batch of the API as are sufficient
to conduct [***] full testings of the API in accordance with this Agreement. 
 6.2 Testing of API. Prior to release of
the API, Chemport shall test the API in accordance with the Validation testing procedures described in the (a) applicable Drug Applications, (b) API Specifications, (c) cGMPs, (d) Legal Requirements, (e) Quality Agreement
and (f) those procedures and in-plant quality control checks applicable to any products packaged by Chemport. Chemport shall provide Amarin with a copy of the records pertaining to such testing if reasonably requested, subject to redaction of
any Chemport Confidential Information. Additionally, Chemport shall provide Amarin with a Certificate of Analysis and/or any other certificate required by any applicable Governmental Body for release

  
 17 

 
of API (collectively, the “Certificates”) for each batch of API. Amarin shall be under no obligation to accept any shipment of API without the accompanying Certificates. For the
avoidance of doubt, all information provided to Amarin under this Section 6.2 is Chemport Confidential Information and nothing in this Section 6.2 shall be construed as giving Amarin any right to use or disclose (A) any Chemport
Intellectual Property (except as may be permitted by any express license from Chemport), or (B) any Chemport Confidential Information (except as may be permitted under Article XIII hereof). 

6.3 Amarin Holds, Rejections and Revocation of Acceptance. 

(a) General. Amarin may test or cause to be tested the API delivered by Chemport for a Nonconformity or reasonably
suspected Nonconformity (as described below in Section 6.4). During such testing, at Amarin’s reasonable request, Chemport shall provide appropriate analytical reference standards for such testing to Amarin or its designee. If Amarin
wishes to hold the API delivered to it by Chemport for investigation of a Nonconformity or reasonably suspected Nonconformity, Amarin shall so notify Chemport stating the basis for the hold. Amarin’s failure to comply with provisions of this
Section 6.3 and 6.4, including timely notification of Chemport of any Nonconformity, shall be deemed to be an irrevocable acceptance of any such relevant API by Amarin. 

(b) Independent Testing. If the Parties disagree as to whether API subject to hold, rejection or revocation of
acceptance is subject to a Nonconformity, Chemport’s and Amarin’s respective designees shall confer to review samples and/or batch records, as appropriate, and Chemport shall initiate a formal investigation. If the disagreement is not
resolved within [***], then samples, batch records and other data relating to the batch in dispute shall promptly be submitted for testing and evaluation to a mutually acceptable independent Third Party (including a qualified testing laboratory to
perform such testing using validated methods) mutually approved in writing by the Parties. The findings of such independent Third Party shall be binding on the Parties, absent manifest error. The expenses incurred by the Parties for the testing and
evaluation by the Third Party shall be borne by Chemport unless Amarin has claimed that the API is subject to a Nonconformity, and the API in question is ultimately found not to be Nonconforming API. 

(c) Interim Replacement. During the pendency of any dispute concerning whether API is subject to a Nonconformity,
Chemport shall replace the shipment under dispute, at the request of Amarin, as soon as reasonably practicable. 
 6.4
Nonconformity. 
 (a) Nonconformity. If, within [***] following manufacture of a batch of API,
either Party becomes aware or has a reasonable basis to believe that any batch or shipment of API may have a Nonconformity, at any time regardless of the status of Chemport’s testing and quality assurance activities, such Party shall notify the
other Party within [***] of becoming aware of a Nonconformity. “Nonconformity” means a product characteristic that (i) results from Chemport’s failure to manufacture, test, package, store, label, release or ship API in accordance
with the API Specifications, cGMPs, ICH guidelines, Legal Requirements, this Agreement or the Quality Agreement, (ii) causes any API to fail to conform to the API Specifications, cGMPs or Legal Requirements, or (iii) constitutes an
adulteration. In the event of a Nonconformity or reasonably suspected Nonconformity identified within [***] following manufacture of an affected batch of API, the Parties shall immediately (and in any case within [***]) conduct an investigation in
accordance with Section 6.8 below and, until resolution of the investigation, handle the API as provided in Section 6.4(b) below. 

  
 18 

 (b) API That May Be Subject to a Nonconformity. Any batch or shipment
of API that reasonably may be suspected to be subject to a Nonconformity shall be handled as follows and consistent with the Quality Agreement: 
 (i) such API held in inventory at Chemport shall be placed on “Hold” and shall not be shipped to Amarin or its designee, unless, upon completion of investigations pursuant to Section 6.8,
such API is found to be not Nonconforming or it is directed otherwise by Amarin; 
 (ii) any such API shipped to
Amarin or its designee and held in stock by Amarin or its designee shall maintain a “hold” or “rejected” status and shall not be released into approved inventory of Amarin or its designee until the Parties have completed any
investigations pursuant to Section 6.8; and 
 (iii) payment for such API whether shipped or unshipped shall
[***]. 
 Upon learning of a Nonconformity, Amarin shall have the right to [***]. 

(c) Remedy for Nonconforming API. 

(i) In the event that any quantity of API is found to be Nonconforming API prior to it being converted into Product and
Amarin notifies Chemport of such Nonconformity within [***] following manufacture of such batch of API, then Amarin may, at Amarin’s discretion: (1) [***] and/or [***]; provided, however, that, with respect to the payment payable
pursuant to [***], in no event shall such payment exceed an amount equal to [***] times [***] of [***]. For clarity, once API has been delivered by Chemport under Section 3.5(a), it may not be reworked or reprocessed in the event it is found to
be Nonconforming API. 
 (ii) In the event that any Nonconforming API is held in inventory at Chemport, then
Chemport shall have such Nonconforming API destroyed. 
 (iii) In connection with the destruction of API, Amarin
under Section 6.4(c)(i)(B)(3) or Chemport under Section 6.4(c)(ii) shall be solely responsible for compliance with all Legal Requirements in connection with the destruction and shall be liable for any Losses resulting from such
destruction, and the Party not directing the destruction of such API, as the case may be, may, if it so requests, (A) be present at such destruction, or (B) receive written documentation of such destruction. 

(iv) Chemport shall use commercially reasonable efforts to perform any replacement of Nonconforming API on a priority
basis and shall deliver such replacement API as soon as possible. 
 (d) Credit/Reimbursement for
Nonconforming API. In the event that Chemport is obligated to Amarin pursuant to Section 6.4(c), Chemport shall, at Amarin’s discretion, reimburse or credit Amarin for (i) [***] and [***]. Amarin shall provide Chemport with such
documentation as Chemport may reasonably request to confirm any of the foregoing charges, costs or expenses. Chemport shall pay any unused credit amounts under this Section as of the expiration or termination of this Agreement to Amarin within [***]
after this Agreement is terminated. 
 6.5 Quantitative Deficiencies. In the event Amarin determines there is a
quantitative deficiency in any shipment, with respect to the API volumes indicated on the applicable Purchase 

  
 19 

 
Order(s), Amarin shall properly document such deficiency and notify Chemport thereof in writing. Upon such notice, Amarin may, at its option: (a) pay only for actual quantities delivered, or
(b) pay only for actual quantities delivered and require Chemport to rectify any such deficiency by shipping the appropriate quantities of API to or as directed by Amarin, in which case Amarin shall be obligated to pay for any such additional
quantities pursuant to the terms and conditions of this Agreement. Chemport shall use commercially reasonable efforts to rectify any such deficiency on a priority basis and deliver such additional quantities of API as soon as possible. 

6.6 Product Complaints Reports. 
 (a) Received by Chemport. Any and all complaints of which Chemport becomes aware relating to the Product shall promptly be forwarded to Amarin’s head of regulatory affairs, or his or her
designee, consistent with the Quality Agreement. Without limiting the foregoing, Chemport shall forward any such complaint that might be associated with an Adverse Event (as defined below in Section 6.7) no later than [***] following its
receipt. 
 (b) Received by Amarin. Amarin shall as soon as possible inform Chemport of any and all
complaints that Amarin receives which implicate Chemport’s manufacturing or other processes at the Facility. Notification shall be given by telephone, with a facsimile confirmation immediately following. 

6.7 Adverse Events. 
 (a) Definition. For the purposes of this Agreement, “Adverse Event” shall mean any adverse event associated with the use of the Product in humans, whether or not considered drug-related,
including but not limited to “adverse event” as defined in ICH guidelines. 
 (b) Chemport Notice to
Amarin. Chemport shall notify Amarin’s head of regulatory affairs, or any successor department specified by Amarin, as soon as possible, but no later than [***] following its receipt, of information concerning a possible Adverse Event.
Notification shall be given by telephone, with a facsimile confirmation immediately following. Chemport shall provide to Amarin all of the information Chemport has available concerning the Adverse Event and shall reasonably cooperate with any
investigation conducted or directed by Amarin as set forth in Section 6.8 below. 
 (c) Amarin Notice to
Chemport. To the extent an Adverse Event of which Amarin becomes aware implicates Chemport’s manufacturing or other processes at the Facility, Amarin shall inform Chemport of such Adverse Event as soon as possible, but no later than [***]
following its receipt of such information, and shall disclose to Chemport any information Amarin has regarding that Adverse Event which implicates Chemport’s manufacturing or other processes at the Facility. Notification shall be given by
telephone, with a facsimile confirmation immediately following. 
 6.8 Investigations; Chemport’s Obligations.

 (a) General. The Parties shall investigate all reports of Nonconformity, Product complaints,
out-of-trend analytical results, out-of-trend manufacturing yields, stability failure and Adverse Events. The Parties shall act promptly and shall cooperate fully in such investigations. 

  
 20 

 (b) Direction. 

(i) Investigations Related to Product or API Following Shipment. Amarin shall have the sole right, in its
discretion, to control and direct any or all aspects of an investigation conducted under this Section 6.8 with respect to matters related to API following shipment by Chemport or with respect to the Product. Amarin shall advise Chemport from
time to time throughout such investigation of Amarin’s intentions regarding control and direction of such aspects of the investigation. Amarin shall reasonably consult with Chemport and shall reasonably afford Chemport the opportunity to
provide comments or suggestions regarding such investigation, which Amarin agrees to consider in good faith. 

(ii) Investigations Related to API Prior to Shipment. Chemport shall have the sole right, in its discretion, to
control and direct any or all aspects of an investigation conducted under this Section 6.8 to the extent related to API prior to its shipment by Chemport. Chemport shall advise Amarin from time to time throughout such investigation of
Chemport’s intentions regarding control and direction of such aspects of the investigation. Chemport shall reasonably consult with Amarin and shall reasonably afford Amarin the opportunity to provide comments or suggestions regarding such
investigation, which Chemport agrees to consider in good faith. 
 (iii) Mutual Assistance. Upon written
request by a Party in connection with an investigation, the other Party shall provide all reasonably requested testing results, assistance and information to the requesting Party in connection with an investigation of any Nonconformity, Product
complaint or Adverse Event, including chemical/microbial analysis of complaint samples (if available), analysis of retained samples and review of batch records. The Party not directing an investigation shall have the right to conduct at its own
expense any further tests it deems appropriate regarding such investigation provided that it shall share the results with the other Party. Any information provided by a Party shall be considered such Party’s Confidential Information and may be
used or disclosed only as permitted under Article XIII hereof. 
 (c) Reporting. 

(i) The Party directing an investigation shall provide to the other Party [***], and [***]. 

(ii) Any final report regarding a Nonconformity shall be submitted by Chemport within [***] of the notification regarding
that Nonconformity given under Section 6.4 above. 
 (iii) Amarin shall provide to Chemport a written report
of [***]. Each Party shall hold all communications related to such investigation, testing or other requested assistance in confidence, and those communications shall be subject to the terms of Article XIII hereof. 

(d) Costs of Investigations. Chemport shall reimburse Amarin for [***] incurred by Amarin in connection with [***].
Amarin shall reimburse Chemport for [***] incurred by Chemport in connection with [***]. 
 (e) Notwithstanding
the foregoing, in the event it is determined in Amarin’s reasonable discretion that API supplied by Chemport hereunder was not the cause of a Product complaint or Adverse Event, Chemport shall have no further obligation under this
Section 6.8 except to reasonably cooperate with Amarin’s investigation upon reasonable request by Amarin. 

  
 21 

 6.9 Certain Product Events. 

(a) Notification and Cooperation. In the event that Amarin shall be required (or shall voluntarily decide) to
initiate a recall, withdrawal or field correction of, field alert report or comparable report with respect to any Product, Amarin shall notify Chemport’s authorized quality assurance officer, and Chemport shall reasonably cooperate with Amarin
to implement the same. 
 (b) Coordination of Efforts. In the event that Chemport becomes aware of
information that may warrant Amarin taking any action with respect to any Product, Chemport shall immediately provide the Amarin head of regulatory affairs such information. The Parties shall cooperate with each other in determining the necessity
and nature of such action; provided, however, that Chemport shall take no action to effect the same without the written concurrence of Amarin. 
 (c) Contacts and Statements. With respect to any recall, withdrawal, field correction, field alert report or comparable report with respect to any Product, Amarin or its designee shall make all
contacts with the applicable Governmental Body and shall be responsible for coordinating all of the necessary activities in connection with any such recall, withdrawal, field correction, field alert report or comparable report. Amarin or its
designee shall make all statements to the media, including press releases and interviews for publication or broadcast. Chemport agrees to make no statement to the media, unless otherwise required by Legal Requirements, and, in any such event,
Chemport shall reasonably collaborate with Amarin on the content of any such statement. 
 (d) Other
Notice. Notwithstanding anything herein, Chemport agrees to notify Amarin as promptly as possible of any incident pertaining to the Product or API that would require notification to any Governmental Body, including, but not limited to, fire,
explosion, environmental event, serious injury or physical damage at the Facility or Chemport-controlled facility related to the API Third Party Materials, or Intermediate. 
 Article VII  
 Regulatory Matters 

7.1 Consents. Chemport shall obtain and hold all Consents required to be obtained by Chemport under the Legal Requirements for the
performance of its obligations under this Agreement and Amarin shall reasonably cooperate with Chemport with respect thereto. At all times, Chemport shall maintain and comply with all of the Consents which may from time to time be required by any
Governmental Body having jurisdiction with respect to Chemport’s manufacturing operations and facilities and otherwise to be obtained by Chemport to permit the performance of its then-current obligations under this Agreement. Chemport shall
bear all expenses incurred in connection with its obligations under this Section 7.1. In the event any Consent held by Chemport relating to the Facility or its ability to manufacture the API in accordance with this Agreement is hereafter
suspended or revoked, or Chemport has material restrictions imposed upon it by any Governmental Body affecting the API or the Facility, Chemport shall immediately provide written notification to Amarin identifying such material restrictions, a
schedule of compliance and such other information related thereto as is reasonably requested by Amarin. Without limiting the foregoing, Chemport will cooperate with Amarin in a reasonable and timely manner in preparation for pre-approval inspection
of API manufactured at the Facility by any Governmental Body. 

  
 22 

 7.2 Establishment of cGMP Facility. 

(a) Chemport shall use commercially reasonable best efforts to perform the work under the Development and Process
Validation Plan relating to the Facility by the date or dates specified therein in order to establish the Facility as a cGMP facility by the date specified in the Development and Process Validation Plan and Amarin shall reasonably cooperate with
Chemport with respect thereto. 
 (b) Amarin shall have the right, pursuant to the audit procedures in
Section 9.2, to have its Approved Representatives undertake a quality assurance audit of Chemport’s procedures and facilities for API production as soon as practicable after the date the Expansion is completed. If Amarin undertakes such an
audit, Amarin shall provide Chemport with a written audit report and, if applicable, shall highlight therein areas where Amarin judges that Chemport needs to make changes to procedures or facilities in advance of any Pre-Approval Inspection. Both
Parties shall cooperate in good faith to agree and implement the necessary changes. If Amarin’s written audit report identifies any areas for improvement, within [***] following delivery of Amarin’s audit report, Chemport shall prepare an
action plan (and promptly deliver a copy of such plan to Amarin for review and comment), which plan shall address the findings of the audit report and include accomplishment dates for corrective actions. Thereafter, once the Parties mutually agree
on a corrective action plan, the Parties agree to amend the Development and Process Validation Plan to include such corrective actions. 
 (c) Amarin agrees to cooperate with Chemport by making its Approved Representatives available for consultation and advice to Chemport, as may be reasonably requested by Chemport, regarding implementation
of cGMP and related procedural systems and any other matters as may be mutually agreed. 
 (d) Chemport shall use
reasonable best efforts to be prepared for any Pre-Approval Inspection. Amarin will cooperate with Chemport in a reasonable and timely manner in preparation for such Pre-Approval Inspection. 

7.3 Compliance. In carrying out their respective obligations under this Agreement, the Parties shall comply in all respects with
cGMPs and the Legal Requirements, as applicable to such Party, in effect from time to time. 
 7.4 Drug Application
Documentation. 
 (a) Amarin shall draft the CMC section of the Drug Application for the Product based on
information to be provided by Chemport as follows: (i) the Quality Section for API manufacturing (in the CMC section) will be drafted by Chemport in the form of a DMF that will be sent to the FDA Documentation room by Chemport;
(ii) Chemport will make available to Amarin information in the DMF that does not constitute Chemport Confidential Information; and (iii) such access to the DMF will be only through a letter of access issued to Amarin by Chemport. Once
the CMC section of the Drug Application for the Product is drafted by Amarin, if requested by Amarin, Chemport shall assist Amarin by critically reviewing and providing corrections to any relevant section of the Amarin’s CMC in a timely
fashion. Chemport agrees that Amarin may reference Chemport as the manufacturer of the API in Amarin’s Drug Application and any other documentation required under any regulatory filings for the API, and Chemport will provide the
relevant Government Body with all required documentation, including development and analytical reports to support such filings. Amarin shall own all regulatory files (excluding the DMFs) with respect to the API including without limitation
regulatory data and documentation prepared by Chemport under this Section 7.4 respecting the 

  
 23 

 
manufacture of the API, including without limitation the CMC section of any Drug Application filed with the FDA related to the API. For the avoidance of doubt, (i) the DMFs shall be
owned by Chemport, and (ii) all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute Chemport Confidential Information and shall not be disclosed to
Amarin under any circumstances, notwithstanding anything herein to the contrary; provided, however, Chemport shall provide the relevant Governmental Body with all information necessary to support Amarin’s Drug Application filings in a timely
manner. 
 (b) Upon reasonable request from Chemport, Amarin shall provide Chemport with information regarding
Drug Applications, or discrete sections thereof, to the extent available and necessary for Chemport to perform its obligations under this Agreement; provided, however, that information provided hereunder shall not be provided or disclosed to any
other Person without Amarin’s prior Consent. In the event that any Governmental Body makes an inquiry of or provides any information to Chemport that is or may be related to a Drug Application, Chemport shall promptly forward such inquiry or
information to Amarin. 
 7.5 DMFs. Chemport shall create and maintain the Drug Master Files for API in the [***] (if
designated by Amarin in its reasonable discretion) and other jurisdictions agreed to by the Parties (the “DMFs”). Amarin agrees to assist Chemport by making its Approved Representatives available for consultation and advice to Chemport, as
may be reasonably requested by Chemport, regarding preparation and maintenance of the DMFs. Chemport hereby grants to Amarin the right to reference the DMFs in any relevant Drug Application or other documentation to the extent such reference is
necessary for the approval and maintenance of a Drug Application. The Approved Representatives may share with Amarin any information they receive or obtain in connection with their activities under this Section 7.5. Additionally, from time to
time during the Term, Chemport shall provide such information as Amarin may reasonably request related to the DMFs, which shall be handled by Amarin as Chemport Confidential Information, subject to Article XIII. Chemport shall own all regulatory
files with respect to the API including without limitation the DMFs. 
 7.6 Regulatory Changes. The Parties will promptly
notify each other of any material revisions, amendment of or additions to the DMFs and cGMPs and will confer with each other with respect to the best means to comply with such requirements. 

7.7 Regulatory Inspections. 
 (a) Procedures. If Chemport is notified that API or the portion of the Facility relating to the supply of API will be subject to an inspection by any Governmental Body, Chemport shall: 

(i) within [***] advise Amarin’s head of regulatory affairs, or his or her designee, by telephone and facsimile and
provide all relevant information known to Chemport regarding such inspection; 
 (ii) reasonably cooperate with
and allow any such inspection to the extent required by Legal Requirements; 
 (iii) direct all inquiries related
to API, Product, any Drug Application or Amarin’s Confidential Information covered by Article XIII of this Agreement to Amarin; 
 (iv) have a consultant with the required expertise present for such inspections at Chemport’s sole cost and expense. Chemport will provide a copy of the 483 inspection observations upon conclusion of
the inspection and the 483 responses to Amarin when prepared and sent to the inspecting Governmental Body; 

  
 24 

 (v) within [***] (within [***] if any serious or critical deficiencies are
identified by the Governmental Body) send Amarin a copy of any inspection report observations issued by any Governmental Body related to the manufacture, generation, processing, storage, transportation, distribution, treatment, disposal or other
management of API or Third Party Materials; 
 (vi) provide each proposed response to any inspection reports
prepared in accordance with this Section 7.7 not less than [***] before the required response date and consider any comments or suggestions received from Amarin in good faith; and 

(vii) respond to all inspection report observations by any Governmental Body in a timely manner and take all appropriate
corrective actions required or recommended by such Governmental Body. 
 Notwithstanding the foregoing provisions of this
Section 7.7(a), nothing shall require Chemport to disclose information to Amarin specifically relating to any other customer of Chemport or those customers’ products to which the inspection relates. 

(b) Notification. If any Governmental Body shall take any action which shall require a response or action by
Chemport with respect to API, Product, API Specifications, Third Party Materials, the Facility or any operating procedure affecting the API, Chemport agrees [***] to notify Amarin of the required response or action and, in the case of API, Product
and/or API Specifications, shall proceed only with the prior advice and written Consent of Amarin, which shall not be unreasonably withheld or delayed. Notwithstanding anything contained in this Agreement to the contrary, Chemport shall not initiate
or participate in any communications with any Governmental Body concerning the API, Product or the API Specifications unless required to do so by Legal Requirements or requested to do so by Amarin and only after consultation with Amarin. 

7.8 Other Regulatory Matters. Chemport shall provide to each Governmental Body and, at Amarin’s request, shall provide to
Amarin, all documents and information requested by each such Governmental Body in support of Chemport’s and Amarin’s regulatory filings, including, without limitation, all relevant DMFs. Copies of all documents to be provided to any
Governmental Body shall be provided to Amarin at least [***] in advance of delivery to such Governmental Body, if possible, or otherwise as soon as practicable thereafter. 
 7.9 Confidential Information. Notwithstanding anything to the contrary contained herein, Chemport may redact or limit from any deliveries of or access to data, reports or any other information, any
Third Party confidential information or Chemport Confidential Information, at Chemport’s sole discretion; provided, however, that Chemport may not redact or limit any Chemport Confidential Information that is reasonably necessary for Amarin to
comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute Chemport Confidential
Information and shall not be disclosed to Amarin under any circumstances, notwithstanding anything herein to the contrary; provided, however, Chemport shall provide the relevant Governmental Body with all information necessary to support
Amarin’s Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to Amarin under this Article VII is Chemport Confidential Information and nothing in this
Article VII shall be construed as giving Amarin any right to use or disclose (A) any Chemport Intellectual Property (except as may be permitted by any express license from Chemport), or (B) any Chemport Confidential Information (except as
may be permitted under Article XIII hereof). 

  
 25 

 Article VIII  
 Intellectual Property 
 8.1 Ownership. 

(a) Chemport Ownership. Amarin acknowledges and agrees that Chemport owns all rights in and to the Chemport
Intellectual Property, including all Intellectual Property rights in and to the API and the documentation, specifications and processes associated with the API. Except as expressly provided in Section 8.3 below, nothing in this Agreement shall
be deemed to transfer or convey, expressly or by implication, any license or any other right, title or interest in or to the Chemport Intellectual Property. 
 (b) Amarin Ownership. Chemport acknowledges and agrees that Amarin owns all rights in and to the Amarin Intellectual Property, including all Intellectual Property rights in and to the Product, the
Drug Applications, and the documentation, specifications and processes associated with the Product that is not Chemport Intellectual Property. Chemport does not have, by virtue of this Agreement or otherwise, a license or any other right, title or
interest in or to the Amarin Intellectual Property. 
 8.2 New Developments. 

(a) API Product Developments. All Intellectual Property relating to the API or the development or manufacture of
the API, that is conceived, reduced to practice, authored or otherwise invented, discovered, generated or developed in whole or in part by Chemport in the course of activities under this Agreement, whether patentable or not, and any authorship of
works relating to the API that are created by Chemport, including but not limited to any trademarks, trade dress, trade secrets or copyrights, shall be “API Product Developments.” 

(b) Ownership of API Product Developments. Subject to the rights and licenses granted in Section 8.3 below,
Chemport shall own all right, title and interest in and to all API Product Developments and all rights to Intellectual Property arising therefrom. 
 (c) Patents. Notwithstanding any obligation of confidentiality between Chemport and Amarin under Section 13.3 hereto or any other agreement, Chemport, at its own expense, may elect to file and
prosecute appropriate patent applications and maintain patents issuing therefrom covering such API Product Development. Upon Chemport’s reasonable request and at its expense, Amarin shall take such reasonable actions as Chemport deems necessary
or appropriate to assist Chemport in obtaining patent or other proprietary protection in Chemport’s name with respect to all API Product Developments. If Chemport declines to pursue a patent for an API Product Development, Chemport shall be
obligated to assign its rights to pursue such patent to Amarin and shall provide reasonable assistance if Amarin decides to file a patent application for an API Product Development. 

8.3 Grant of License to API (including API Product Developments). Subject to the terms and conditions of this Agreement, Chemport
hereby grants Amarin (a) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use the API Product Developments for the manufacture
and sale of Product using API supplied by Chemport, and (b) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use

  
 26 

 
the Chemport Intellectual Property (other than the API Product Developments) for the manufacture and sale of Product using API supplied by Chemport. This license shall terminate upon the later of
(i) the expiration or termination of this Agreement or (ii) such time that Amarin is no longer in possession of API supplied by Chemport, including API that has been incorporated into Product that has not reached expiry. For the avoidance
of doubt, regardless of the termination or expiration of this Agreement, Amarin shall have a license to use the Chemport Intellectual Property (including API Product Developments) for the manufacture and sale of the Product for so long as necessary
to sell all inventory that incorporates API (including API Product Developments) provided by Chemport under this Agreement. The license granted in this Section 8.3 shall be referred to as the “Amarin License.” 

8.4 Infringement. 
 (a) Amarin shall promptly notify Chemport of any suspected or threatened infringement, misappropriation or other unauthorized use of the Chemport Intellectual Property licensed by Chemport to Amarin under
the Amarin License that comes to Amarin’s attention. The notice shall set forth the facts of such suspected or threatened infringement in reasonable detail. Chemport shall have the sole right, but not the obligation, to institute, prosecute and
control, at its expense, any action or proceeding against the Third-Party infringer of such Chemport Intellectual Property. If Chemport institutes an action against such infringer, Amarin shall give Chemport reasonable assistance and authority to
control, file and prosecute the suit as necessary at Chemport’s expense. Amarin shall have the right to participate in the applicable action or proceeding with its own counsel at its own expense and without reimbursement hereunder. If Amarin
elects to so participate, Chemport shall provide Amarin with an opportunity to consult regarding such action or proceeding. 
 (b) If Chemport elects not to bring any action or proceeding for infringement, misappropriation or other unauthorized use of the Chemport Intellectual Property licensed by Chemport to Amarin under the
Amarin License, then it shall promptly advise Amarin of its decision, and Amarin thereafter shall have the right, but not the obligation, to institute, prosecute and control, at its expense, any action or proceeding against the Third-Party infringer
of such Chemport Intellectual Property. If Amarin institutes an action against such infringer, Chemport shall give Amarin reasonable assistance and authority to control, file and prosecute the suit as necessary at Amarin’s expense, and shall
join such action if reasonably requested by Amarin or required by applicable Legal Requirements. Chemport shall have the right to participate in the applicable action or proceeding with its own counsel at its own expense and without reimbursement
hereunder (except for any out-of-pocket costs and expenses incurred by Chemport following its joinder as a party to such action or proceeding pursuant to Amarin’s reasonable request or as required by applicable Legal Requirements). If Chemport
elects to participate (but is not joined as a party to such action or proceeding), Amarin shall provide Chemport with an opportunity to consult regarding such action or proceeding. Amarin shall retain any damages or other monetary awards that it
recovers in pursuing any action under this Section 8.4(b). 
 (c) In the event that either Party exercises
the rights conferred in this Section 8.4 and recovers any damages or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred
by the Parties in connection therewith (including attorneys fees), unless such Party is expressly not entitled to reimbursement under this Section 8.4. If such recovery is insufficient to cover all such costs and expenses of both Parties, the
controlling Party’s costs shall be paid in full first before any of the other Party’s costs. Each Party seeking reimbursement under this Section 8.4 shall furnish promptly to the other Party appropriate documentation of its
out-of-pocket costs and expenses incurred. 

  
 27 

 8.5 Data. As between Chemport and Amarin, Amarin shall be and remain the sole and
exclusive owner of any and all data and information, in any form, relating to: (a) the business of Amarin; (b) licensees, customers and suppliers of Amarin; (c) the Product and the development and manufacture thereof (excluding
Chemport’s data and information related to the API); and (d) the API Specifications. All information provided to Amarin by Chemport under this Article VIII shall be handled by Amarin as Chemport Confidential Information, subject to Article
XIII. 

  
 28 

 Article IX  
 Information; Access; Audit Rights 
 9.1 Provision of Information.

 (a) Data. Chemport shall provide to Amarin copies (in electronic or hard-copy form, as requested by
Amarin) of or access to data as may be reasonably requested from time to time by Amarin on a bona fide need-to-know basis, except as may be restricted for confidential information or trade secrets. Chemport shall provide final reports for batch
failures, including recommendation for API disposition for all investigations involving (i) foreign matter or particulate contamination; or (ii) any test results indicating non-compliance with the applicable Drug Applications, cGMPs or the
API Specifications. 
 (b) Annual Report. Chemport shall prepare and provide to Amarin a written annual
report no later than [***] following the end of each Calendar Year, documenting, subject to redaction of Chemport Confidential Information, (i) the prior Calendar Year’s batch records; (ii) packaging changes; (iii) process
changes; (iv) changes in API testing methods performed pursuant to Article VI hereof; (v) changes in API Specifications; (vi) batches of API rejected or aborted; (vii) any other discrepancies that require reporting pursuant to
cGMP or Legal Requirements; (viii) “trends” in the manufacture of API during the prior Calendar Year; and (ix) ICH stability data summary. 
 9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the
right, upon a prior written consent of Chemport, not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and
those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each
[***]; provided, however, that Amarin may conduct additional “for cause” audits during a [***] to the extent Chemport supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API. Chemport
may redact from such deliveries to Amarin any Third Party confidential information or Chemport Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party
Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be). Chemport agrees to reasonably cooperate and assist Amarin (and to require any Material Third Party Supplier or
Subcontractor to cooperate and assist Amarin) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved
Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of Chemport or a Material Third Party Supplier or Subcontractor)
or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to Chemport (or any Material Third Party Supplier or Subcontractor) of [***], to conduct
an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation,
distribution or other handling or receiving of API and Third Party Materials. Chemport shall ensure that Approved Representatives have access to Material Third Party Supplier’s and Subcontractor’s facilities in the manner set forth in this
Section 9.2. Chemport shall as soon as practicable take any corrective action reasonably requested by Amarin in connection with this Section 9.2. 

  
 29 

 9.3 Record Retention. Each Party shall maintain, in accordance with and for the
period required under the applicable Drug Application, cGMPs and Legal Requirements, complete and adequate records pertaining to all activities in connection with, and facilities used for, the manufacture, generation, storage, testing, treatment,
holding, transportation, distribution or other handling or receiving of the API, Third Party Materials and Product. 
 9.4
Confidential Information. Notwithstanding anything to the contrary contained in this Agreement, Chemport may redact or limit from any deliveries of or access to data, reports or any other information any Third Party confidential information
or Chemport Confidential Information, at Chemport’s sole discretion; provided, however, that Chemport may not redact or limit any Chemport Confidential Information that is reasonably necessary for Amarin to comply with all Legal Requirements.
In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute Chemport Confidential Information and shall not be disclosed
to Amarin under any circumstances, notwithstanding anything herein to the contrary; provided, however, Chemport shall provide the relevant Governmental Body with all information necessary to support Amarin’s Drug Application filings in a timely
manner. Furthermore, for the avoidance of doubt, all information provided to Amarin under this Article IX is, subject to Section 13.4, Chemport Confidential Information and nothing in this Article IX shall be construed as giving Amarin any
right to use or disclose (A) any Chemport Intellectual Property (except as may be permitted by any express license from Chemport), or (B) any Chemport Confidential Information (except as may be permitted under Article XIII hereof).

 Article X  
 Representations and Warranties 
 10.1 Representations and Warranties of
Chemport. Chemport represents and warrants that: 
 (a) Compliance. The manufacture, generation,
processing, distribution, transport, treatment, storage, disposal and other handling of any Third Party Materials and API by Chemport shall be in accordance with and conform to the API Specifications, cGMPs, ICH guidelines, all Legal Requirements,
this Agreement and the Quality Agreement. The API shall comply with the applicable Drug Applications, cGMPs, API Specifications, ICH guidelines and Legal Requirements; shall be free from defects in materials and workmanship; and shall not be
adulterated or misbranded within the meaning of applicable Legal Requirements. 
 (b) Status;
Enforceability. Chemport is a validly existing corporation in good standing under the laws of the jurisdiction of its incorporation; the execution, delivery and performance of this Agreement by Chemport has been duly authorized by all requisite
corporate action; this Agreement constitutes a legal, valid and binding obligation of Chemport, enforceable against Chemport in accordance with the terms hereof; and the execution, delivery and performance of this Agreement by Chemport will not
violate or conflict with any other agreement or instrument to which Chemport is a party. 
 (c) Certain
Persons. Chemport has not used, and will not use, in any capacity associated with or related to the manufacture of the API, the services of any Persons who have been, or are in the process of being, (i) debarred under 21 U.S.C.
§ 335a(a) or (b) or any comparable Legal Requirements, or (ii) excluded from participation in the Medicare program, any state Medicaid program or any other health care program. Furthermore, neither Chemport nor any of its
officers, employees or consultants has been convicted of an offense under 

  
 30 

 
(x) either a federal or state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval or suspension, (y) any other law cited in any comparable
Legal Requirements as a ground for debarment, denial of approval or suspension. Chemport shall notify Amarin immediately upon learning of any circumstance that would cause this certification under this Section 10.1(c) to become false or
inaccurate. 
 (d) Regulatory Consents. Chemport has or will have all Consents necessary to timely perform
its obligations hereunder and to manufacture the API used in Product for commercial sale. 
 (e) Maintenance
of Facility. During the Term of this Agreement, Chemport shall maintain the Facility, required local licenses, the equipment used to manufacture the API, Chemport Intellectual Property and any applicable contracts necessary to manufacture the
API in accordance with the API Specifications, Legal Requirements, cGMPs, the Quality Agreement and Chemport’s standard operating procedures. 
 (f) Negative Pledge. The transfer of the API by Chemport to Amarin is and shall be rightful and free and clear of any liens or encumbrances. 

(g) Security Measures. Chemport shall maintain reasonable security policies at the Facility and shall use
commercially reasonable efforts to have security measures in place to protect the integrity of the API, Third Party Materials, data and works-in-process at the Facility. 

(h) Non-Infringement. To Chemport’s best knowledge, Chemport’s performance of its obligations under this
Agreement will not infringe upon, nor cause Amarin’s use of the API to infringe upon, the Intellectual Property rights of any Third Party. 
 10.2 Representations and Warranties of Amarin. Amarin represents and warrants that: 
 (a) Status; Enforceability. Amarin is a validly existing corporation in good standing under the laws of the jurisdiction of its incorporation; the execution, delivery and performance of this
Agreement by Amarin has been duly authorized by all requisite corporate action; this Agreement constitutes the legal, valid and binding obligation of Amarin, enforceable against Amarin in accordance with the terms hereof; and the execution, delivery
and performance of this Agreement by Amarin will not violate or conflict with any other agreement or instrument to which Amarin is a party. 
 (b) Certain Persons. Amarin has not used, and will not use, in any capacity associated with or related to the Product, the services of any Persons who have been, or are in the process of being,
(i) debarred under 21 U.S.C. § 335a(a) or (b) or any comparable Legal Requirements, or (ii) excluded from participation in the Medicare program, any state Medicaid program or any other health care program. Furthermore,
neither Amarin nor any of its officers, employees or consultants has been convicted of an offense under (x) either a federal or state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval or suspension,
(y) any other law cited in any comparable Legal Requirements as a ground for debarment, denial of approval or suspension. Amarin shall notify Chemport immediately upon learning of any circumstance that would cause this certification under this
Section 10.2(b) to become false or inaccurate. 
 (c) Regulatory Consents. Amarin has all Consents
necessary to perform its obligations hereunder and will, prior to commercial sale of Product, have all Consents necessary for the commercial sale of Product once Product is approved by FDA or any other Governmental Body. 

  
 31 

 (d) Non-infringement. To Amarin’s best knowledge, Amarin’s
commercial sale of Product will not infringe upon the Intellectual Property rights of any Third Party. 
 10.3
Disclaimer. OTHER THAN AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTIES, EITHER EXPRESS OR IMPLIED, AND THE PARTIES EXPRESSLY DISCLAIM ALL IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NONINFRINGEMENT. 
 Article XI  

Liability and Indemnification 
 11.1 Indemnity by Chemport. Chemport shall defend, indemnify and hold harmless Amarin and Amarin’s Affiliates and licensees and distributors and its and their respective directors, officers,
employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with any of Chemport’s covenants, agreements, obligations, representations or warranties
under this Agreement or the terms of this Agreement; or (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or strict liability of, Chemport or Chemport Affiliates, their respective directors, officers,
employees, agents or Subcontractors. 
 11.2 Indemnity by Amarin. Amarin shall defend, indemnify and hold harmless
Chemport and Chemport’s Affiliates and its and their respective directors, officers, employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with
any of Chemport’s covenants, agreements, obligations, representations or warranties under this Agreement or the terms of this Agreement; or (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or
strict liability of, Amarin or Amarin Affiliates, their respective directors, officers, employees, agents or contractors. 

11.3 Procedures. Any person that may be entitled to indemnification under this Agreement (an “Indemnified Party”) shall
give written notice to the Person obligated to indemnify it (an “Indemnifying Party”) with reasonable promptness upon becoming aware of any claim or other facts upon which a claim for indemnification will be based. The notice shall set
forth such information with respect thereto as is then reasonably available to the Indemnified Party. The Indemnifying Party shall have the right to undertake the defense of any such claim with counsel reasonably satisfactory to the Indemnified
Party, and the Indemnified Party shall cooperate in such defense and make available all records, materials and witnesses reasonably requested by the Indemnifying Party at the Indemnifying Party’s expense. If the Indemnifying Party shall have
assumed the defense of the claim with counsel reasonably satisfactory to the Indemnified Party, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by the Indemnified Party in connection
with the defense thereof. The Indemnifying Party shall not be liable for any claim settled without its Consent, which Consent shall not be unreasonably withheld. The Indemnifying Party shall obtain the written Consent of the Indemnified Party, which
shall not be unreasonably withheld, prior to ceasing to defend, settling or otherwise disposing of any claim if, as a result thereof, the Indemnified Party would become subject to injunctive or other equitable relief or if the Indemnified Party may
reasonably object to such disposition of such claim based on a continuing adverse effect on the Indemnified Party. 
 11.4
Special Indemnity. In the event this Agreement is terminated by Amarin pursuant to Section 15.5(a), Chemport shall pay to Amarin the amount of [***], which shall be Amarin’s sole and exclusive remedy with respect thereto, and in the
event this Agreement is terminated by Amarin pursuant to Section 15.5(g), Chemport shall pay to Amarin the amount of [***], which shall be Amarin’s sole and exclusive remedy with respect thereto. 

  
 32 

 11.5 Limitation of Liability. Subject to Section 11.6, in no event, regardless
of the form of the claim or cause of action, whether based on contract, warranty, infringement, tort, strict liability or otherwise, shall a Party’s cumulative liability for claims under or relating to this Agreement, including, but not limited
to, liquidated damages for delay in delivery or Nonconformity, exceed the aggregate amount of [***]. 
 11.6 No Special
Damages. Notwithstanding anything to the contrary contained herein, except for breaches of confidentiality obligations, the Parties shall not be liable to each other for any special, indirect, incidental or consequential damages (including for
lost profits). 
 Article XII  
 Insurance 
 12.1 Coverage Requirements. Each Party shall maintain in
full force and effect beginning no later than [***] and during the remaining Term of this Agreement and for a period of [***] after expiration or termination of this Agreement, worker’s compensation, property, general liability and product
liability insurance coverage in such amounts and with such scope of coverages as are adequate to cover such Party’s obligations under this Agreement and as are customary in the industry for companies of like size and activities and taking into
account the nature of the API to be manufactured under this Agreement and the Product. Without limiting any of the foregoing, (a) each Party’s product liability insurance coverage limits shall be no less than [***];
(b) Chemport’s insurance shall include coverage for [***]; and (c) Chemport’s policy(ies) shall include [***]. Each Party shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no
less than [***] notice of any cancellation, non-renewal or material change in the policy(ies). 
 Article XIII 

 Confidentiality 
 13.1 Definition of “Amarin Confidential Information”. As used herein, the term “Amarin Confidential Information” shall mean all confidential business and technical
communications, documents and other information, in each case not constituting Chemport Confidential Information, Chemport Intellectual Property or data, whether in written, oral or other form, which Amarin or an Amarin Affiliate furnishes or
discloses to Chemport or which Chemport otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to Amarin, an Amarin Affiliate or any Third Party for which Amarin has an obligation of confidentiality),
including the API Specifications and the terms of this Agreement and any information disclosed by Amarin prior to the Effective Date. 
 13.2 Definition of “Chemport Confidential Information”. As used herein, the term “Chemport Confidential Information” shall mean (a) all confidential business information,
and (b) technical communications, documents or other information, in each case not constituting Amarin Confidential Information, Amarin Intellectual Property or data, whether in written, oral or other form, of Chemport or a Chemport Affiliate
that are disclosed to Amarin by Chemport or a Chemport Affiliate or Amarin otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to Chemport, a Chemport Affiliate or any Third Party for which Chemport
has an obligation of confidentiality), including the terms of this Agreement and any information disclosed by Chemport prior to the Effective Date. The fact that a Party is required by a provision of this Agreement to disclose certain information to
the other Party shall not have any effect regarding whether such information is Amarin Confidential Information or Chemport Confidential Information, as the case may be, and all use 

  
 33 

 
and disclosure of such Confidential Information is subject to this Article XIII. In responding to such a required disclosure, a Party may redact information relating to Third Parties from any
documents deliverable to the other Party that are not relevant to the subject matter of this Agreement. 
 13.3 Treatment of
Confidential Information. Both during the Term of this Agreement and thereafter, Amarin Confidential Information and Chemport Confidential Information (collectively for this Section 13.3 “Confidential Information”) shall be
treated in accordance with the requirements of this Article XIII. 
 (a) Nondisclosure and Non-Use. A
Party receiving Confidential Information of the other Party shall (i) maintain in confidence such Confidential Information to the same extent such Party maintains its own proprietary information of similar kind and value (but at a minimum each
Party shall use commercially reasonable efforts to maintain Confidential Information in confidence); (ii) not disclose such Confidential Information to any Third Party without prior written Consent of the disclosing Party, except, in the case
of Amarin, for disclosures to Amarin’s licensees and commercial partners for the Product who agree to be bound by obligations of non-disclosure and non-use at least as stringent as those contained in this Article XIII; and (iii) not use
such Confidential Information for any purpose except those purposes permitted by this Agreement. 
 (b)
Exceptions. Notwithstanding any other provision of this Agreement, the receiving Party may disclose Confidential Information of the disclosing Party to a Third Party: (i) to the extent and to the Persons as required by an applicable
Legal Requirements, legal process or court order, or an applicable disclosure requirement of any Governmental Body, the U.S. Securities and Exchange Commission, the Nasdaq market or any other securities exchange or market; or (ii) to the extent
necessary to exercise the rights granted to the receiving Party under this Agreement in filing or prosecuting patent applications, prosecuting or defending litigation or otherwise establishing rights or enforcing obligations under this Agreement, or
conducting clinical trials or seeking regulatory approval of the Product; provided, however, that the receiving Party shall first have given prompt notice to the disclosing Party to enable the disclosing Party to seek any available exemptions from
or limitations on any applicable disclosure requirement and shall reasonably cooperate in such efforts by the disclosing Party. Chemport shall reasonably cooperate with Amarin in providing prospective commercial partners with access to the Facility
during normal business hours and allowing the prospective partners to perform reasonable due diligence related to the manufacture and supply of API hereunder to the extent such access to the Facility or information does not interfere with the daily
operation of Chemport’s business, and subject to Chemport’s right to deny access to or disclosure of Chemport Confidential Information at Chemport’s sole and absolute discretion. Notwithstanding, the Parties agree that all process
information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute Chemport Confidential Information and shall not be disclosed to Amarin or any prospective commercial partners
under any circumstances. 
 (c) Terms of Agreement. The Parties agree that the existence of and the
material terms of this Agreement shall be considered Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth below in this Section 13.3(c) (in lieu of the authorized disclosure provisions set
forth in Section 13.3(b), to the extent of any conflict) and without limiting the generality of the definition of Confidential Information set forth in Sections 13.1 and 13.2. If either Party desires to make a public announcement concerning
this Agreement or the terms hereof, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval. A Party shall not be required to seek the permission of the
other Party to repeat any information as to the existence 

  
 34 

 
and terms of this Agreement that has already been publicly disclosed by such Party in accordance with the foregoing or by the other Party. Either Party may disclose the terms of this Agreement to
such Party’s existing investors, directors and professional advisors and to potential investors, acquirors or merger partners and their professional advisors who are bound by written or professional obligations of non-disclosure and non-use
that are at least as stringent as those contained in this Article XIII or are customary for such purpose. Chemport acknowledges that Amarin or its Affiliates may be obligated to file a copy of this Agreement with the U.S. Securities and Exchange
Commission with its next quarterly report on Form 10-Q, annual report on Form 10-K or current report on Form 8-K or with any registration statement filed with the U.S. Securities and Exchange Commission pursuant to the Securities Act of 1933, as
amended, and Amarin shall be entitled to make such filings. 
 13.4 Excluded Information. Notwithstanding any provision
herein to the contrary, the requirements of this Article XIII shall not apply to any information of either Party which: 
 (a) at the time of disclosure hereunder is generally available to the public; 
 (b) after disclosure hereunder becomes generally available to the public, except through breach of this Article XIII by the receiving Party or its Affiliates; 

(c) was not acquired directly or indirectly from the disclosing Party or its Affiliates and which the receiving Party
lawfully had in its possession prior to disclosure by the disclosing Party without confidentiality, nondisclosure and non-use obligations; 
 (d) is independently developed by employees or agents of the receiving Party without the use of the Confidential Information of the disclosing Party; or 

(e) becomes available to the receiving Party from a Third Party that is not legally prohibited from disclosing such
Confidential Information, provided such information was not acquired by such Third Party directly or indirectly from the disclosing Party or its Affiliates. 
 13.5 Return of Confidential Information. At any time upon the request of the other Party, to the extent such Confidential Information is not reasonably necessary to enable a Party to perform its
obligations under this Agreement, or upon expiration or termination of this Agreement, the Party receiving Confidential Information will cease its use and, upon request, within thirty (30) days either return or destroy (and certify as to such
destruction) all Confidential Information of the other Party, including any copies or other embodiments thereof, except that the receiving Party may retain a copy for archive purposes. The return and/or destruction of such Confidential Information
as provided above shall not relieve the receiving Party of its other obligations under this Article XIII. 
 13.6 Redaction
of Chemport Confidential Information. Notwithstanding Chemport’s right to redact or limit Chemport Confidential Information from deliveries of or access to data, reports or any other information, Chemport may not redact or limit any
Chemport Confidential Information that is reasonably necessary for Amarin to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or
otherwise, shall, subject to Section 13.4, constitute Chemport Confidential Information and shall not be disclosed to Amarin under any circumstances, notwithstanding anything herein to the contrary; provided, however, Chemport shall provide any
relevant Governmental Body with all information necessary to support Amarin’s Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to Amarin under this
Agreement is Chemport Confidential Information and nothing in this Agreement shall be construed as giving Amarin any right to use or disclose (A) any Chemport Intellectual Property (except as may be permitted by any express license from
Chemport), or (B) any Chemport Confidential Information (except as may be expressly permitted under this Agreement). 

  
 35 

 Article XIV  
 Force Majeure Event 
 14.1 General. Except for any obligation to pay
money, neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this Agreement when
such failure or delay is due to a Force Majeure Event, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, a “Force Majeure Event” is defined as: acts of God; war; civil commotion;
destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; failure of public utilities and similar events which are beyond the reasonable control of the Party affected. In the
event of a Force Majeure Event, Amarin or Chemport, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be
excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any Force Majeure
Event. 
 14.2 Termination Due to Event of Force Majeure; Transition. If, as a result of the conditions referred to in
Section 14.1, a Party is unable to fully perform its obligations for a period of [***], the other Party shall have the right to terminate this Agreement upon [***] prior notice to the non-performing Party. 

Article XV  

Term; Termination; Remedies 
 15.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated by either Party in accordance with this Article XV, will continue until the seventh (7th) anniversary of the approval of the Drug Application by the FDA
(the “Initial Term”) and shall renew automatically for successive five (5) year renewal terms unless either Party notifies the other Party of its intent to not renew by providing written notice to the other Party no less than two
(2) years prior to the expiration of the Initial Term or applicable renewal term. The Initial Term together with any renewal term(s) is the “Term.” 
 15.2 Termination for Breach. This Agreement may be terminated by either Party in the event of the material breach by the other Party of the terms and conditions hereof; provided, however, the other
Party shall first give to the breaching Party written notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefor. Upon receipt of such notice, the breaching Party shall have sixty (60) days to respond
by curing such breach. If the breaching Party does not cure such breach within such cure period, then (a) if Chemport is the breaching Party, Amarin (i) shall have the right to terminate this Agreement and (ii) shall have the remedies
set forth in Section 15.6; or (b) if Amarin is the breaching Party, Chemport shall (i) have the right to terminate this Agreement and (ii) shall have the remedies set forth in Section 15.8. 

15.3 Insolvency; Bankruptcy. To the extent permitted by Legal Requirements, each Party will have the right to terminate this
Agreement immediately upon notice to the other Party, if any of the following occurs: (a) such other Party is declared bankrupt or insolvent, (b) such other Party generally fails to pay its debts as they become due, (c) there is an
assignment for the benefit of such other Party’s creditors, (d) a receiver is appointed or there is a voluntary or involuntary petition filed or an action or proceeding commenced for bankruptcy, reorganization, dissolution or winding up of
such other Party that is not dismissed within sixty (60) days, or (e) there is a foreclosure or sale of a material part of such other Party’s assets by or for the benefit of any creditor or governmental agency. 

  
 36 

 15.4 Discontinuance or Suspension of Product Program. Amarin may terminate this
Agreement upon thirty (30) days’ written notice to Chemport if Amarin, in its sole and absolute discretion, discontinues or indefinitely suspends the development and/or commercialization of the Product. Upon the termination of this
Agreement pursuant to this Section 15.4, Amarin’s sole obligation shall be for it to reimburse Chemport for all documented direct costs and expenses properly and reasonably incurred by Chemport pursuant to this Agreement up to the
effective date of such termination in connection with Amarin’s then-outstanding obligation to purchase quantities of API forecasted with respect to the binding portion of an applicable [***] Forecast; provided, however, that Chemport shall use
commercially reasonable efforts to mitigate such costs and expenses by cancelling any cancelable orders for Third Party Materials, returning returnable Third Party Materials, and/or using non-returnable Third Party Materials for its own or its other
customers’ behalf. For avoidance of doubt, if Amarin terminates this Agreement pursuant to this Section 15.4, Amarin shall be obligated to purchase the quantities set forth in any Purchase Orders and quantities set forth in any binding
portion of a [***] Forecast, but not obligated to purchase any minimum purchase requirements set forth in Section 2.2. 

15.5 Termination by Amarin. Without limiting any other Section of this Article XV, Amarin may terminate this Agreement upon thirty
(30) days’ written notice to Chemport upon the occurrence of any of the following: 
 (a) Failure to
Validate Manufacturing Process. Chemport fails to complete the Validation of the Initial Manufacturing Process on or before the Expansion completion date set forth in Section 4.1. 

(b) Failure to Achieve Acceptance of Pre-Approval Inspection. Chemport (i) receives at any time correspondence
from FDA indicating that the Facility or facility of a Third Party Supplier is not approved for the manufacture of API, or (ii) fails to obtain official correspondence from FDA stating that the Facility has been approved for the manufacture of
API on or before the [***] after the first FDA inspection of the Facility relating to the Expansion. 
 (c)
Failure to Supply Unrelated to Force Majeure. In the event of the continued failure of Chemport to deliver API to Amarin, Amarin shall have the right to terminate this Agreement upon thirty (30) days’ prior written notice to
Chemport. “Continued” for purposes of determining a continued failure to supply shall be a failure to deliver at least [***] of the API required to be delivered over a [***] period. 

(d) Supply of Nonconforming API. Chemport delivers Nonconforming API pursuant to [***] or more Purchase Orders in
any [***] period. 
 (e) Late Shipment. Chemport ships API pursuant to [***] or more Purchase Orders after
the applicable Shipment Date during any [***] period. 
 (f) Failure to Obtain or Maintain Consents.
Chemport fails to obtain, maintain and comply with all Consents required for the performance of its obligations under this Agreement. 
 (g) Failure to Ship Commercial Batches. Chemport fails to deliver [***] batches of API (each batch being [***]) to Amarin’s carrier by the Shipment Date(s) specified in the relevant Purchase
Order(s), which Shipment Date(s) shall be within [***] from the completion date of the Expansion. 

  
 37 

 15.6 Effect of Termination by Amarin. In the event Amarin terminates this Agreement
pursuant to Sections 14.2, 15.2, 15.3 or 15.5, (a) Amarin shall have the right to terminate, in whole or in part, any Purchase Order issued under this Agreement; (b) Amarin shall be relieved of its requirement to purchase quantities of API
associated with any binding portion of a [***] Forecast; and (c) Amarin shall be relieved of its the minimum purchase requirements set forth in Section 2.2. 
 15.7 Termination by Chemport. Without limiting any other Section of this Article XV, Chemport may terminate this Agreement upon thirty (30) days’ written notice to Amarin upon the
occurrence of any of the following: 
 (a) Failure to Obtain Approval of the Drug Application.
Amarin’s failure to obtain approval of the Drug Application for the Product from the FDA by [***]. 
 (b)
Failure to Place Purchase Orders. Amarin’s failure to place Purchase Orders within [***] of the date on which the Chemport Approvals are obtained. 
 (c) Failure to Accept API Unrelated to a Force Majeure Event. Amarin’s continued failure to accept conforming API delivered by Chemport unrelated to a Force Majeure Event.
“Continued” for purposes of determining a continued failure to accept conforming API shall be a failure to accept at least [***] of the API delivered over a [***] period. 

(d) Failure to Pay. Amarin’s failure to pay Chemport invoiced amounts for conforming API (that is not subject
to an active investigation of Nonconformity or otherwise disputed in good faith by Amarin) within [***] from the applicable due dates for [***] consecutive Purchase Orders. 

(e) Failure to Order Minimum Quantities. Amarin’s failure to order the relevant minimum annual quantities of
API for [***] consecutive [***]. For purposes of determining the quantities ordered by Amarin, (i) all quantities subject to Purchase Orders placed in such Calendar Year, (ii) all quantities of Validation batches of API purchased pursuant
to Section 5.4(a) in such Calendar Year, (iii) all quantities ordered from a Secondary Supplier due to Chemport’s failure to supply API hereunder in such Calendar Year and (iv) all quantities ordered from a Secondary Supplier due
to a Force Majeure Event in such Calendar Year shall be included in such determination. 
 15.8 Effect of Termination by
Chemport. In the event Chemport terminates this Agreement pursuant to Sections 14.2, 15.2, 15.3 or 15.7, (a) Chemport may, upon [***] written notice, require Amarin to [***] and (b) Chemport shall, otherwise, be relieved of any of its
obligations to supply any quantities of API under this Agreement. 
 15.9 Termination of Related Agreement. This
Agreement may be terminated by either Party upon written notice to the other Party (notwithstanding the 30-day notice requirement described above) upon the termination of that certain agreement entered into between the Parties on the date of this
Agreement related to Amarin’s investment. 

  
 38 

 Article XVI 
 Miscellaneous 
 16.1 Notices. In addition to the other specific
procedures for notification provided herein, all notices, demands, requests and other communications made hereunder shall be in writing and shall be given either by personal delivery, by facsimile or by internationally recognized overnight courier
(with charges prepaid) and shall be deemed to have been given or made: (a) if personally delivered, on the day of such delivery; (b) if sent by facsimile, on the day it is sent or, if not sent on a business day, the next business day; or
(c) if sent by overnight courier, on the business day following the date deposited with such overnight courier service, in each case pending the designation of another address, addressed as follows: 

If to Amarin: 
 Amarin Pharmaceuticals Ireland Ltd. 
 c/o Byrne Wallace; Attention: [***]

 2 Grand Canal Square 
 Dublin 2 
 Ireland 

Telephone +353 1 691 5000 
 Fax +353 1 691 5010 
 and 

Amarin Pharmaceuticals Ireland Ltd. 
 c/o Amarin Pharma, Inc. 
 Mystic Packer Building, Suite 300 

12 Roosevelt Avenue 
 Mystic, CT 06355 
 USA 

Attention: Vice President, Corporate Development 
 Telephone: +1 860-572-4979 
 Fax: +1 860-572-4940 

With a copy (which shall not constitute notice) to: 
 Dan L. O’Korn 
 Smith, Anderson, Blount, Dorsett, Mitchell 

& Jernigan, L.L.P. 
 150 Fayetteville Street, 25th Floor (zip: 27601) 
 P.O. Box 2611 

Raleigh, North Carolina 27602-2611 
 Facsimile: (919) 821-6800 
 If to Chemport: 

Chemport Inc. 

15-1 Dongsu-dong, Naju-si 
 Jeollanam-do 520-330, Korea 
 Attention: [***], CTO/Senior Managing Director

 Fax: +82-61-330-9770 
 Email: [***] 

  
 39 

 With a copy (which shall not constitute notice) to: 

Chemport Inc. 

2-1704 Ace Hightech City, 55-20 
 Munrae-dong 3-ga, Yeongdeungpo-gu 
 Seoul 150-834 Korea 

 

			
	Attention:	  	[***], CFO/Director
	Fax:	  	+82-2-3439-2266
	Email:	  	[***]

 16.2 Independent Contractors. Each Party shall be treated as an independent contractor of the
other. Neither Party shall be deemed to be a co-venturer, partner, employee or a legal representative of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other
Party or incur any charges or expenses for or in the name of the other Party. 
 16.3 Entire Understanding. The Parties
agree, on their own and their respective Affiliates’ behalf, that this Agreement, including Schedules hereto, and any other document identified herein, constitutes the entire agreement between the Parties and their Affiliates relating to the
subject matter hereof, and all prior agreements or arrangements, written or oral, between the Parties and their Affiliates relating to the subject matter hereof are hereby superseded and merged with this Agreement. 

16.4 Assignment. This Agreement will be binding upon and inure to the benefit of the Parties, their successors and permitted
assigns. Neither Party shall delegate, transfer, convey, assign or pledge this Agreement, in whole or in part, or any of its rights or obligations under this Agreement, without the prior written Consent of the other Party in each instance, and any
such action without Consent shall be void and have no effect. However, notwithstanding the foregoing, a Change of Control of either Party shall not be deemed to be an assignment of this Agreement and shall not be subject to the other Party’s
Consent. 

  
 40 

 16.5 Dispute Resolution. If the Parties fail to resolve any claim, dispute or
controversy of whatever nature arising out of or relating to this Agreement (other than one relating to the validity, enforceability, infringement or misappropriation of Intellectual Property rights, which shall not be subject to this
Section 16.5), the Parties shall refer the dispute, to their respective officers designated below or such other officers as the Parties may designate in writing from time to time, for attempted resolution by good faith negotiations within [***]
after so submitting the dispute. The designated officers are as follows: 
 For Amarin: 

Amarin Pharmaceuticals Ireland Ltd. 
 c/o Amarin Pharma, Inc. 
 Mystic Packer Building, Suite 300 

12 Roosevelt Avenue 
 Mystic, CT 06355 
 USA 

Attention: President 
 Telephone: +1 860-572-4979 
 Fax: +1 860-572-4940 

For Chemport: 

Chemport Inc. 

15-1 Dongsu-dong, Naju-si 
 Jeollanam-do 520-330, Korea 
 Attention: [***], CTO/Senior Managing Director

 Fax: +82-61-330-9770 
 Email: [***] 
 With a copy to: 

Chemport Inc. 

2-1704 Ace Hightech City, 55-20 
 Munrae-dong 3-ga, Yeongdeungpo-gu 
 Seoul 150-834 Korea 

 

			
	Attention:	  	[***], CFO/Director
	Fax:	  	+82-2-3439-2266
	Email:	  	[***]

 If such dispute is not resolved by the end of the [***] period, then either Party shall be entitled to refer the matter
to be finally settled by arbitration to be held in accordance with the then-current Rules of Arbitration and Conciliation of the International Chamber of Commerce by three (3) arbitrators to be appointed in accordance with the said Rules. The
Parties agree that any such unresolved dispute, and any claim or dispute related to the validity of this arbitration clause, may be resolved solely by binding arbitration under this Section 16.5. The arbitration shall take place in London,
England if the claim giving rise to such arbitration is brought by Chemport and the arbitration shall take place in Singapore if the claim giving rise to such arbitration is brought by Amarin. In each case, the proceedings shall be conducted and all
documentation shall be presented in the English language. The award of the arbitrators shall be final and without appeal. Any competent court shall be able to order enforcement of the award. Each Party will bear its own attorneys’ fees and
other costs and expenses incurred pursuant to this Section 16.5. For avoidance of doubt, the foregoing shall not prohibit or delay a Party from seeking appropriate injunctive or other equitable relief. 

16.6 Subcontractors. Chemport may utilize Subcontractors with appropriate expertise and experience in the performance of its
obligations under this Agreement; provided, however, that Amarin must give its written Consent in each instance prior to the use of Subcontractors by Chemport (such Consent not to be unreasonably withheld or delayed). Nothing in this
Section 16.6 shall relieve Chemport from any obligation under this Agreement. 

  
 41 

 16.7 Amendment. This Agreement, including any Schedule hereto, may not be amended or
modified in any manner except by an instrument in writing signed by a duly authorized officer of each Party. 
 16.8
Severability. If and to the extent that any court of competent jurisdiction holds any provision (or any part thereof) of this Agreement to be invalid or unenforceable, such holding shall in no way affect the validity or enforceability of the
remainder of this Agreement, and the invalid or unenforceable provision shall be fully severed from this Agreement, and there shall automatically be added in lieu thereof a provision as similar in terms and intent to such severed provision as may be
legal, valid and enforceable. 
 16.9 Waiver. Any failure of a Party to comply with any obligation, covenant, agreement
or condition herein contained may be expressly waived, in writing only, by the other Party hereto, and such waiver shall be effective only in the specific instance and for the specific purpose for which made or given. 

16.10 Survival. Articles I (to the extent required to enforce other surviving rights or obligations), VIII, IX, X, XI, XII, XIII,
XV, XVI and Sections 6.1(b), 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.5, 7.7, and 7.9, and any other provision which by its terms specifically shall so state, together with any obligations accrued hereunder at the time of termination or expiration,
shall survive the termination or expiration of this Agreement. 
 16.11 Drafting Ambiguities. Each Party to this
Agreement and its counsel have reviewed and revised this Agreement. The rule of construction to the effect that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of this Agreement or any
amendment or Schedules hereto. 

  
 42 

 16.12 Headings; Schedules; Counterparts. 

(a) Headings. The headings of the Sections of this Agreement are for reference purposes only, are not part of this
Agreement and shall not in any way affect the meaning or interpretation of this Agreement. 
 (b)
Schedules. All Schedules and Exhibits delivered pursuant to this Agreement shall be deemed part of this Agreement and incorporated herein by reference as if fully set forth herein. In the event that any Schedule conflicts with any of the
terms or provisions of this Agreement, the terms and provisions of this Agreement shall prevail. 
 (c)
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. Facsimile signatures shall be treated as
original signatures. 
 16.13 Governing Law. This Agreement and all matters arising out of or relating to this Agreement
shall be governed, construed and enforced in accordance with the laws of the State of New York, USA, without regard to principles of conflicts of law. The Parties agree that the provisions of the United Nations Convention on Contracts for the
International Sale of Goods shall not apply. 
 16.14 Remedies. Unless otherwise expressly provided in this Agreement,
none of the remedies set forth in this Agreement are intended to be exclusive, and each Party shall have available to it all remedies available under law or in equity or in any other agreement between the Parties. 

16.15 Injunctive Relief. In the event that either Chemport or Amarin breaches or threatens to breach any provision of
Article VIII or Article XIII of this Agreement, the Parties agree that irreparable harm to the other Party should be presumed, and the damages to such Party would probably be very difficult to ascertain and would be inadequate. Accordingly, in
the event of such circumstances, each of Chemport and Amarin agree that, in addition to any other right and remedies available at law or in equity, the other Party shall have the right to seek injunctive relief from any court of competent
jurisdiction. 
 16.16 Standard Forms. In all communications, Amarin and Chemport may employ their standard forms, but
nothing in those forms shall be construed to be in addition to or modify or amend the terms and conditions of this Agreement, and, in the case of any conflict herewith, the terms and conditions of this Agreement shall control. 

16.17 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other
acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 16.18
Counterparts. This Agreement may be executed in two counterparts and by facsimile or PDF signature, each of which shall be deemed an original and which together shall constitute one instrument. 

16.19 English Language. The English language version of this Agreement will be controlling on the Parties. All information,
documents, reports, notices, writings and communications to be provided by one Party to the other Party hereunder will be provided in the English language. 
 [Remainder of page intentionally left blank.] 

  
 43 

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be duly executed
as of the date first written above. 
  

			
	AMARIN PHARMACEUTICALS IRELAND LTD.
		
	By:	 	 /s/ Thomas G. Lynch

	Name:	 	 Thomas G. Lynch

	Title:	 	 Director

	
	CHEMPORT INC.
		
	By:	 	 /s/ Young Joo Kim

	Name:	 	 Young Joo Kim

	Title:	 	 CEO/President

		 	5/25/2011

 SCHEDULE 3.1 
 PRICING SCHEDULE 
 Price Schedule 

[***] 

  
 45 

 SCHEDULE 3.1(e) 

API PRICE ADJUSTMENT 
 [***] 

  
 46 

 SCHEDULE 4.1 
 EXPANSION PLANS 
 [***] 

  
 47 

 SCHEDULE 4.5 
 SECOND EXPANSION PLANS 
 [***] 

  
 48 

 SCHEDULE 5.1 

API SPECIFICATIONS1 
 [***] 
  

	1 	 [***] 

  
 49 

 SCHEDULE 6.2 

FORM OF CERTIFICATE OF ANALYSIS 
 [***] 

  
 50

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]